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ABSTRACT OF THE DISSERTATION 
Discovery and characterization of a novel class of metabolic regulators in the malaria parasite 
Plasmodium falciparum 
Ann M. Guggisberg 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Genetics and Genomics 
Washington University in St. Louis, 2016 
Dr. Audrey R. Odom John, Chairperson 
 
The malaria parasite, Plasmodium falciparum, infects hundreds of millions of people per year 
and causes hundreds of thousands of deaths. Within the host red blood cell, the parasite relies on 
glycolysis for energy and synthesis of essential biomolecules. One such anabolic fate of glucose 
is the synthesis of isoprenoids, a broad and essential class of compounds that participate in a 
variety of cellular functions. In the face of ever-evolving drug resistance, new inhibitors and 
better understanding of parasite metabolism are required. The antibiotic fosmidomycin (FSM) 
targets the methylerythritol phosphate pathway for isoprenoid synthesis and is a well-validated 
inhibitor of P. falciparum growth. A forward selection for FSM resistance generated a number of 
parasite strains with increased drug tolerance. We identify mutations in two members of the 
haloacid dehalogenase-like hydrolase (HAD) superfamily, PfHAD1 and PfHAD2, as causal for 
resistance. Enzymatic characterization and metabolic profiling reveal that these mutations are 
deleterious and confirm the role of PfHAD1 and PfHAD2 as novel negative regulators of glucose 
and isoprenoid metabolism. Despite their homology and shared role in FSM resistance, PfHAD1, 
a sugar phosphatase, and PfHAD2, a purine nucleotidase, appear to mediate FSM resistance via 
 xvii 
distinct enzymatic mechanisms. To further understand the role of PfHADs as metabolic 
regulators, we harness a growth defect in FSM-resistant PfHAD2 mutants to select for 
suppressors of FSM resistance. We identify suppressor mutations in the key glycolytic enzyme 
phosphofructokinase (PfPFK9) and describe the effect of these mutations on enzyme function 
and parasite metabolism. 
 
Given its safety in humans and its specificity as a MEP pathway inhibitor, FSM is a strong 
candidate for clinical development and is currently being evaluated in clinical trials as part of an 
antimalarial combination therapy. Unfortunately, previous studies have observed high rates of 
recrudescence following FSM treatment when paired with the antibiotic clindamycin (CLN). To 
understand whether any genetic changes correlate with recrudescence, we performed whole 
genome sequencing on patient parasite populations before and after recrudescence. We 
demonstrate the use of a selective amplification method to amplify and sequence parasite 
genomes from blood spots. Our genotyping does not reveal any genetic changes responsible for 
recrudescence, but rather support the hypothesis that FSM-CLN treatment failure is due to 
formulation or partner drug selection. We encourage further development of FSM and other 
MEP pathway inhibitors as antimalarial therapies.  
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Chapter 1 
 
Introduction !! !
2 
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3 
1.1 THE MALARIA PARASITE, PLASMODIUM FALCIPARUM 
 
Severe malaria remains a threat to human health worldwide, with over 250 million cases per 
year. Malaria is a leading cause of death in children, with almost one million deaths each year 
[1,2]. Despite ongoing and intensive control efforts, malaria remains endemic on five continents. 
Widespread resistance to former first-line agents, most notably chloroquine, has severely limited 
malaria control efforts [2]. Currently, the recommended standard of care for malaria infection is 
combination therapy using artemisinin-based therapeutics. However, decreased sensitivity to 
artemisinin has been recognized in the field, particularly in Southeast Asia. The spread of 
artemisinin resistance threatens the progress that has been made in control of malaria, 
particularly in sub-Saharan Africa [3–5]. New antimalarial agents, particularly agents with novel 
mechanisms of action, are urgently needed. 
 
Malaria is caused by infection with protozoan parasites in the genus Plasmodium. Most cases of 
life-threatening malaria are attributable to infection with a single species, Plasmodium 
falciparum, although P. vivax and P. knowlesi have also been associated with severe disease [6–
9]. Plasmodium infection is transmitted through the bite of anopheline mosquitoes (Figure 1 
depicts their life cycle). Expelled from mosquito salivary glands, malaria sporozoites first traffic 
to the liver, where 10 to 100,000 daughter parasites are generated from a single invading cell. 
Upon egress from the liver, the parasite enters the host bloodstream. There, the malaria parasite 
begins an asexual cycle of growth and development within erythrocytes. This intraerythrocytic 
cycle leads to the signs and symptoms associated with malaria infection, including fever, anemia, 
and multiorgan dysfunction due to vascular adherence of parasitized red blood cells. New 
4 
antimalarials must therefore target this pathogenic stage of parasite development. A small 
proportion of asexual-stage parasites leave the asexual cycle and commit to the production of 
sexual forms, known as gametocytes. Upon a new blood meal, gametocytes return to the 
mosquito midgut, where they complete sexual development and begin the life cycle anew. 
 
1.2 ISOPRENOID SYNTHESIS IN THE APICOPLAST 
 
One cellular peculiarity of Plasmodium species, as well as other apicomplexan parasites, such as 
Toxoplasma and Babesia species, is the presence of an unusual plastid organelle, the apicoplast 
(Figure 2A and B). The apicoplast is surrounded by four membranes, suggesting an ancient 
secondary endosymbiotic event between a protozoan parasite ancestor and red algae, similar to 
that of the chloroplast [10–12]. While the apicoplast was previously believed to be of green algal 
origin, the recent discovery and genome sequencing of the alveolate Chromera velia has revealed 
C. velia as an evolutionary link between apicomplexans and their red algal ancestors [11,12]. C. 
velia can potentially serve as a useful tool to study the evolution of plastid pathways in 
apicomplexan parasites. While photosynthetic capabilities have been lost over time, the malaria 
parasite has retained some plantlike metabolic pathways that hold particular value as targets for 
antimalarial drug development, since these pathogen-specific processes are not present in 
humans. 
 
Key among apicoplast metabolic pathways is that of isoprenoid biosynthesis. Isoprenoids 
comprise a very large and diverse group of biomolecules derived from the sequential assembly of 
two 5-carbon isomers, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate 
5 
(DMAPP). Chains of isoprene units are subsequently modified through cyclizations, oxidations, 
reductions, and additions to generate the array of over 25,000 isoprenoids found in nature [13]. 
In humans (as well as fungi, archeabacteria, cytoplasm of plants, and other metazoans), the 
isoprenoid building blocks IPP and DMAPP are produced through a mevalonate-dependent 
pathway from acetyl-coenzyme A (CoA). The rate-limiting step in the mevalonate pathway is the 
conversion of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA to mevalonic acid by the enzyme 
HMG-CoA reductase; this enzyme is the target for the widely used statin class of cholesterol-
lowering drugs [14]. 
 
In Plasmodium species, IPP and DMAPP are produced via an alternative biosynthetic route that 
does not utilize mevalonate [15,16]. This pathway, also called the MEP (2-C-methyl-D-erythritol 
4-phosphate) pathway or DOXP (1-deoxy-D-xylulose 5-phosphate) pathway, converts 
glyceraldehyde 3-phosphate and pyruvate to IPP and DMAPP through seven enzymatic steps 
(Figure 2C). At least two enzymes of this pathway catalyze rate-limiting steps in IPP production: 
DOXP synthase (DXS) (EC 2.2.1.7, PlasmoDB identifier [ID] PF3D7_1337200) converts 
glyceraldehyde 3-phosphate and pyruvate to DOXP, and DOXP reductoisomerase (DXR) (EC 
1.1.1.267, PF3D7_1467300) converts DOXP to MEP [17,18]. The mechanism by which IPP and 
DMAPP are exported from the apicoplast for use in the cytoplasm remains unknown. 
Given the structural diversity of isoprenoids, it is not surprising that these molecules serve 
diverse cellular functions. Plants in particular elaborate an incredible range of specialized 
isoprenoid end products, including pharmacologically active compounds like paclitaxel 
(originally named taxol) [19] and artemisinin [20], as well as terpenes, volatile isoprenoids that 
confer the characteristic odors, flavors, and colors of plants. Other roles of isoprenoids include 
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regulation of cell growth and energy production, intracellular signaling, and membrane structural 
support [15,21,22]. 
 
1.3 THE MEP PATHWAY INHIBITOR FOSMIDOMYCIN 
 
1.3.1 Fosmidomycin as a chemical tool 
An important reagent in the study of the MEP pathway has been the selective MEP pathway 
inhibitor, fosmidomycin. Fosmidomycin is a small, three-carbon phosphonate compound that 
was first identified from Streptomyces lavendulae by its antibacterial properties [23]. Subsequent 
in vitro studies revealed that fosmidomycin competitively inhibits DXR, the first dedicated 
enzyme of the MEP pathway [24–26] (Figure 2C). The charged nature of fosmidomycin means 
that this compound is typically excluded from cells unless actively imported, which has limited 
its utility against many organisms, including the apicomplexan Toxoplasma gondii [27] and the 
agent of tuberculosis, Mycobacterium tuberculosis [28]. Intraerythrocytic malaria parasites 
elaborately remodel the host red blood cell, significantly increasing the cellular uptake of many 
nutrients [29–31]. These so-called new permeability pathways likely facilitate the uptake of 
fosmidomycin, as fosmidomycin is excluded from uninfected red blood cells but inhibits the 
growth of Plasmodium and a related, tick-borne intraerythrocytic apicomplexan pathogen, 
Babesia divergens [32]. It remains unclear what cellular machinery is required for fosmidomycin 
uptake into P. falciparum cells. 
 
Fosmidomycin is well validated as a specific inhibitor of DXR. Analysis of MEP pathway 
intermediates in bacteria and P. falciparum has established that fosmidomycin reduces the 
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intracellular levels of downstream MEP pathway metabolites and isoprenoid products [33–35]. 
In addition, the growth inhibitory effects of fosmidomycin are chemically rescued in bacteria and 
malaria parasites through supplementation of the medium with IPP or unphosphorylated 
isoprenols (farnesol and geranylgeraniol). The 50% inhibitory concentration (IC50) for 
fosmidomycin increases 10-fold when the medium is supplemented with farnesol or 
geranylgeraniol [33,36]. Supplementation of the medium with geranylgeraniol also rescues 
protein mislocalization and the organelle disruption effects of fosmidomycin treatment [37]. 
Treatment with high concentrations of fosmidomycin is not completely rescued by prenyl 
alcohol supplementation, perhaps due to the toxicity of these compounds at high concentrations 
[38]. 
 
In asexual parasites, the MEP pathway may be the only essential function of the apicoplast 
organelle in which it resides. Treating parasites with inhibitors of apicoplast replication forces P. 
falciparum to lose its apicoplast genome and structure. These parasites nonetheless survive when 
supplemented with exogenous IPP [36]. 
 
Small-molecule inhibitors that target apicoplast replication often result in a delayed-death 
phenotype in P. falciparum, in which drug-treated parasites complete the first cell cycle after 
treatment and arrest in the second [39]. In contrast, fosmidomycin treatment inhibits 
intraerythrocytic growth of P. falciparum during the first cell cycle. Interestingly, fosmidomycin-
treated parasites develop within the red blood cell, begin hemoglobin digestion, and initiate DNA 
replication prior to cell cycle arrest as multinucleate schizonts [37]. The requirement of the new 
permeability pathways mentioned above for fosmidomycin import into P. falciparum cells may 
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explain this delayed action, as these pathways are not fully developed until the trophozoite stage 
[29,30]. Liver-stage parasites are also sensitive to fosmidomycin. Treatment of liver-stage 
Plasmodium berghei inhibits the development of the apicoplast and reduces the number of 
merosomes, the result of liver-stage replication. Thus, the MEP pathway appears to be required 
for optimal growth in hepatocytes [27]. Little is known about isoprenoid synthesis in the 
gametocyte and mosquito stages of the parasite life cycle, although proteomics studies have 
identified MEP pathway enzymes expressed in late gametocytes [40]. 
 
1.3.2 Fosmidomycin as a clinical antimalarial 
Fosmidomycin was originally clinically developed for its antibacterial properties [41]. Its use as 
an antimalarial was first demonstrated in 1999 [42]. It is currently being evaluated as a partner 
agent part of an antimalarial combination therapy. Given its specificity for the MEP pathway, 
fosmidomycin is well-tolerated in humans [43,44]. Studies have evaluated the synergy of FSM 
with other antimalarials, including chloroquine, artemisinin, atovaquone, proguanil, and 
clindamycin [45]. This study identified synergy between FSM and the antibiotic clindamycin 
(CLN) [45,46]. Like FSM, clindamycin also has a short half life (1-3 h) [41,47] and thus was an 
unusual choice of partner drug for FSM. Nonetheless, several clinical trials have evaluated the 
efficacy of FSM-CLN in various populations (clinical trial identifiers NCT02198807, 
NCT01361269, NCT01002183, NCT00214643, and NCT00217451) [43,48]. The combination 
initially showed promise, with high cure rates [46,49], although recrudescence has been observed 
in recent pediatric studies [50]. Currently, a Phase II clinical trial is underway to test the efficacy 
of fosmidomycin paired with a new partner, the antimalarial piperaquine (NCT02198807). 
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1.4 FUNCTIONS OF ISOPRENOIDS IN P. FALCIPARUM 
 
1.4.1 5-carbon isoprenoids: IPP and DMAPP 
The most proximally produced compounds of the MEP pathway are the end products and 
isoprenoid building blocks, isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl 
pyrophosphate (DMAPP). In bacteria, DMAPP is used as a substrate for tRNA isopentenylation 
[51]. In this process, an isopentenyl group is added to an adenosine in the tRNA, targeting the 
tRNA to the ribosome and improving translation fidelity. Evidence suggests that P. falciparum 
produces isopentenylated tRNAs, as its apicoplast genome encodes four tRNAs that represent 
probable candidates for isopentenylation [52]. P. falciparum encodes a homologue of the 
Escherichia coli tRNA isopentenyltransferase MiaA (EC 2.5.1.75, PF3D7_1207600) [52]. P. 
falciparum also possesses a homolog of the isopentenyl-adenosine tRNA methylthiolase MiaB 
(EC 2.8.4.-, PF3D7_0622200), an enzyme whose bacterial homologs participate in downstream 
tRNA isopentenylation steps [52,53]. 
 
As previously described, supplementation of medium with farnesol or geranylgeraniol rescues 
fosmidomycin treatment of malaria parasites. These isoprenols are presumed to be 
phosphorylated intracellularly by nonspecific kinases to generate their cognate diphosphates, 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Fosmidomycin-
treated parasites supplemented with farnesol (15-carbon) or geranylgeraniol (20-carbon) 
therefore do not have a known source of 5- or 10-carbon isoprenoids but are still capable of 
intraerythrocytic growth [33]. These studies cannot rule out a role for tRNA isopentenylation in 
maintaining apicoplast function, but they do suggest there may not be additional roles for tRNA 
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isopentenylation outside the maintenance of isoprenoid biosynthesis within the apicoplast. 
 
1.4.2 Monoterpenes (10-carbon isoprenoids) 
Condensation of two isoprene units produces the 10-carbon isoprenoid geranyl pyrophosphate 
(GPP). GPP is utilized by monoterpene synthases and monoterpene cyclases to produce 10-
carbon monoterpenes. Monoterpenes are the most abundant compounds found in plant essential 
oils. Terpene mixtures such as citronellal (citronella) and citral (lemon) are produced by plants to 
deter herbivores [54]. Some monoterpenes have been found to have antimicrobial properties; 
thymol, a monoterpene component of the essential oil in thyme, has been shown to decrease 
counts of Salmonella enterica serovar Typhimurium and Staphylococcus aureus [55]. To date, 
no studies have identified evidence of monoterpene synthesis in P. falciparum. Homology-based 
searches do not identify potential monoterpene synthases or monoterpene cyclases in the P. 
falciparum genome, although this class of enzymes is remarkably diverse [56]. 
 
1.4.3 Sesquiterpenes and diterpenes (15- and 20-carbon isoprenoids) 
FPP and GGPP are also used to produce sesquiterpenes and diterpenes. In P. falciparum, the 
condensation of GPP and IPP (to produce FPP) and of FPP and IPP (to produce geranylgeranyl 
diphosphate [GGPP]) appears to be catalyzed by a bifunctional FPP-GGPP synthase 
(PF3D7_1128400) [57]. The crystal structure of the P. vivax enzyme has been solved [58,59]. 
This bifunctional enzyme is sensitive to bisphosphonates, such as zoledronate and risedronate 
[57]. These compounds bind to bone minerals and are traditionally used to inhibit bone 
resorption in the treatment of diseases like osteoporosis [60]. Metabolic-labeling studies using 
[14C]mevalonate, [14C]IPP, and [14C]DMAPP validate FPP synthesis as the target of 
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bisphosphonate inhibition [61]. Bisphosphonates, as well as their analogs, have been shown to 
bind FPP-GGPP synthase in the active site of both the human and parasite enzymes [59]. 
Bisphosphonates compete with GPP for binding, and their efficacy is enhanced by IPP 
stabilization of the enzyme inhibitor complex [62,63]. Treatment with bisphosphonates inhibits 
parasite growth and decreases protein prenylation [58,59,64–66]. Partial rescue of parasite 
growth can be achieved by the addition of FPP or GGPP to the culture medium, indicating that 
bisphosphonates target FPP and GGPP synthesis in P. falciparum [64]. 
 
P. falciparum utilizes sesquiterpenes and diterpenes for protein prenylation. In protein 
prenylation, lipophilic farnesyl (15-carbon) and geranylgeranyl groups (20-carbon) are attached 
to C-terminal cysteines, which results in protein association with membranes. Prenylation is 
crucial for the function of a variety of membrane-bound enzymes, such as the Ras, Rho, and Rab 
families of small GTPases. Farnesyl transferase (EC 2.5.1.58, PF3D7_1242600 [α subunit] and 
PF3D7_1147500 [β subunit]) and geranylgeranyl transferase type I (EC 2.5.1.59, 
PF3D7_1242600 [α subunit] and PF3D7_0602500 [β subunit]) transfer FPP and GGPP moieties 
to the target protein via recognition of a C-terminal CaaX motif [67]. This motif is composed of 
a cysteine (C), two aliphatic amino acids (aa), and the C-terminal amino acid (X). These two 
prenyltransferases share an α subunit but have distinct β subunits [68]. Geranylgeranyl 
transferase type II (EC 2.5.1.60, Rab geranylgeranyltransferase, PF3D7_1442500 [α subunit] and 
PF3D7_1214300 [β subunit]) utilizes a different mechanism of substrate recognition, which 
requires a Rab escort protein (REP) [69]. The REP binds Rab proteins, facilitates their 
prenylation, and delivers them to their target membrane. REPs are part of the REP/GDI 
superfamily, which also includes GDP dissociation inhibitor (GDI) proteins. GDI proteins are 
12 
involved in cycling the Rab between membranes and the cytosol [67]. Two members of the 
REP/GDI superfamily are found in the P. falciparum genome (PF3D7_1242800 and 
PF3D7_1038100) [70]. Further studies are required to determine if these proteins function as 
REPs or GDIs. 
 
Protein prenylation appears to be an essential use of isoprenoids in P. falciparum, as the parasite 
is sensitive to chemical inhibition of protein prenylation. Prenyltransferase inhibitors, major 
candidates for anticancer therapy, have shown potent antimalarial activity [71–73]. These 
include a number of peptidomimetics of the CaaX motif [71,74,75]. Additionally, certain 
monoterpenes have been shown to inhibit the growth of P. falciparum via inhibition of 
prenylation [38,76]. Limonene has been shown to inhibit the prenylation of 21 to 26 kDa 
proteins in mammalian cell culture and in vitro [77–79]. P. falciparum parasites treated with 
limonene are unable to progress from the ring to the trophozoite stage [76]. 
 
Feeding P. falciparum with labeled [3H]FPP and [3H]GPP identifies 21 to 24 kDa and 50 kDa 
prenylation target proteins that are differentially labeled by FPP and GPP [76]. Overall, it 
appears that the majority of prenylated proteins are small and preferentially geranylgeranylated 
in vivo, with the exception of a single 50 kDa protein [73]. Bioinformatic methods have been 
used to compile a list of predicted prenylation targets in P. falciparum [68]. These include a 
number of GTP-binding proteins, such as Rab2 and Rab11a. 
 
A number of studies have identified specific prenylation targets in P. falciparum. The 
localization of the small GTPase Rab7 to endosomal vesicles was shown to be prenylation 
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dependent. These vesicles are predicted to participate in endosomal trafficking [80]. The SNARE 
protein Ykt6.1 of P. falciparum (PfYkt6.1) has been shown to be a farnesyltransferase substrate 
in vitro, and its localization is disrupted when lacking a CaaX motif, suggesting it is also a 
prenylation target in vivo [81]. Similarly, the P. falciparum tyrosine phosphatase PfPRL is a 
substrate for farnesylation in vitro [82]. 
 
Inhibition of isoprenoid synthesis by fosmidomycin produces prenylation phenotypes in P. 
falciparum. Similar to metabolic labeling, probing for prenylation using a prenylation-specific 
antibody identifies proteins of 21 to 24 kDa and 50 kDa [37,77]. Prenylation of these targets is 
reduced in fosmidomycin-treated parasites, confirming that prenyl groups are indeed products of 
the MEP pathway. The P. falciparum geranylgeranyltransferase substrates PfRab5a and PfRab5c 
mislocalize from hemoglobin-containing vesicles to the host cell membrane upon treatment with 
fosmidomycin, and this mislocalization correlates with changes to food vacuole morphology and 
integrity. Proper localization is restored by geranylgeraniol supplementation [37]. 
Geranylgeraniol supplementation also substantially rescues growth inhibition by fosmidomycin, 
suggesting that geranylgeranylation may be the only essential form of protein prenylation in P. 
falciparum [33,36]. 
 
The group of compounds collectively known as vitamin E (tocopherols and tocotrienols) 
function as antioxidants and membrane stabilizers [83–85]. Recently, a metabolic labeling study 
using [3H]FPP and [3H]GPP identified de novo vitamin E synthesis by P. falciparum. Parasite 
growth is sensitive to usnic acid, an inhibitor of vitamin E biosynthesis. Growth is partially 
rescued by α-tocopherol, indicating that vitamin E synthesis is essential in malaria parasites [86]. 
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In plants, the homogentisic acid head group of vitamin E is synthesized via the shikimate 
pathway. This head group is then prenylated with phytyl diphosphate (20-carbon) or 
geranylgeranyl diphosphate to generate 2-methyl-6-phytyl-1,4-benzoquinol, the first committed 
intermediate for the synthesis of tocopherols and tocotrienols. This prenylation is catalyzed by 
homogentisate prenyltransferases (EC 2.5.1.115 and EC 2.5.1.116) [87]. As no obvious 
homogentisate prenyltransferase homologs exist in the P. falciparum genome, further work will 
be required to understand the mechanism by which the parasite synthesizes vitamin E. 
 
1.4.4 Sterols 
Sterols are 30-carbon isoprenoids that are ubiquitous among eukaryotes and are utilized for a 
variety of cellular functions. In particular, cholesterol is essential for membrane architecture in 
eukaryotes, and its production is tightly regulated [88,89]. Cholesterol is also a precursor for 
signaling molecules, such as sex steroids and mineralocorticoids in mammals and 
brassinosteroids in plants. Squalene synthase (EC 2.5.1.21) commits the isoprenoid pathway to 
sterol biosynthesis by converting two molecules of FPP to squalene; squalene then serves as the 
backbone for subsequent modifications [90]. 
 
The animal host synthesizes cholesterol de novo and is also able to import it from dietary sources 
[91]. Radioactive labeling experiments show no evidence for cholesterol biosynthesis in P. 
falciparum [92,93]. Homology searches do not identify a squalene synthase in the P. falciparum 
genome. Instead, Plasmodium spp. appear to obtain cholesterol from the host cell. P. knowlesi 
was shown to import host-derived 14C-labeled cholesterol, and cellular uptake by the host cell 
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itself was also increased upon infection with malaria parasites [94–96]. P. falciparum import of 
cholesterol has been studied within hepatocytes, a site of high cholesterol synthesis and parasite 
replication early in infection. Inhibition of host cell isoprenoid synthesis decreases sterol levels 
in the liver-stage parasite [97]. While cholesterol is essential for the maintenance of parasite 
membrane stability [98], these studies suggest that cholesterol synthesis does not occur in P. 
falciparum and is therefore not an essential function of de novo isoprenoid synthesis by the 
parasite. 
 
1.4.5 Carotenoids 
Carotenoids are 40-carbon isoprenoids derived from the condensation of two GGPP molecules 
by phytoene synthase (EC 2.5.1.32, PF3D7_0202700). Carotenoids are synthesized by plants and 
algae, as well as some bacteria and fungi. In plants, algae, and photosynthetic bacteria, 
carotenoids like carotene, lycopene, xanthophyll, and lutein function in photosynthesis and 
protect against free radical damage [99–103]. In plants, carotenoid synthesis occurs in the 
chloroplast [104,105]. Fungi also utilize carotenoid pigments for protection against free radicals 
[106,107]. In animals, which cannot synthesize carotenoids, dietary carotenoids are used for the 
synthesis of vitamin A [99]. An exception is found in insects that have acquired carotenoid 
synthesis from fungi through lateral gene transfer [108,109]. Commercial synthesis of 
carotenoids is of interest for their use as nutraceuticals, dietary supplements, and pigments 
[110,111]. 
 
Carotenoids have recently been detected in the intraerythrocytic stages of P. falciparum; 
schizonts contain the highest concentrations, indicating that carotenoid synthesis begins in the 
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ring stage and builds during the schizont stage [112]. Geranyl pyrophosphate serves as a 
substrate for carotenoid synthesis by phytoene synthase (EC 2.5.1.32, PF3D7_0202700). 
Phytoene is then converted to carotenoid products by phytoene desaturase (EC 1.3.99.30, locus 
unknown). P. falciparum is sensitive to the small molecular herbicide norflurazon, which inhibits 
phytoene desaturase. Norflurazon treatment causes an accumulation of phytoene and a decrease 
in carotenoid content. Inhibition by norflurazon can be partially rescued with lycopene [112]. 
While carotenoids serve important functions in plants, algae, bacteria, and fungi, it is not yet 
known what physiological role they play in Plasmodium. As in other organisms, they may play a 
role in the cellular response to oxidative stress. 
 
In plants, the phytohormone abscisic acid is also produced from carotenoid intermediates [113]. 
The Plasmodium relative and apicomplexan parasite, Toxoplasma gondii, has been shown to 
produce abscisic acid to control calcium signaling for processes like protein secretion and 
parasite egress. The abscisic acid response genes identified in T. gondii are conserved in P. 
falciparum, but it is not known whether P. falciparum also synthesizes this isoprenoid product. 
The route for abscisic acid synthesis from isoprenoid precursors in apicomplexan parasites 
remains unknown, as no clear biosynthetic route is readily identified bioinformatically [114]. 
 
1.4.6 Coenzyme Q (ubiquinone) 
In most eukaryotes, mitochondria are the site of energy generation through oxidative 
phosphorylation. Within the mitochrondrial matrix, the tricarboxylic acid cycle uses 2-carbon 
metabolites generated from the breakdown of glucose, amino acids, and fatty acids to produce 
high-energy electron carriers. In the inner mitochondrial membrane, the electron transport chain 
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uses high-energy electrons to harness energy in the form of ATP. In the mitochondria of asexual 
Plasmodium parasites, however, the electron transport chain is not a primary source of ATP and 
the parasite instead relies on glycolysis for most of its ATP production [115]. Indeed, little of the 
parasitic glucose supply is completely oxidized, and glucose is instead excreted as lactic acid 
[116,117]. Additionally, the parasites show relatively little oxygen consumption, consistent with 
minimal respiration [118]. However, ATP generation by the electron transport chain may be 
essential for parasite stages within the mosquito host, where extracellular glucose levels are 
lower and the parasite cannot rely solely on glycolysis for ATP production [119,120]. 
 
In asexual-stage parasites, the electron transport chain operates to provide a continuous supply of 
reduced coenzyme Q. Coenzyme Q, or ubiquinone, typically functions as an electron acceptor in 
the electron transport chain. It is maintained in asexual Plasmodium parasites as an electron 
acceptor for dihydroorotate dehydrogenase (DHODH) (EC 1.3.98.1, PF3D7_0603300), an 
enzyme required for pyrimidine synthesis. DHODH is essential for survival, as the parasite is 
incapable of pyrimidine salvage, and small molecules targeting DHODH have potent 
antimalarial activity [37,121–124]. Ubiquinone levels have been shown to peak at the beginning 
of schizogony and are sensitive to fosmidomycin treatment [34]. 
 
Synthesis of coenzyme Q requires the addition of an isoprenyl side chain to a benzoquinone ring. 
The parasite possesses an octaprenyl pyrophosphate synthase (EC 2.5.1.90, PF3D7_0202700) 
that is capable of synthesizing these side chains. This multifunctional enzyme produces 40-
carbon, 45-carbon, and 55-carbon isoprenoid products and has been shown to also have phytoene 
synthase activity [112,125]. The addition of these isoprenoids to 4-hydroxybenzoate is 
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performed by 4-hydroxybenzoate octaprenyltransferase (EC 2.5.1.39, PF3D7_0607500) 
[126,127]. Labeling studies in P. falciparum identify coenzyme Q isoforms coenzyme Q8 and 
Q9, which have 8 and 9 isoprene units (40-carbon and 45-carbon), respectively, in their side 
chains [128,129]. Incorporation of labeled FPP results in the detection of coenzyme Q8, and 
incorporation of labeled GGPP detects coenzyme Q9 [128]. In another study using labeled p-
hydrobenzoic acid, coenzyme Q8 was found to be the dominant form of coenzyme Q [129]. 
 
Nerolidol, a sesquiterpene alcohol, was found to inhibit the synthesis of the isoprenyl side chain 
destined for coenzyme Q, likely because of its structural similarity to FPP. Treatment with 
nerolidol inhibits the intraerythrocytic development of P. falciparum [125,128]. 
 
1.4.7 Dolichols 
Dolichols are long-chain hydrocarbon compounds made of various numbers of isoprene units. In 
the form of dolichyl phosphate or pyrophosphate, dolichols are essential for the transfer of sugars 
onto proteins, i.e., dolichylation, O-linked glycosylation, N-linked glycosylation, and the 
production of glycophosphatidylinositol (GPI) anchors, which are essential for successful 
infection [130]. 
 
Multiple studies have demonstrated the presence of dolichols and their intermediates in P. 
falciparum, specifically, those composed of 11 and 12 isoprene units (55 and 60 carbons). 
Labeling experiments demonstrate that these dolichols are formed from FPP and GPP, 
respectively [131,132]. As expected, dolichol synthesis is also sensitive to fosmidomycin 
treatment [35]. 
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Dolichyl pyrophosphate is produced from IPP by a polyprenol reductase (EC 1.3.1.94) and from 
GGPP via a dehydrodolichol pyrophosphate intermediate. Dolichyl pyrophosphate is then 
converted to dolichyl phosphate by dolichyldiphosphatase (EC 3.6.1.43). Dolichyl phosphate is 
utilized for glycosylation and synthesis of GPI anchors. P. falciparum possesses homologs of 
both polyprenol reductase (PF3D7_1455900) and dolichyldiphosphatase (PF3D7_0805600). 
 
Posttranslational addition of dolichols to proteins has been demonstrated in P. falciparum. 
Labeling using [3H]FPP and [3H]GGPP identified a dolichol with 11 isoprene units attached to 
21 to 28 kDa protein(s). The target proteins and enzyme(s) responsible for dolichylation of 
proteins in P. falciparum remain unknown [132]. 
 
P. falciparum synthesizes GPI anchors for protein modification [133]. The parasite is sensitive to 
known inhibitors of GPI synthesis, such as the mannose analogue 2-deoxyglucose [134,135]. 
Studies have identified a number of parasite proteins as targets for GPI addition, including 
merozoite surface antigens, a serine protease, and a heat shock 70 protein [136,137]. Merozoite 
surface antigens appear to be the primary targets of GPI anchor addition and are of great interest 
as antigens for vaccine development [138]. The enzyme GPI1 (EC 2.4.1.198, PF3D7_0618900) 
transfers N-acetylglucosamine to phosphatidylinositol in GPI biosynthesis. The P. falciparum 
GPI1 homolog was shown to complement a yeast gpi1 mutant, confirming its function [139]. 
Dolichol phosphate mannose synthase (EC 2.4.1.83, PF3D7_1141600) catalyzes the addition of 
sugar moieties in both GPI anchor glycosylations and N-linked glycosylations. The P. 
falciparum enzyme has been shown to be of a novel clade distinct from animal or yeast synthases 
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of the same type [140]. 
 
While GPI anchors appear to constitute most of the glycosylation in P. falciparum, there is also 
evidence for O- and N-linked glycosylation of proteins [141–143]. The presence of N-linked 
glycosylation has long been debated [144,145]. However, the parasite is sensitive to 
tunicamycin, an inhibitor of N-linked glycosylation [143], and parasite proteins have been shown 
to be capable substrates of N-linked glycosylation when expressed in heterologous systems 
[146]. 
 
1.5 GLYCOLYSIS AND PHOSPHOFRUCTOKINASE IN 
MALARIA PARASITES 
 
Isoprenoid synthesis via the MEP pathway is one of many of the anabolic fates of glucose and 
begins with the import of two glycolytic metabolites, phosphoenolpyruvate (PEP) and 
dihydroxyacetone phosphate (DHAP), into the apicoplast. Two apicoplast transporters, PfiTPT 
(PF3D7_0530200) and PfoTPT (PF3D7_0508300), have been found to be responsible for import 
of PEP and DHAP into the organelle [147,148] (Figure 2C). Within the apicoplast, PEP and 
DHAP are converted into the DXS substrates pyruvate and glyceraldehyde 3-phosphate by 
apicoplast-localized pyruvate kinase (PK, PF3D7_1037100) [149] and triosephosphate isomerase 
(TPI) [52], respectively. 
 
It has been established that Plasmodium parasites are ravenous consumers of glucose. Infected 
erythrocytes import nearly 100-fold more glucose than uninfected erythrocytes [150–152]. The 
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parasite is able to import glucose from the host cell via at least one hexose transporter 
(PF3D7_0204700) [153]. As it is expected that host (erythrocyte) glucose is readily 
phosphorylated to glucose 6-phosphate (glu6P), the parasite may employ a phosphatase to 
convert glu6P to glucose for import [115,154]. 
 
In the intraerythrocytic asexual stage parasite forms, the parasite relies on anaerobic glycolysis as 
the primary source of ATP [155]. As previously mentioned, only a small proportion of the 
parasite glucose is oxidized [116,117] and the parasite shows relatively little oxygen 
consumption, consistent with a lack of aerobic respiration for ATP generation [118]. Most 
parasite glucose is converted to and excreted as lactate [119,156]. Labeling studies confirm that 
flux of glucose into the TCA cycle is low during the asexual stages, but increases in the 
gametocyte (sexual) stages of the parasite lifecycle [157]. 
 
The dependence of P. falciparum on glucose is underscored by the parasite’s lack of 
gluconeogenesis. Many organisms, including the related apicomplexan T. gondii, metabolize 
other carbon sources (acetate, amino acids, etc.) and convert them to glucose via 
gluconeogenesis [158]. Recent work has shown that T. gondii regulates constitutive expression 
of gluconeogenic enzymes to fine-tune its metabolism [158]. Notably, the P. falciparum genome 
does not appear to encode a fructose bisphosphatase (FBPase), an enzyme essential for 
gluconeogenesis [159]. However, early labeling studies indicate that Plasmodium parasites have 
a limited capacity to utilize metabolites such as pyruvate, glutamate, and lactate [160–162].  
 
The parasite maintains and expresses all the canonical enzymes of glycolysis (Figure 3) 
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[159,163]. Imported glucose is converted to glucose 6-phosphate by hexokinase (EC 2.7.1.1, 
PF3D7_0624000). As glucose 6-phosphate is also shunted into the pentose phosphate pathway 
and fructose 6-phosphate is used for the synthesis of N-glycans and dolichols, the glycolytic 
enzyme phosphofructokinase (PFK) (EC 2.7.1.11, PF3D7_0915400) catalyzes the first 
committed enzymatic step of glycolysis [164].  
 
Studies of glycolysis in other organisms have identified and established the enzymatic step 
catalyzed by PFK as a key regulatory step of glycolysis. ATP-utilizing PFKs (such as the human 
enzyme) are usually allosterically inhibited by ATP and citrate. This inhibition is reversed by the 
allosteric activators AMP, ADP, and fructose 2,6-bisphosphate [165]. PFKs are often comprised 
of alpha and beta domains, with the alpha domain usually considered regulatory and the beta 
domain catalytic [165–168]. 
 
PPi-utilizing PFKs have been found in photosynthetic plants, some bacteria, and the parasitic 
amoeba Entamoeba histolytica, with many of these organisms possessing both a PPi- and ATP-
PFK [169–172]. PPi-PFK regulation appears to differ in some aspects when compared to ATP-
PFKs. PPi-PFKs are generally insensitive to regulation by ATP, ADP, and AMP. Plant PPi-PFKs 
are sensitive to regulation by fructose 2,6-bisphosphate [173]. Some PPi-PFKs have been shown 
to be regulated via differential oligomerization of their subunits [174,175]. The PFKs of only a 
few apicomplexans have been studied, although sequence alignments have shown that they are 
related to plant PPi-PFKs [176]. PFK from the rodent parasite Plasmodium berghei is ATP-
dependent [177]. However, T. gondii and Crytosporidium possess PPi-PFKs, neither of which are 
activated by fructose 2,6-bisphosphate [178,179]. P. falciparum possess two PFK-encoding 
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ORFs, designated by their chromosome locations as PfPFK9 (PF3D7_0915400) and PfPFK11 
(PF3D7_1128300). It appears that PfPFK9 is the main PFK for asexual stage parasites, as 
PfPFK11 is expressed primarily in gametocytes [163] and has been speculated to be missing key 
residues for catalysis [176]. One study, which measured PFK activity from parasite cell lysate, 
found PfPFK9 to be ATP-utilizing, despite its overall homology to PPi-PFKs. PfPFK9 activity 
from lysate was sensitive to regulation by ADP, but not citrate, fructose 2,6-bisphosphate, or 
PEP [176]. However, this work was only performed on the beta subunit, as full-length 
recombinant PfPFK9 could not be purified. Further studies are required to understand the 
regulation and behavior of the full-length PfPFK9 enzyme and the possible regulatory role of the 
PfPFK9 alpha subunit. 
 
1.6 THE HALOACID DEHALOGENASE-LIKE HYDROLASE 
(HAD) PROTEIN FAMILY 
 
Given its obvious importance for energy and the synthesis of essential biomolecules, microbes 
have evolved many ways to regulate sugar metabolism. One such set of regulators is the haloacid 
dehalogenase-like hydrolase (HAD) superfamily of enzymes. The HAD superfamily (Pfam 
PF08282, Interpro IPR023214) [180,181] is comprised of thousands of proteins found in 
organisms in all three kingdoms of life [182]. The large size of the HAD superfamily has 
allowed its members to evolve diverse functions [183]. While HADs perform a variety of 
chemical reactions and participate in many biological processes, they share similar domain 
organization and structural features, such as a Rossmann-like fold and active site aspartate 
nucleophile [182]. Structurally, HAD proteins are characterized by the insertion of various cap 
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domains, which vary in size and insert location in the protein sequence. C0 caps are small and 
relatively simple, while C1 and C2 caps are larger [183].  
 
The HAD protein family is dominated by phosphatases (>75%) [183], including the Cof-like 
hydrolase subfamily of phosphatases (IPR000150) [181]. Modification of the C2 cap has allowed 
for diverse substrate utilization within this group. Most members of this subfamily are found in 
bacteria and, similar to other members of the HAD superfamily, remain uncharacterized. 
However, studies have uncovered the functions of a number of bacterial members of this 
subfamily. A genome-wide screen for HAD enzyme activity in E. coli revealed that members of 
this subfamily (YidA, YbhA, YigL, YbiV, YbjI) possess broad sugar phosphatase activity, with 
substrates participating in key metabolic pathways such as glycolysis and the pentose phosphate 
pathway. Notably, most of these HADs possess a relatively low affinity (Km > 1 mM) for their 
substrate(s), drawing into question whether or how this substrate utilization is physiologically 
relevant [184].  
 
While a number of bacterial Cof-like hydrolases have been studied, the expansion of the HAD 
protein family in bacteria and the overlapping substrate profiles of its members have presented a 
challenge in determining their in vivo functions. E. coli YidA was identified as a potential 
positive regulator in a screen for increased lycopene production [185]. Bacterial strains with 
attenuated YbiV have been patented for increased amino acid production [186]. A 
bioengineering study showed that YidA and YbiV expression in E. coli resulted in increased 
ribose production, supporting these proteins’ role in sugar phosphate metabolism [187]. YbhA is 
a member of the molybdate transport operon in E. coli [188]. YigL expression has been shown to 
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be repressed under aneroebic conditions and increased under phosphosugar stress [189,190]. 
While further studies are require to confidently define the in vivo function of these bacterial 
HADs, collective evidence points to their function as metabolic regulators through hydrolysis of 
sugar phosphate substrates. 
 
Given their expansion in bacteria, it is perhaps not surprising that HAD family members are 
found in organisms that possess a plastid organelle (plants and apicomplexan parasites). HAD 
proteins that have been characterized from plants have functions similar to their bacterial 
homologs. The Cof-like hydrolase YbeY from Arabidopsis thaliana functions as a chloroplast 
endoribonuclease [191] and PvNTD1 from the French bean Phaseolus vulgaris is a nucleotidase 
[192]. The sugar phosphatases AtGpp1, AtGpp2, and AtSgpp from A. thaliana show the broad 
substrate specificity and low substrate affinity (Km > 1 mM) seen in bacterial HADs and are 
hypothesized to be involved in stress response and phosphate homeostasis [193,194]. 
 
1.7 AIM AND SCOPE OF THE DISSERTATION 
 
Similar to what has been proposed in bacteria and other systems [182], the domain organization 
and broad substrate utilization of the HAD superfamily lends itself to adaptation to diverse 
metabolic niches. One such metabolic niche is that of P. falciparum, an obligate intracellular 
parasite dependent on constant glucose consumption for production of ATP and essential 
biomolecules, including isoprenoids. Despite the essentiality of this metabolism and the need to 
identify and characterize additional antimalarial targets, relatively little is known regarding 
metabolic regulation in the parasite.  
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We hypothesized that resistance to inhibition of isoprenoid synthesis would uncover novel 
regulators of this critical pathway. We utilize a forward genetics approach and the isoprenoid 
synthesis inhibitor FSM to identify the PfHADs, a class of novel regulators whose loss confers 
resistance to FSM. We provide the first characterization for this protein family in P. falciparum 
and elucidate the effects of its members on parasite metabolism, fitness, and drug tolerance.  
 
We also evaluated parasite survival following FSM treatment in clinical populations and find 
that there does not appear to be a genetic biomarker of recrudescence following FSM treatment 
failure. Together, this work expands our understanding of both metabolic regulation and drug 
resistance in a clinically important pathogen. 
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1.8 FIGURES  
 
Figure 1. Life cycle of Plasmodium falciparum.  
Infection begins with the injection of sporozoites into the host bloodstream by the bite of an 
Anopheles mosquito. Parasites multiply in the liver and are released back into the host 
bloodstream as merozoites, where they begin the intraerythrocytic developmental cycle (RBCs, 
red blood cells). Inside the erythrocyte, parasites grow into large trophozoites. They eventually 
divide to become multinucleate schizonts, which erupt from the host cell and reenter the blood as 
merozoites. A proportion of these blood-stage parasites become gametocytes and are taken up by 
the mosquito vector, where they complete sexual replication.  
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Figure 2. Synthesis of isoprenoid products in P. falciparum. 
Electron micrograph of a P. falciparum cell, with labels showing the red blood cell (RBC), 
nucleus (N), food vacuole (FV), and apicoplast (Ap). Scale bar represents 500 nm. (B) The P. 
falciparum apicoplast is the site of isoprenoid synthesis by the MEP pathway. It is surrounded by 
four membranes, indicative of secondary endosymbiotic origins. Scale bar represents 100 nm. 
(C) Isoprenoid products produced by P. falciparum. Abbreviations used: phosphoenol pyruvate 
(PEP), dihydroxyacetone phosophate (DHAP), pyruvate kinase (PK), triose phosphate isomerase 
(TPI), 1-deoxy-D-xylulose 5-phosphate synthase (DXS), 1-deoxy-D-xylulose 5-phosphate 
(DOXP), DOXP reductoisomerase (DXR), fosmidomycin (FSM), 2-C-methyl-D-erythriol 4-
phosphate (MEP), MEP cytidyltransferase (IspD), 4-diphosphocytidyl-2-C-methylerythritol 
(CDP-ME), CDP-ME kinase (IspE), 4-diphosphocytidyl-2-C-methylerythritol 2-phosphate 
(CDP-MEP), 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP), MEcPP synthase 
(IspF), (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), HMB-PP synthase (IspG), 
HMB-PP reductase (IspH), dimethylallyl pyrophosphate (DMAPP), isopentenyl pyrophosphate 
(IPP), isopentenyl pyrophosphate isomerase (IPPI), tRNA isopentenyltransferase (TIPT), tRNA 
methylthiolase (TMT), farnesyl pyrophosphate synthase (FPPS), bisphosphate (BisP), geranyl 
pyrophosphate (GPP), polyprenol reductase (PPR), farnesyl pyrophosphate (FPP), octaprenyl 
pyrophosphate synthase (OPPS), nerolidol (NER), farnesyl transferase (FTase), prenyltransferase 
inhibitors (PTI), geranylgeranyl transferase (GGTase), geranylgeranyl pyrophosphate (GGPP), 
phytoene synthase (PS), phytoene desaturase (PD), norflurazon (NOR), dolichyl pyrophosphate 
(dolichyl-PP), 2-methyl-6-phytyl-1,4-benzoquinol (MPBQ), and usnic acid (UA). 
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Figure 3. Enzymatic steps of glycolysis.  
Abbreviations used: HK, hexokinase; glu6P, glucose 6-phosphate; PGI, phosphoglucose 
isomerase; fru6P, fructose 6-phosphate; PFK, phosphofructokinase; FBP, fructose 1,6-
bisphosphate; ALD, aldoase; gly3P, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone 
phosphate; TPI, triose phosphate isomerase; PGK, phosphoglycerate kinase; 1,3BPG, 1,3-
bisphosphoglycerate; PGM, phosphoglycerate mutase; 3-PGA, 3-phosphoglyceric acid; ENO, 
enolase; 2-PGA, 2-phosphoglyceric acid, PK, pyruvate kinase, PEP, phosphoenolpyruvate, LDH, 
lactate dehydrogenase. 
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The sugar phosphatase PfHAD1 is a metabolic regulator in 
malaria parasites !! !
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2.1 ABSTRACT 
 
Isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway generates 
commercially important products and is a target for antimicrobial drug development. MEP 
pathway regulation is poorly understood in microorganisms. Here we employ a forward genetics 
approach to understand MEP pathway regulation in the malaria parasite, Plasmodium 
falciparum. The antimalarial fosmidomycin inhibits the MEP pathway enzyme deoxyxylulose 5-
phosphate reductoisomerase (DXR). Fosmidomycin-resistant P. falciparum are enriched for 
changes in the PF3D7_1033400 locus (hereafter referred to as PfHAD1), encoding a homologue 
of haloacid dehalogenase (HAD)-like sugar phosphatases. We describe the structural basis for 
loss-of-function PfHAD1 alleles and find that PfHAD1 dephosphorylates a variety of sugar 
phosphates, including glycolytic intermediates. Loss of PfHAD1 is required for fosmidomycin 
resistance. Parasites lacking PfHAD1 have increased MEP pathway metabolites, particularly the 
DXR substrate, deoxyxylulose 5-phosphate. PfHAD1 therefore controls substrate availability to 
the MEP pathway. Because PfHAD1 has homologs in plants and bacteria, other HAD proteins 
may be MEP pathway regulators. 
 
2.2 INTRODUCTION 
 
Isoprenoids are the largest and most diverse class of biomolecules [1]. Isoprenoids perform 
essential cellular functions such as respiration (ubiquinone) and membrane localization of 
proteins (prenylation). There is considerable commercial interest in the production of isoprenoid-
derived secondary metabolites as pharmaceuticals (for example, artemisinin and taxol) and 
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biofuels. Isoprenoids are synthesized from two five-carbon precursor molecules, isopentenyl 
pyrophosphate and its isomer, dimethylallyl pyrophosphate. Two metabolically and 
enzymatically distinct pathways exist for the synthesis of isopentenyl pyrophosphate and 
dimethylallyl pyrophosphate. Archaea, fungi and animals utilize a mevalonate-dependent 
pathway. In contrast, plastid-containing eukaryotes and most bacteria use an alternate route that 
proceeds through the key metabolite methylerythritol phosphate (MEP) (Figure 1) [2]. 
 
In the MEP pathway, two glycolytic intermediates (glyceraldehyde 3-phosphate (gly3P) and 
pyruvate) are combined to generate deoxyxylulose 5-phosphate (DOXP) by DOXP synthase 
(DXS; E.C. 2.2.1.7). DOXP is subsequently reduced and isomerized to MEP in the first 
dedicated step of the MEP pathway, catalyzed by deoxyxylulose phosphate reductoisomerase 
(DXR; E.C. 1.1.1.267). These first two steps of the MEP pathway are rate limiting in MEP-
dependent isoprenoid biosynthesis [3–5]. Organisms may increase flux through the MEP 
pathway by increasing DXS and DXR production, or by increasing substrate availability for 
these enzymes [6]. 
 
The phosphonic acid antibiotic, fosmidomycin (FSM), competitively inhibits DXR in vitro [7]. 
Metabolic profiling of FSM-treated cells confirms that FSM inhibits MEP pathway metabolism 
within cells [8]. The growth effects of FSM are rescued by supplementation with downstream 
isoprenoids, confirming that the biological effects of FSM are mediated through isoprenoid 
biosynthesis inhibition [8–10]. These studies validate the use of FSM as a specific tool to probe 
the MEP pathway. Because chlorophyll biosynthesis requires MEP pathway-derived isoprenoids, 
FSM is a herbicide [11]. FSM resistance in the model plant, Arabidopsis thaliana, has been used 
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to gain insight into MEP pathway regulation, and these studies have revealed post-transcriptional 
control of MEP pathway enzymes through an RNA metabolism protein (Rif10) [12]. 
 
In contrast, there is little understanding of the MEP pathway regulation in non-model organisms. 
The malaria parasite, Plasmodium falciparum, depends on de novo isoprenoid biosynthesis 
through the MEP pathway [9,13]. Since drug resistance is one of the greatest challenges in 
malaria eradication, the MEP pathway is an attractive parasite-specific target for antimalarial 
drug development. As in plants, the MEP pathway in apicomplexan parasites is localized to a 
plastid-like organelle. The parasite organelle is called the apicoplast [14], and isoprenoid 
synthesis may be the only required function of the apicoplast during blood-stage development 
[9,10]. Though not photosynthetic, the apicoplast shares a similar endosymbiotic origin with the 
plant chloroplast [15]. This uniquely positions P. falciparum in studies of MEP pathway biology 
as a plastid-containing eukaryote that is also a globally important pathogen. 
 
Here, to gain insight into how malaria parasites regulate isoprenoid precursor synthesis, we 
screen for P. falciparum strains able to survive MEP pathway inhibition by FSM. We uncover 
the first regulator of MEP pathway metabolism in malaria parasites, PF3D7_1467300 (PfHAD1), 
a member of the haloacid dehalogenase (HAD) superfamily. Using detailed structural and 
biochemical studies, we show that FSM resistance is correlated with changes in PfHAD1 that 
ablate function. Further, we find that PfHAD1 is a cytosolic sugar phosphatase that 
dephosphorylates the intermediates of glycolysis. Loss of PfHAD1 function increases substrate 
availability to the MEP pathway and increases levels of isoprenoid precursors, thus conferring 
FSM resistance. Since close homologs of PfHAD1 are present in other MEP pathway-containing 
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organisms, sugar phosphatases may represent a common strategy to regulate MEP pathway flux. 
 
2.3 METHODS 
 
2.3.1 Reagents 
Reagents were purchased from Sigma-Aldrich unless otherwise indicated. 
 
2.3.2 Maintenance of P. falciparum cultures 
The P. falciparum strain used for FSM selection is derived from genome reference strain 3D7 
[16]. The ACPL-GFP (expresses apicoplast-targeted GFP) strain used for immunofluorescence 
microscopy is described in Waller, et al. [17]. 3D7 and ACPL-GFP were obtained from the 
Malaria Research and Reference Reagent Resource Center (strains MRA-102 and MRA-568, 
respectively, MR4, ATCC, Manassas, Virginia). Unless otherwise stated, P. falciparum strains 
were cultured at 37!°C in a 2% suspension of human erythrocytes in RPMI-1640 medium 
(Sigma-Aldrich, SKU R4130) supplemented with 27!mM sodium bicarbonate, 11!mM glucose, 
5!mM HEPES, 1!mM sodium pyruvate, 0.37!mM hypoxanthine, 0.01!mM thymidine, 10!µg/ml 
gentamycin and 0.5% albumax (Life Technologies) in a 5% O2/5% CO2/90% N2 atmosphere, as 
previously described [8,18]. Culture growth was monitored by microscopic analysis of Giemsa-
stained blood smears. 
 
2.3.3 Generation of FSMR P. falciparum 
A 3D7 parental strain was cloned by limiting dilution and used as the parental strain for all 
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selections. Independent selections are defined as those cultures that were cultured in separate 
wells before and during selection. The parental strain was at 4% parasitemia in 4 ml cultures at 
the initiation of FSM selection. Parasites were initially cultured in media containing 0.5–1!µM 
FSM and gradually scaled to final concentrations of 2–4!µM FSM. The following FSMR strains 
were cloned by limiting dilution: E1, D6, MK1, D3, AM1 and AM2. 
 
2.3.4 Quantification of FSM resistance 
Asynchronous P. falciparum cultures were diluted to 1% parasitemia and were treated with FSM 
(Life Technologies) at concentrations ranging from 0.025–500!µM. Growth inhibition assays 
were performed in opaque 96-well plates at 100!µl culture volume. After 3 days, parasite growth 
was quantified by measuring DNA content using Picogreen (Life Technologies), as previously 
described [19]. Picogreen fluorescence was measured on a FLUOstar Omega microplate reader 
(BMG Labtech) at 485!nm excitation and 528!nm emission. IC50 values were calculated by 
nonlinear regression analysis using GraphPad Prism software. 
 
2.3.5 Whole genome sequencing and variant discovery 
Genomic DNA was isolated from P. falciparum cells by a standard phenol-chloroform extraction 
and ethanol precipitation protocol [20]. Sequencing libraries were prepared and sequenced by the 
Washington University Genome Technology Access Center (GTAC). Briefly, 5!µg of genomic 
DNA was sheared to an average size of 175!bp. Fragments were end repaired and an ‘A’ base 
was added to the 3′ end. Adapters containing index sequences were ligated to the fragments. 
Resulting libraries were sequenced on an Illumina HiSeq 2000 to obtain 101!bp paired end reads. 
Bioinformatic analyses were performed by GTAC. Reads were not merged, but were aligned to 
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the P. falciparum reference genome using Novoalign (Novocraft Technologies). PCR duplicates 
were removed using Picard and variants were analyzed using SAMtools. SNPs were called if 
present in >50% of the reads. For all samples, at least 75% of coding regions were sequenced at 
≥5X coverage. All whole genome sequencing data is available in the NCBI BioProject database 
and Sequence Read Archive. 
 
2.3.6 Sanger sequencing of PfHAD1 
The region of interest was amplified from P. falciparum genomic DNA using the following 
gene-specific primers: 5′-GGTTCAAGGGTGATAGATAGGA-3′, 5′-
CGAAGGTCCAACATAAGCAG-3′, 5′-ATGCACGAAATTGTAGATAAGAATG-3′, 5′-
AATTCATGTATCTCCATTTTCAAGTC-3′ and 5′-GATCACTACATTTTGGACGTACAC-3′. 
Purified PCR products were sequenced by the Washington University Protein and Nucleic Acid 
Laboratory using BigDye Terminator v3.1 Cycle Sequencing reagents (Life Technologies). 
Chromatogram files were analyzed using DNAStar SeqMan software. Representative traces for 
all strains are available through the NCBI Trace Archive. 
 
2.3.7 Recombinant expression and purification of PfHAD1 variants 
All PfHAD1 (PlasmoDB ID PF3D7_1033400) alleles were amplified from P. falciparum 
genomic DNA using the following primers: 5′–
CTCACCACCACCACCACCATATGCACGAAATTGTAGATAAGAA-3′ and 5′- 
ATCCTATCTTACTCACTTATATGTCACAGAATGTCTTCA-3′. The PCR product was 
cloned by ligation-independent cloning into vector BG1861 [21], which introduces an N-terminal 
6xHis tag and the construct was verified by Sanger sequencing. BG1861:6xHis-PfHAD1 was 
 56 
transformed into BL21(DE3)pLysS Escherichia coli cells (Life Technologies). Following 
induction with isopropyl-β-D-thiogalactoside, cells were collected by centrifugation and stored at 
−20!°C. Pellets were resuspended in lysis buffer containing 10!mM Tris HCl (pH 7.5), 20!mM 
imidazole, 01!mM MgCl2, 01!mM dithiothreitol, 1!mg/ml lysozyme, 100!U benzonase and 
Complete Mini EDTA-free protease inhibitor tablets (Roche Applied Science). 6xHis-PfHAD1 
was bound to nickel agarose beads (Gold Biotechnology), eluted in 300!mM imidazole, 20!mM 
Tris HCl (pH 7.5) and 150!mM NaCl, and dialyzed in buffer lacking imidazole before analysis. 
Protein was flash frozen and stored at −80!°C. 
 
2.3.8 Crystallization and structure determination 
PfHAD1 was further purified by gel chromatography using a HiLoad 16/600 Superdex 200!pg 
column (GE Healthcare) equilibrated with 10!mM Tris (pH 8.0), 150!mM NaCl and 5!mM 
dithiothreitol. The fractions containing PfHAD1 were pooled and concentrated to 20!mg/ml 
using a centrifugal filter. 
 
Crystals of PfHAD1 were obtained by vapor diffusion using hanging drops equilibrated at 18!°C 
against 500!µl of a reservoir containing 0.1!M HEPES (pH 7.5) and 20–25% PEG 8000. Crystals 
were cryo-protected with 0.1!M HEPES (pH 7.5) and 30% PEG 8000 before flash-freezing under 
liquid nitrogen for data collection. X-ray data were collected from a single crystal using a 
wavelength of 1!Å at synchrotron beamline 4.2.2 of the Advanced Light Source in Berkeley, CA. 
Data were processed with XDS [22] and the coordinates from PDB 2B30 were used as a search 
model for phase determination by molecular replacement using PHENIX [23]. Rigid-body 
refinement followed by automatic model rebuilding were performed in PHENIX [23]. 
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Subsequent iterated manual building/rebuilding and refinement of models were performed using 
Coot [24] and PHENIX [23], respectively. The structure validation server MolProbity [25] was 
used to monitor refinement. The final refined model results in a Ramachandran plot with 96.75% 
of residues in the favored region and 3.25% in the allowed region. A complete summary of the 
final crystallographic refinement statistics are given in Table 1 and a stereo image of a 
representative region of the electron density map is shown in Supplementary Figure 5. Figures 
were prepared using PyMOL Molecular Graphics System, Version 0.99rc6, Schrödinger, LLC. 
Structure data is deposited in the RSCB Protein Structure Database. 
 
2.3.9 pTEOE110:PfHAD1-GFP plasmid construction 
The construct used to express PfHAD1 in FSMR strains, pTEOE110, was a gift from Daniel 
Goldberg (Washington University, St. Louis). The construct contains the heat shock protein 110 
(Hsp110, PF3D7_0708800) 5′ UTR [26] and a carboxyl-terminal GFP tag. The human 
dihydrofolate reductase selectable marker confers resistance to WR92210. These sites are 
flanked by inverted terminal repeats [27] that allow for integration of the segment containing the 
Hsp110 5′ UTR, the gene of interest, GFP and human dihydrofolate reductase into the genome, 
facilitated by a co-expression from a plasmid encoding the piggyBac transposase (pHTH, 
MRA912, MR4, ATCC, Manassas, Virginia). 
 
PfHAD1 was amplified using the following primers: 5′-
CATGCTCGAGATGCACGAAATTGTAGATAAGAA-3′ and 5′-
CATGCCTAGGTATGTCACAGAATGTCTTCAAG-3′. The resulting PCR product was cloned 
into the XhoI and AvrII sites in pTEOE110 to generate pTEOE:PfHAD1. Successful insertion 
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was confirmed by colony PCR and Sanger sequencing. 
 
2.3.10 P. falciparum transfection 
Seventy-five micrograms of each plasmid (pTEOE110: PfHAD1 and pHTH) was combined, 
precipitated and resuspended in 400!µl Cytomix (120!mM KCl, 0.15!mM CaCl2, 2!mM EGTA, 
5!mM MgCl2, 10!mM K2HPO4, 25!mM HEPES, pH 7.6). 
 
A 4-ml culture of FSMR strain AM1 was synchronized by treatment with 5% sorbitol to obtain 
ring-stage parasites at >4% parasitemia. Cells were washed with Cytomix and resuspended in 
400!µl DNA/Cytomix solution. Cells were electroporated using a Biorad GenePulser II 
electroporator set to 950!µF capacitance and 0.31!kV. Transfected cells were washed with media 
and returned to the previously described culture conditions. Culture media was replaced daily for 
one week. Cultures were maintained under selection with 5!nM WR92210 (Jacobus 
Pharmaceutical Co.) beginning 48!h post transfection. Parasite growth was monitored by 
microscopy. Successful transfectants were cloned by limiting dilution. The resulting strain was 
verified by microscopy, western blot and sequencing of the endogenous PfHAD1 locus. 
 
2.3.11 Generation of PfHAD1 polyclonal antisera 
PfHAD1 rabbit polyclonal antisera was produced by Cocalico Biologicals (Reamston, PA) using 
their standard protocol. Purified recombinant 6XHis-PfHAD1 was used as an antigen. Titermax 
was used as an adjuvant. 
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2.3.12 Immunoblotting 
P. falciparum cells were obtained by treatment of infected erythrocytes with 0.1% saponin. 
Lysates were separated on a polyacrylamide gel and transferred to polyvinylidene fluoride 
membrane. For the detection of PfHAD1, the membrane was blocked and probed with 1:20,000 
anti-PfHAD1 polyclonal antisera (Cocalico Biologicals), followed by 1:20,000 HRP-conjugated 
goat anti-rabbit IgG polyclonal antibody (Life Technologies). The membrane was stripped by 
treatment with 200!mM glycine, 0.1% sodium dodecyl sulfate, 1% Tween-20 (pH 2.2) and 
reprobed with 1:5,000 anti-heat shock protein 70 antibody (Agrisera) as a loading control. 
 
2.3.13 Enzymatic assays 
All assays were performed in clear 96-well half-area plates using a FLUOstar Omega microplate 
reader (BMG Labtech) at 37!°C. Reaction rates were determined using GraphPad Prism software. 
 
Phosphatase activity was measured using the substrate pNPP (New England Biolabs). Reactions 
were performed in 50!µl volumes with 10!mM pNPP, 50!mM Tris HCl (pH 7.5), 5!mM MgCl2 
and 0.5!mM MnCl2. Reactions contained 2!µg purified recombinant enzyme. Para-nitrophenyl 
production was quantified by absorbance at 405!nm. 
 
Enzyme activity against phosphorylated sugar substrates was measured using the Enzchek 
Phosphate Assay Kit (Life Technologies) according to supplier instructions. Each assay 
contained 200!ng recombinant purified enzyme and 1!mM substrate. Substrates were purchased 
from Sigma-Aldrich, except for DOXP and MEP (Echelon Biosciences), fructose 1-phosphate 
(Santa Cruz Biotechnology) and FSM (Life Technologies). 
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For the determination of kinetic parameters, assays were performed using 50!ng 6XHis-PfHAD1 
and 0.03–12!mM substrate. Data were fit to Michaelis–Menten curves using GraphPad Prism 
software. 
 
2.3.14 Microscopy 
For immunofluorescence microscopy, cells at ~10% parasitemia were fixed in 4% 
paraformaldehyde in PBS. Fixed cells were washed with 50!mM ammonium chloride, 
permeabilized by treatment with 0.075% NP-40 in PBS and blocked using 2% bovine serum 
albumin. Cells were incubated with the following antibody dilutions: 1:10,000 rabbit polyclonal 
anti- PfHAD1 (described above) and 1:1,000 mouse monoclonal anti-GFP (Life Technologies 
#A11120) for the detection of GFP in the ACPL-GFP strain (MRA-568). Hoechst 33258 (Life 
Technologies) was used as a nuclear counterstain. Secondary antibodies used were 1:200 
dilutions of Alexa Fluor 568 goat anti-rabbit IgG (Life Technologies #A11011) and Alexa Fluor 
488 goat anti-mouse IgG (Life Technologies #A11029). Images were obtained on an Olympus 
Fluoview FV1000 confocal microscope. 
 
For imaging of live cells, cells were stained with 10!ng/µl Hoechst 33258 for 10!min and 
mounted under coverslips on polysine adhesion slides. Cells were visualized on an Olympus 
BH8 microscope at room temperature for no longer than 15!min. 
 
For all microscopy, minimal adjustments in brightness and contrast were applied equally to all 
images. 
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2.3.15 Sample preparation for mass spectrometry analysis 
P. falciparum were cultured in 75!ml volumes in 150 × 25!mm tissue culture dishes at 4% 
hematocrit until >6% parasitemia was reached. Cultures were synchronized by one to two 
treatments with 5% sorbitol until >8% parasitemia and >75% of parasites were in ring-stage 
growth. Once these criteria were met, 75!ml cultures were split into 3 × 25!ml samples. Ring-
stage cultures were then treated +/− 5!µM FSM (Life Technologies) for either 0 or 10!h. At each 
time point, parasite-infected erythrocytes were lysed with 0.1% saponin, the parasite pellets 
washed with PBS and the pellets stored at −80!°C until extraction. Samples were extracted and 
analyzed by liquid chromatography-mass spectrometry as previously described [8]. Briefly, 
samples were extracted in chloroform, methanol and acetonitrile (2:1:1, v/v/v) and homogenized. 
Water was added and the sample was homogenized again. The polar phase was separated by 
centrifugation, lyophilized and resuspended in water for analysis. 
 
2.3.16 Quantitative PCR of PfDXS and PfDXR transcripts 
Infected erythrocytes were lysed by treatment with 0.1% saponin. Parasite pellets were stored at 
−80!°C until extraction. Total RNA was isolated using the Ambion Purelink RNA Mini kit (Life 
Technologies) according to the supplier’s instructions. After the first wash step, samples 
underwent an on-column DNase treatment (Qiagen) for 30!min. RNA was eluted in RNase-free 
water, quantified and stored at −80!°C until further use. At least 100!ng of RNA was used to 
synthesize cDNA using the Quantitect Reverse Transcription kit (Qiagen), according to the 
supplier’s instructions. 
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Amplification of cDNA was performed using an Applied Biosystems Fast RT PCR System and 
Applied Biosystems Fast SYBR Green PCR Master Mix (Life Technologies). PfDXS (PlasmoDB 
ID PF3D7_1337200) was amplified using the following primers: 5′-
AACGTGGATAAAGTACACATTGC-3′ and 5′-TGATATACTTACGGCATTTGTTGG-3′ and 
PfDXR (PlasmoDB ID PF3D7_1467300) was amplified using the following primers; 5′- 
ACATGGCCTGATAGAATAAAAACA-3′ and 5′- TTCATTTGACGCATTTAGTACAGTT-3′ 
(Sigma-Aldrich). The gene encoding beta tubulin (PF3D7_1008700) was used as a control and 
was amplified using the following primers: 5′-ATCCCATTCCCACGTTTACATT-3′ and 5′-
TCCTTTGTGGACATTCTTCCTC-3′ (Eurofins MWG Operon). Standard curves were used to 
verify primer efficiency (r2 >0.97, E >80%). In addition to SYBR Master Mix, reactions 
contained 10!ng cDNA and 300!nM of each primer. All reactions were performed in MicroAmp 
Fast Optical 96-well plates (Life Technologies). 
 
Thermocycling parameters were as follows: 95!°C for 30!s, 40 cycles of 95!°C for 3!s and 60!°C 
for 30!s. Agarose gel electrophoresis, as well as melt-curve analysis, with temperatures ranging 
from 60 to 95!°C, confirms production of a single product from each primer pair. Controls 
lacking either reverse transcriptase or template produced no significant signals. Ct values were 
generated using 7500 Fast System software (Applied Biosystems). 
 
Relative PfDXS and PfDXR expression levels were calculated using the ΔΔCt method. ΔCt 
values were calculated by subtracting the Ct of the reference gene (beta tubulin) from the target 
gene (PfDXS or PfDXR). ΔΔCt values were then calculated by normalizing to the ΔCt of the 
parental sample. Relative expression changes were calculated as 2−ΔΔCt. 
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2.4 RESULTS 
 
2.4.1 Selection of FSM-resistant (FSMR) P. falciparum 
The MEP pathway is essential for the synthesis of isoprenoids in P. falciparum [8,9,13]. The 
phosphonic acid antibiotic FSM specifically inhibits this pathway, primarily via competitive 
inhibition of PfDXR [7] (Figure 1). A FSM-sensitive 3D7 parental strain was subjected to FSM 
treatment at ~two to fourfold the wild-type half maximal inhibitory concentration (IC50; Figure 
2A, Supplementary Table 1). This selection generated 20 independent FSMR strains of P. 
falciparum with increased IC50s for FSM ranging from 1.5–8.1!µM (Figure 2B, Supplementary 
Table 1). FSMR strains are also resistant to the related antibiotic, FR-900098 [28] 
(Supplementary Figure 1). 
 
FSM resistance has been associated with copy number variations in the FSM target, PfDXR 
(PF3D7_1467300) [29]. However, copy number changes that result in drug resistance often 
revert when selection is relieved [30]. To discourage PfDXR copy number variants, FSMR strains 
were cycled on and off drug treatment. All strains maintain their resistance phenotype after 
prolonged growth without FSM, and no changes in PfDXR transcript levels are observed in 
FSMR strains (Supplementary Figure 2). 
 
To control for genetic changes arising from prolonged culture or culture stresses, we performed 
control selections in which the parental 3D7 strain was cultured continuously for >3 months and, 
in some cases, was subjected to culture stresses such as depleted or incomplete media and aged 
 64 
(>90 days) erythrocytes. These strains retain their FSM sensitivity as measured by IC50 (mean 
IC50 1.8 ± 0.4!µM). 
 
2.4.2 FSMR strains are enriched for genetic changes in PfHAD1 
To uncover genetic changes correlated with FSM resistance, we genotyped the parent strain, six 
FSMR strains, and two control strains by whole genome sequencing with at least 15X genome 
coverage. Sanger sequencing was used to verify single-nucleotide polymorphisms (SNPs) and 
insertion–deletions (indels) and to genotype loci of interest in strains whose genomes were not 
sequenced. We prioritized genetic changes found in coding regions and did not evaluate changes 
in highly variable loci (such as var and rifin genes) [31,32]. A list of SNPs uniquely identified in 
the FSMR strains is found in Supplementary Data 1 (available online [33]). The resulting data 
reveal a significant enrichment for nonsynonymous changes in PF3D7_1033400 in FSMR strains 
compared with control strains (Figure 3A). We hereafter refer to PF3D7_1033400 as PfHAD1. 
Seventeen of the twenty FSMR strains have a nonsynonymous change in PfHAD1, while seven 
control laboratory strains do not have any sequence changes in PfHAD1 (P<0.01, Fisher’s Exact 
Test).  
 
Thirteen alleles were represented in the seventeen strains with PfHAD1 changes. Of these alleles, 
four indels and two nonsynonymous substitutions result in a truncated amino acid sequence 
(Supplementary Table 1).  Six alleles are nonsynonymous substitutions that result in single 
amino acid changes, once of which results in a loss of the start codon. Five of these alleles are 
predicted to have deleterious effects on protein function by Polyphen-2, an algorithm for 
predicting the probability of functional effects of missense mutations (Polyphen-2 score >0.9) 
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[34]. We also identify one strain with a whole-gene deletion of PfHAD1 (Supplementary Table 
1). Overall, FSMR strains are significantly enriched for likely deleterious changes in PfHAD1, a 
previously uncharacterized gene, compared with FSM-sensitive control strains. 
 
In addition to the 3D7 PfHAD1 allele that we designate as wild-type, a nonsynonymous N70S 
variant has also been reported in sequenced clinical and laboratory isolates of P. falciparum 
[35,36]. This allele is not predicted to be deleterious (Polyphen-2 score=0.007) [34]. Two strains 
that possess the N70S allele, HB3 and Dd2, are not resistant to FSM (FSM IC50s of 1.3 ± 0.2!µM 
and 0.6 ± 0.09!µM, respectively). Five additional strains whose sequence data are available on 
public databases (7G8, D10, GHANA1, K1 and V1_S, plasmodb.org, accessed 4 November 
2013) also possess the N70S allele. The minimal sequence variation in this gene in natural 
populations suggests that PfHAD1 has an important cellular function in P. falciparum. 
 
2.4.3 PfHAD1 is a Cof-like hydrolase member of the HAD superfamily 
Sequence homology places PfHAD1 in the HAD superfamily (Pfam PF08282) [37]. Members of 
this large superfamily are found in all three kingdoms of life and catalyse carbon- or phosphoryl-
transfer reactions [38]. The promiscuous substrate profiles and low levels of sequence similarity 
between HADs have made determining the in vivo function of many superfamily members 
difficult [39]. 
 
Within the HAD superfamily, PfHAD1 has the greatest sequence similarity to the Cof-like 
hydrolase subfamily (Interpro IPR000150) [40]. This family is named for an Escherichia coli 
enzyme involved in thiamin biosynthesis [39,41]. Most members of the Cof subfamily are 
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bacterial and most remain uncharacterized. Biochemical characterization suggests that members 
of this family utilize phosphorylated sugar substrates [39,42]. 
 
2.4.4 Sequence changes map to core and active site of PfHAD1 
PfHAD1 changes found in FSMR strains map along the entire gene body (Figure 3A). To define 
the structural basis for the role of these point mutations in PfHAD1 function, we solved the 
crystal structure of PfHAD1 to 2.05!Å (Figure 3B, Table 1). Clear electron density was not 
observed for the 6xHis tag in either chain, or the amino-terminal (N-terminal) region in chain B 
(residues 1–19), and were therefore not modeled. Like other members of the HAD superfamily, 
PfHAD1 consists of two distinct domains: a catalytic core domain (residues 1–106 and 212–288) 
and a cap domain (residues 107–211). The cap domain is inserted into the linker immediately 
following the third beta-strand. 
 
The four sequence motifs required for the catalysis [38] of HAD superfamily members are 
structurally conserved in PfHAD1: motif I—DXD sequence at the end of strand I; motif II—a 
conserved threonine/ serine at the end of strand II; motif III—a conserved lysine at the N 
terminus of the helix before strand IV; motif IV—a DD, GDxxxD or GDxxxxD on strand IV 
(Figure 3C) [38]. The sequence 27-DLD-29 in PfHAD1 corresponds to motif I, Thr-61 
corresponds to motif II, Lys-215 corresponds to motif III and the sequence 237-GDGEND-242 
corresponds to the GDxxxD signature of motif IV. These structural motifs make up the substrate-
binding site, located on the interface between the core and cap domains. These motifs are 
conserved among PfHAD1 homologs found in MEP pathway-containing organisms, including E. 
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coli, Mycobacterium tuberculosis, the alga Chlamydomonas reinhardtii and Arabidopsis thaliana 
(Figure 3C). 
 
Catalysis by PfHAD1 is metal–ion dependent, and the side chains of Asp-27 and Asp-238, and 
the backbone carbonyl oxygen of Asp-29, coordinate a magnesium ion in the structure (Figure 
3C). On the basis of homology to other HAD family phosphatases [38], it is predicted that the 
phosphoryl group of sugar phosphate compounds binds by coordinating the magnesium ion and 
the side chains of Thr-61, Lys-215 and Asp-29. Asp-27 is predicted to perform nucleophilic 
attack of the phosphate group. As PfHAD1 was crystallized in the absence of a sugar phosphate 
substrate, a chloride ion occupies the likely phosphate-binding site based on structural similarity 
to other HAD sugar phosphatases. 
 
The point mutations identified in FSMR strains (T26R, G30E, A60E, W130R and Y148C) were 
mapped onto the PfHAD1 crystal structure (Figure 3B). Trp-130 and Tyr-148 are located in a 
tightly packed hydrophobic inner region of the cap domain. Mutations of these aromatic residues 
to a charged arginine and a small polar cysteine residue, respectively, likely result in the 
misfolding of the cap domain. Similarly, Thr-26 and Ala-60 are located in the hydrophobic inner 
region of the core domain, and mutation of these residues to a charged glutamate and arginine, 
respectively, are predicted to result in the misfolding of the core domain. Finally, Gly-30 is 
located in the active site of PfHAD1, and a mutation to a glutamate with a much larger side chain 
is predicted to interfere with substrate binding. Together, the structural mapping of FSMR 
PfHAD1 mutations suggests that, similar to nonsense mutations, the FSMR nonsynonymous 
mutations result in the loss of function of PfHAD1 activity through drastic changes in the core or 
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catalytic regions of PfHAD1. The N70S variant is not suspected to have changes in activity, as 
Asn-70 is located on the surface of PfHAD1 and away from the substrate-binding site. 
 
2.4.5 FSMR PfHAD1 alleles result in loss of phosphatase activity 
We next investigated the enzymatic activity of PfHAD1. Because PfHAD1 has sequence 
homology to known phosphatases [39] (Figure 3C), we predicted that PfHAD1 is also a 
phosphatase. We expressed and purified recombinant wild-type PfHAD1, the N70S variant and 
three full-length variants (G30E, A60E and Y148C) found in FSMR strains. Recombinant 
PfHAD1 is active against a non-specific phosphatase substrate, para-nitrophenyl phosphate 
(pNPP) (Figure 4). This compound has been used in phosphatase screens as an effective 
indicator of phosphatase activity [39,43]. Activity against pNPP is significantly reduced in each 
of the FSMR PfHAD1 variants (Figure 4). The N70S variant found in sequenced isolates has 
activity similar to the wild-type enzyme (P=0.59, unpaired Student’s t-test). 
 
2.4.6 PfHAD1 complementation restores FSM sensitivity 
Because our FSMR strains are enriched for changes that result in loss of PfHAD1 function, we 
confirmed that restoring PfHAD1 expression would restore sensitivity to FSM. Using a 
piggyBac transposon system [27], functional PfHAD1 was expressed in FSMR strain AM1, 
which possesses a premature truncation at amino acid 208 of the PfHAD1 locus and lacks 
detectable PfHAD1 (Figure 5A). The expression construct produces green fluorescent protein 
(GFP)-tagged PfHAD1. The rescued strain, AM1 Hsp110: PfHAD1-GFP, retains its original 
mutation at the endogenous locus and successfully expresses PfHAD1-GFP. The expression 
pattern of Hsp110 is similar to that of PfHAD1 [44]. The expression of functional PfHAD1 
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restores FSM sensitivity in AM1. While the FSM IC50 of AM1 is 5.5 ± 1.5!µM, AM1 Hsp110: 
PfHAD1-GFP has an IC50 of 1.4 ± 0.2!µM, similar to the parental IC50 of 1.1 ± 0.2!µM, 
indicating that loss of PfHAD1 function leads to FSM resistance in our strains (Figure 5B). 
 
2.4.7 PfHAD1 is a sugar phosphatase 
Within the HAD superfamily, PfHAD1 has the greatest sequence similarity to the Cof-like 
hydrolase subfamily of sugar phosphatases. We assayed recombinant wild-type PfHAD1 with a 
number of phosphorylated sugar substrates (Figure 6). PfHAD1 has a wide substrate utilization 
profile and low substrate specificity, consistent with other members of this enzyme family 
[39,45,46]. PfHAD1 does not directly utilize FSM as a substrate. 
 
In vitro, PfHAD1 is most active against monophosphorylated three to six-carbon 
monosaccharides, including intermediates of glycolysis, the pentose phosphate pathway and the 
MEP pathway (Figure 6). Kinetic parameters for the top three substrates as well as gly3P, a MEP 
pathway precursor, can be found in Supplementary Table 2. The substrate profile of PfHAD1 is 
similar to that of related HADs in E. coli and A. thaliana [39,45]. Like other HADs, PfHAD1 
dephosphorylates a variety of substrates in vitro. Catalytic efficiencies (kcat/Km) for the four 
measured substrates were within an order of magnitude and do not clearly indicate a preferred in 
vivo substrate, which is typical of this enzyme class. None of the purified recombinant FSMR 
PfHAD1 variants have significant activity against sugar phosphate substrates (maximum mean 
activity <0.9!µmol/min/mg for all variants against man6P, glu6P, fru6P, rib5P, gly3P and 
DHAP). 
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2.4.8 PfHAD1 is localized to the cytoplasm 
MEP pathway enzymes are localized to the apicoplast in P. falciparum [14,47]. To help elucidate 
the mechanism by which PfHAD1 affects MEP pathway function, we examined the subcellular 
localization of PfHAD1. We raised specific polyclonal rabbit antisera against recombinant 
PfHAD1 and performed confocal immunofluorescence to localize PfHAD1. PfHAD1 is highly 
expressed in blood-stage parasites [48]. PfHAD1 appears to be cytoplasmic and has minimal 
overlap with the apicoplast marker ACPL-GFP (described by Waller, et al. [17]; Figure 7). Live 
fluorescent localization of PfHAD1-GFP (in strain AM1 Hsp110: PfHAD1-GFP) was similar to 
that of PfHAD1 immunolocalization in the fixed parental strain (Supplementary Figure 4). In 
addition, PfHAD1 lacks an apicoplast localization signal as predicted by the PlasmoAP and 
PATS algorithms [49,50]. Given the localization of PfHAD1, the enzyme likely utilizes 
phosphorylated sugars available in the cytoplasm, such as glycolytic intermediates. 
 
2.4.9 FSMR strains increase levels of MEP pathway intermediates 
Since PfHAD1 dephosphorylates glycolytic intermediates, we predicted that the loss of PfHAD1 
function would increase substrate availability to the MEP pathway, which requires gly3P and 
pyruvate. We evaluated the levels of MEP pathway intermediates in eight FSMR P. falciparum 
strains with PfHAD1 changes, using our previously described quantitative liquid 
chromatography-mass spectrometry method (Figure 8, Supplementary Table 3) [8]. Parental 3D7 
and eight FSMR strains were treated +/- FSM for 10!h and the levels of MEP intermediates were 
quantified in each strain. Our method quantifies cellular levels of 1-deoxy-D-xylulose 5-
phosphate (DOXP), 2-C-methylerythritol 4-phosphate (MEP), 4-diphosphocytidyl-2-C-
methylerythritol and 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP). 
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FSMR strains with PfHAD1 mutations show an overall increase in levels of MEP pathway 
intermediates. Compared with the parental strain, FSMR strains have a 55.2 ± 5.9-fold increase in 
the levels of DOXP, the substrate for PfDXR (median P<0.01, unpaired Student’s t-test). This 
increase is maintained during treatment with FSM (78.7 ± 10.1-fold increase, median P<0.01; 
Figure 8, Supplementary Table 3) and would allow for DOXP to compete with FSM binding to 
PfDXR. Increased DOXP levels are not due to the increased transcript levels of PfDXS, the 
enzyme that produces DOXP (Supplementary Figure 2). Loss of PfHAD1 is necessary for this 
increase in DOXP, as strain AM1 Hsp110:PfHAD1-GFP has near-parental levels of DOXP 
(Supplementary Figure 6). FSM-treated FSMR strains also have an increase in MEcPP levels 
compared with the parental strain (2.7 ± 0.43-fold, median P<0.01). 
 
In other systems, FSM resistance is due to the lack of FSM uptake or FSM efflux [51–53]. 
Metabolic profiling of FSMR parasites suggests that is not the mechanism of resistance in our 
strains. FSM treatment of FSMR strains results in metabolic changes that are still consistent with 
inhibition of PfDXR, the target of FSM. Specifically, the levels of the upstream metabolite 
DOXP increase, and levels of distal metabolites, such as MEcPP, decrease (Figure 8, 
Supplementary Table 3) [8]. Our data are most consistent with a change in a metabolic regulator 
outside the MEP pathway that influences production of pathway intermediates, namely DOXP. 
 
2.5 DISCUSSION 
 
In this study, we describe the genetic, biochemical, structural and metabolic basis for the 
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resistance to the MEP pathway inhibitor FSM in the malaria parasite, Plasmodium falciparum. 
Our study represents a powerful use of next-generation sequencing to facilitate a forward 
genetics approach in a non-model organism to identify a new regulator of an essential 
biochemical pathway, the MEP pathway of isoprenoid biosynthesis. 
 
We identify a member of the HAD superfamily, PfHAD1, whose loss-of-function confers FSM 
resistance in P. falciparum. To our knowledge, PfHAD1 is the first cellular factor that regulates 
the MEP pathway in P. falciparum. PfHAD1 has structural similarity to other members of the 
HAD superfamily, retains the motifs necessary for catalysis, and is active against sugar 
phosphates. Loss of PfHAD1 function causes dramatically increased levels of MEP pathway 
metabolites, particularly DOXP, the substrate of PfDXR. Our work suggests a model of PfHAD1 
function, shown in Figure 9. We propose that PfHAD1 is a negative regulator of the MEP 
pathway. It typically catalyses the dephosphorylation of cytosolic phosphometabolites, such as 
glycolytic intermediates, to decrease the availability of substrates to the MEP pathway. Loss of 
sugar phosphatase activity in FSMR malaria parasites results in increased pools of DOXP, which 
overcomes competitive inhibition of PfDXR by FSM. 
 
FSMR malaria strains are highly enriched for genetic changes in the PfHAD1 locus. In our study, 
we identified 11 separate deleterious genotypic changes in PfHAD1. If FSM is approved for 
clinical use, these changes may represent the genetic biomarkers of FSM resistance. While other 
genetic changes are also present in the FSMR strains (Supplementary Data 1, available online 
[33]), our data indicate that the loss of PfHAD1 is the primary driver of resistance. In addition, 
changes in PfHAD1 genotype correlate not only with FSM resistance, but also with increased 
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cellular levels of isoprenoid precursor metabolites. Complementation of a deleterious PfHAD1 
allele restores FSM sensitivity. These findings strongly support that the primary biochemical 
change responsible for these phenotypes is the loss of PfHAD1 function. 
 
PfHAD1 is a member of the large, diverse HAD superfamily of aspartate nucleophile hydrolases, 
and belongs to the subfamily of Cof-like hydrolases (Interpro IPR00150). Many HAD family 
members have been structurally and enzymatically characterized [39,42,45,46]. However, the 
cellular functions of this group of enzymes are largely unknown. The Cof-like hydrolases are 
absent from animal and fungal genomes, but are highly expanded in bacteria. In addition, Cof-
like hydrolases are uniformly present in eukaryotes that possess a plastid-like organelle, such as 
chloroplast-containing plants, and the apicomplexan parasites, such as P. falciparum. This 
phylogeny parallels that of the MEP pathway, which is also exclusive to many bacteria and 
plastid-containing eukaryotes, and absent in animals or fungi. Since few studies have addressed 
the potential biological function of these enzymes, additional work is required to determine 
whether PfHAD1 homologs represent regulators of isoprenoid biosynthesis in other MEP 
pathway-containing organisms. Evidence suggests that this may be the case in bacteria, since the 
E. coli PfHAD1 ortholog YidA was identified in a colorimetric screen of E. coli for increased 
lycopene production [54]. 
 
During its intraerythrocytic development cycle, glycolysis is the primary source for ATP 
generation in P. falciparum [55]. As a result, the malaria parasite has great capacity for glucose 
uptake and carbon flux through glycolysis. PfHAD1 has a broad substrate profile, and readily 
dephosphorylates a range of three to six-carbon monophosphorylated substrates, including 
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glycolytic and pentose phosphate intermediates, as well as MEP pathway metabolites. Given this 
promiscuity, it is unclear which metabolite/s represent the natural in vivo substrate(s) for 
PfHAD1 and other Cof-like subfamily members. Thus, our studies do not distinguish which 
upstream metabolic step is regulated by PfHAD1. In addition, it is unclear why malaria parasites 
produce an enzyme whose activity would decrease glycolysis and ATP production. Genetic 
conservation of PfHAD1 in clinical and laboratory isolates of P. falciparum, as well as among 
PfHAD1 homologs in divergent organisms, suggests that these proteins have important cellular 
functions under typical growth conditions. 
 
The MEP pathway is an important target for the development of small-molecule inhibitors, since 
this pathway is absent in animals but essential in plants and key human pathogens, including 
malaria parasites and M. tuberculosis. Our studies highlight what may be a particular challenge 
in developing novel MEP pathway inhibitors. Even though FSMR strains are capable of growth 
in the presence of FSM, drug treatment still substantially reduces levels of the distal MEP 
pathway metabolite, MEcPP. Following FSM treatment, MEcPP levels in FSMR strains are 
reduced to ~20% of the concentrations present in untreated, wild-type parasites. This suggests 
that, at least in malaria parasites, cells direct more flux through the MEP pathway than is 
absolutely required for development, and therefore, they are capable of growth even when MEP 
pathway metabolism is substantially reduced. As novel MEP pathway inhibitors are developed, it 
appears that these compounds must achieve a sobering near-complete inhibition of the cellular 
MEP pathway in order to inhibit malaria parasite growth. 
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2.6 FIGURES  
 
Figure 1. The MEP pathway for isoprenoid biosynthesis.  
The MEP pathway for the synthesis of isoprenoids is specifically inhibited by FSM. FSM 
competitively inhibits PfDXR. CDP-ME, 4-diphosphocytidyl-2-C-methylerythritol; CDP-MEP, 
4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate; DMAPP, dimethylallyl 
pyrophosphate; DXR, DOXP reductase; IPP, isopentenyl pyrophosphate; IspD, CDP-ME 
synthase; IspE, CDP-ME kinase; IspF, MEcPP synthase. 
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Figure 2. Generation of FSM-resistant (FSMR) P. falciparum. 
(a) Schematic of selection of FSMR strains. (b) FSMR strains exhibit a range of resistance 
phenotypes. FSMR strains have an average FSM IC50 of 4.8 ± 0.4!µM compared with the wild-
type IC50 of 1.1 ± 0.2!µM. A complete list of strains and their IC50 values are found in 
Supplementary Table 1. 
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Figure 3. FSMR variants map to the core and active site regions of PfHAD1. 
(a) Schematic of PfHAD1 variants found in FSMR strains. Six of the alleles result in premature 
stop codons. Five alleles produce full-length protein. N70S is a nondeleterious allele reported 
from sequenced clinical and laboratory isolates. Conserved active site motifs are shown as black 
boxes [38]. (b) Overall structure of PfHAD1 with the core domain in blue, cap domain in green 
and polymorphic residues mapped in yellow. Residues W130 and Y148 are located in the 
hydrophobic inner region of the cap domain. Residues T26 and A60 are located in the 
hydrophobic inner region of the core domain. Residue G30 is located in the substrate-binding 
site. (c) The backbone carbonyl oxygen of Asp-29 and the side chains of Asp-27 and Asp-238 
coordinate a magnesium ion to form the active site. The side chains of Asp-29, Thr-61, and Lys-
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215 coordinate a chloride ion, and are correctly positioned to coordinate a phosphate group on 
substrate binding. These active-site residues are conserved in PfHAD1 homologs from organisms 
possessing the MEP pathway. Alignment was produced in T-Coffee [56] using default 
parameters. Accession codes for NCBI protein sequences: E. coli YidA, EOU46719; M. 
tuberculosis Rv3813c, NP_218330; C. reinhardtii FER_156463, ADF43173; A. thaliana 
At2g25870, ABO38782. 
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Figure 4. PfHAD1 FSM-resistance alleles result in loss of phosphatase activity. 
Displayed are the means ± S.E.M. of enzyme activity from at least three independent 
experiments. P-values were determined using a one-way analysis of variance (Tukey’s post test, 
α=0.05) in GraphPad Prism software. ‘NS’=not significant (P>0.05). ‘No enz.’=no enzyme. We 
were unable to obtain soluble T26R and W130R PfHAD1 variants. 
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Figure 5. Loss of PfHAD1 is required for FSM resistance. 
Data shown are representative of at least three independent experiments. (a) Immunoblot of the 
parent strain, FSMR strain AM1 and AM1 Hsp110: PfHAD1-GFP. Full blots are shown in 
Supplementary Figure 3. Marker units are kilodaltons (kDa). Top panel was probed with anti- 
PfHAD1 antisera, and the bottom panel was probed with anti-heat shock protein 70 (hsp70) 
antisera as a loading control. Expected approximate protein masses: native PfHAD1, 33!kDa; 
PfHAD1-GFP, 60!kDa; hsp70, 74!kDa. (b) FSM IC50s of the parent strain, FSMR strain AM1, 
and AM1 Hsp110: PfHAD1-GFP. Displayed are the means ± S.E.M. The parent strain has a 
FSM IC50 of 1.1 ± 0.2!µM, while AM1 has an IC50 of 5.5 ± 1.5!µM. Expression of PfHAD1-GFP 
in AM1 results in an IC50 of 1.4 ± 0.2!µM. Data shown are mean and are normalized such that 
100% growth is defined by that of untreated cells and 0% growth is defined as the smallest value 
in each data set. 
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Figure 6. PfHAD1 dephosphorylates sugar phosphates, including MEP pathway 
intermediates. 
Displayed are the means ± S.E.M. of the enzyme activity from at least three independent 
experiments. DHAP, dihydroxyacetone phosphate; Ery4P, erythrose 4-phosphate; Fru1P, 
fructose 1-phosphate; Fru6P, fructose 6-phosphate; Fru1,6bisP, fructose 1,6-bisphosphate; 
Gal1P, galactose 1-phosphate; Glc2P, glycerol 2-phosphate; Gln1P, glucosamine 1-phosphate; 
Glu1P, glucose 1-phosphate; Glu6P, glucose 6-phosphate; Man1P, mannose 1-phosphate; 
Man6P, mannose 6-phosphate; PEP, phosphoenolpyruvate; Rib5P, ribose 5-phosphate; Ribu5P, 
ribulose 5-phosphate; Sedo7P, sedoheptulose 7-phosphate; Sorb6P, sorbitol 6-phosphate; Tre6P, 
trehalose 6-phosphate; 2drib5P, deoxyribose 5-phosphate; 2-PGA, 2-phosphoglyceric acid; 3-
PGA, 3-phosphoglyceric acid. 
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Figure 7. PfHAD1 is expressed in blood-stage parasites and is localized to the parasite 
cytoplasm. 
Immunofluorescence confocal microscopy of ACPL-GFP trophozoite and schizont [17], stained 
with αGFP and αPfHAD1 antibodies and Hoechst 33258 nuclear stain. Scale bars, 2!µm. 
  
 83 
 
 
Figure 8. Increased levels of MEP pathway intermediates in FSMR strains with the loss of 
PfHAD1 function. 
Ring-stage parental and FSMR P. falciparum parasites were treated +/− 5!µM FSM for 10!h. 
Displayed are the means ± S.E.M. of the metabolite levels from at least three independent 
experiments. Representative FSMR strain E1 is shown, which possesses the K10X PfHAD1 
allele. The complete dataset is found in Supplementary Table 3. CDP-ME, 4-diphosphocytidyl-2-
C-methylerythritol. 
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Figure 9. Model of PfHAD1 function. 
PfHAD1 (blue arrows) may dephosphorylate the intermediates of glycolysis. Loss of PfHAD1 
may increase local levels of sugar phosphates and increase the substrate availability to the 
apicoplast MEP pathway (green). The use of PEP as a substrate is unlikely, given the poor 
PfHAD1 activity against this substrate in vitro (Figure 6). Green reactions and substrates are part 
of the MEP pathway. PfiTPT and PfoTPT are transporters responsible for the import of PEP and 
DHAP into the apicoplast [57,58]. The conversion of PEP and DHAP into pyruvate and gly3P, 
respectively, are catalyzed by apicoplast-localized pyruvate kinase (PK) [59] and triosephosphate 
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isomerase (TPI) [60]. DHAP, dihydroxyacetone phosphate; DMAPP, dimethylallyl 
pyrophosphate; IPP, isopentenyl pyrophosphate; PEP, phosphoenolpyruvate. 
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Supplementary Figure 1. FSMR strains are also resistant to the FSM-related compound, 
FR-900098. Displayed are the means ± S.E.M. of at least three independent experiments. The 
parental strain has an IC50 of 0.23 ± 0.03 µM against FR-900098. FSMR strains AM1, E1, and 
D6 have FR-900098 IC50s of 3.2 ± 0.24 µM, 1.7 ± 0.001 µM, and 2.8 ± 0.17 µM, respectively. 
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Supplementary Figure 2. Relative mRNA expression levels of PfDXS and PfDXR are 
unchanged in FSMR strains. Data represent means and standard error of the mean (S.E.M.) of 
at least two independent experiments. “N.s” = not significant.  P-values are >0.3 (unpaired 
Student’s t-test) for comparisons shown. 
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Supplementary Figure 3. Full immunoblots demonstrating expression of PfHAD1-GFP in 
FSMR strain AM1. Samples shown are the parental strain, FSMR strain AM1, and AM1 
Hsp110:PfHAD1-GFP.  Marker units are kilodaltons. The blot was probed with anti-PfHAD1 
antisera (left), stripped, and re-probed with anti-heat shock protein 70 antisera (right). Expected 
approximate protein masses: native PfHAD1, 33 kDa; PfHAD1-GFP, 60 kDa; hsp70, 74 kDa. 
Data are representative of at least three independent experiments.   
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Supplementary Figure 4. PfHAD1-GFP localization is similar to that of PfHAD1 (Figure 7). 
Shown is live microscopy of AM1 Hsp110:PfHAD1-GFP trophozoite and schizont, stained with 
Hoechst 33258 nuclear stain. Scale bars represent 2 µm. 
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!
Supplementary Figure 5. Stereo image of the electron density maps for a representative 
region of PfHAD1. (a) The 2Fo-Fc electron density map contoured at 1.0 σ is colored blue. (b) 
The composite simulated annealing omit map contoured at 1.0 σ is colored grey. 
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Supplementary Figure 6. Loss of PfHAD1 is necessary for increased DOXP levels in FSMR 
strain AM1. Shown are attograms/cell DOXP as measured by LC-MS/MS in the parental strain, 
FSMR strain AM1, and AM1 Hsp110:PfHAD1-GFP. Displayed are the means and S.E.M. from 
three independent parasite cultures.  
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2.7 TABLES 
 
Table 1. Data collection and refinement statistics. 
 
 
 
 
TABLE 1. Data collection and refinement 
statistics 
  
 PfHAD1 
Data collection  
   Space group P21 
   Cell dimensions  
      a, b, c, (Å) 77.90, 43.80, 83.90 
      α, β, γ (°) 90.00, 101.10, 90.00 
   Resolution (Å)* 20-2.05 (2.15-2.05)* 
   Rmeas 7.5% (72.4%) 
   I/σI 13.84 (2.31) 
Total no. of reflections 130,290 (16,948) 
No. of unique 
reflections 35,166 (4,630) 
   Completeness (%) 99.5% (99.4%) 
   Redundancy 3.70 (3.66) 
  
Refinement  
   Resolution (Å) 20-2.05 
   No. of reflections 35,143 
   Rwork/Rfree 20.19/24.18 
   No. of atoms  
      Protein 4,445 
      Mg 2 
      Cl 2 
      Water 232 
   B-factors  
      Protein 39.90 
      Ligands 51.70 
      Water 37.30 
   R.m.s. deviations  
      Bond lengths (Å) 0.003 
      Bond angles (°) 0.647 
* Highest resolution shell is shown in parenthesis. 
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Supplementary Table 1. FSM IC50s, PfHAD1 alleles, and NCBI database accessions for 
FSMR strains.  
Strain 
FSM 
IC50 
(µM) 
PfHAD1 
change 
PfHAD1 protein 
variant 
Polyphen-2 
score* 
SRA accession 
#$ 
Trace Archive 
TI #s$ 
parental 1.1 none wild-type 
 
SRS561734 2338198571-75 
E1 8.1 A28T K10X n/a* SRS561733 2338198557-60 
B4 2.8 A28T K10X n/a  2338198501-4 
A1 6.1 C77G T26R 0.999 SRS561731 2338198460-63 
D6 8.7 G89A G30E 1.000 SRS561730 2338198553-56 
A3 4.6 ΔA112 
Frameshift, 
results in L47X n/a  2338198468-71 
D2 1.5 C179A A60E 1.000  2338198540-43 
A2 4.6 T388C W130R 0.941  2338198464-67 
A4 5.8 
A403 insertion 
(+A) 
Frameshift, 
results in E140X n/a  2338198472-75 
MK1 3.7 A443G Y148C 0.747 SRS561761 2338198569-70 
AM1 5.5 T623A L208X n/a SRS561775 2338198484-87 
AM2 3.3 T623A L208X n/a SRS561776 2338198488-91 
B1 5.9 Δ681-685 
Frameshift, 
results in E240X n/a SRS561732 2338198492-95 
F1 3.7 Δ681-685 
Frameshift, 
results in E240X n/a  2338198565-68 
D3 4.3 Δ681-685 
Frameshift, 
results in E240X n/a  2338198544-47 
A5 5.4 ΔC698 
Frameshift, 
results in L234X n/a  2338198476-79 
D4 2.0 none wild-type 
 
 2338198548-52 
A6 4.1 none 
whole gene 
deletion# n/a SRS561778 2338198480-83 
E2 4.6 none wild-type 
 
 2338198561-64 
B2 5.0 none M1I# n/a  2338198496-500 
D1 4.7 none wild-type 
 
SRS561777 2338198536-39 
 
* = Polyphen-2 scores cannot be calculated for truncation mutations.  Polyphen-2 is an algorithm 
for predicting the probability of deleterious effects of missense mutations [34].   
$ = Whole genome sequencing data is deposited in the NCBI BioProject and Sequence Read 
Archive databases.  Representative Sanger sequencing data of the PfHAD1 locus is deposited in 
the NCBI Trace Archive. 
# = mutations discovered after the publication of this manuscript. 
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Supplementary Table 2. Kinetic parameters for PfHAD1 with the top three tested 
substrates and gly3P. Shown are means ± S.E.M. of at least three independent experiments. 
Substrate Km (mM) kcat (sec-1) kcat/Km (M-1 sec-1) 
fru1P 2.5 ± 0.6 5.2 ± 0.9 2.1 x 103 
glc2P 6.5 ± 0.8 8.5 ± 0.2 1.3 x 103 
man6P 3.6 ± 0.8 3.1 ± 0.3 0.9 x 103 
gly3P 4.6 ± 0.7 11 ± 4.3 2.4 x 103 
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Supplementary Table 3. FSMR strains possessed increased levels of MEP pathway 
metabolites. Shown are concentrations of MEP pathway intermediates in P. falciparum FSMR 
PfHAD1 strains. Data shown are means ± S.E.M. of at least three independent experiments. 
Compound 
(attograms/
cell) 
DOXP MEP CDP-ME MEcPP 
Strain - FSM + FSM - FSM + FSM - FSM + FSM - FSM + FSM 
parental 0.20 ± 0.01 
0.25 ± 
0.03 
1.03 ± 
0.36 
1.03 ± 
0.38 
0.020 ± 
0.007 
0.015 ± 
0.007 
16.02 
± 0.81 
1.34 ± 
0.29 
B4 6.58 ± 3.14 
18.73 ± 
1.02 
0.87 ± 
0.32 
0.27 ± 
0.02 
0.056 ± 
0.004 
0.049 ± 
0.007 
15.62 
± 0.44 
3.39 ± 
0.21 
E1 10.06 ± 1.41 
17.26 ± 
2.18 
3.97 ± 
0.29 
2.94 ± 
0.28 
0.057 ± 
0.005 
0.029 ± 
0.005 
24.35 
± 3.56 
3.82 ± 
0.45 
A1 17.12 ± 2.52 
33.39 ± 
2.99 
2.77 ± 
0.30 
0.75 ± 
0.10 
0.077 ± 
0.006 
0.056 ± 
0.006 
55.14 
± 5.01 
7.18 ± 
0.85 
D6 8.50 ± 1.35 
13.98 ± 
2.79 
4.19 ± 
0.53 
3.05 ± 
0.42 
0.035 ± 
0.004 
0.018 ± 
0.001 
26.65 
± 4.13 
4.28 ± 
0.82 
A3 10.03 ± 0.86 
14.86 ± 
2.64 
1.51 ± 
0.10 
0.33 ± 
0.10 
0.053 ± 
0.003 
0.031 ± 
0.003 
25.21 
± 2.07 
3.07 ± 
0.41 
A4 11.03 ± 1.54 
14.44 ± 
5.18 
2.02 ± 
0.27 
0.42 ± 
0.18 
0.079 ± 
0.005 
0.038 ± 
0.010 
33.95 
± 2.85 
2.69 ± 
0.71 
AM1 14.71 ± 1.28 
28.2 ± 
3.61 
1.65 ± 
0.14 
0.38 ± 
0.02 
0.064 ± 
0.007 
0.038 ± 
0.002 
20.06 
± 1.45 
3.11 ± 
0.48 
A5 10.31 ± 1.24 
16.63 ± 
3.28 
1.10 ± 
0.12 
0.14 ± 
0.02 
0.104 ± 
0.011 
0.044 ± 
0.005 
12.64 
± 1.53 
1.47 ± 
0.23 
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3.1 ABSTRACT 
 
Novel antimalarial therapies are needed in the face of emerging resistance to artemisinin 
combination therapies. A previous study found a high cure rate in Mozambican children with 
uncomplicated Plasmodium falciparum malaria 7 days post treatment with a fosmidomycin-
clindamycin combination. However, 28-day cure rates were low (45.9%), due to parasite 
recrudescence. We sought to identify any genetic changes underlying parasite recrudescence. To 
this end, we utilized a selective whole genome amplification method to amplify parasite genomes 
from blood spot DNA samples. Parasite genomes from pre-treatment and post-recrudescence 
samples were subjected to whole genome sequencing to identify nucleotide variants. We find 
that our data do not support the existence of a genetic change responsible for recrudescence 
following fosmidomycin-clindamycin treatment. Additionally, we find that previously described 
resistance alleles for these drugs do not represent biomarkers of recrudescence. Future studies 
should continue to optimize fosmidomycin combinations for use as antimalarial therapies. 
 
3.2 INTRODUCTION 
 
Malaria remains a serious global health concern, with ~214 million cases and 483,000 deaths due 
to malaria in 2015 [1]. A majority of severe malaria cases occur in pregnant women and children 
under five years of age and result from infection with the parasite Plasmodium falciparum [1]. 
Artemisinin combination therapies (ACTs) represent the current first-line treatment in endemic 
areas. Historically, the development of drug resistance has hindered malaria control. As delayed 
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parasite clearance has emerged for ACTs in Southeast Asia and has continued to spread [1,2], 
new antimalarials are urgently needed. 
 
One such potential therapeutic is the phosphonic acid antibiotic fosmidomycin (FSM). FSM is a 
well-characterized inhibitor of the first committed step of isoprenoid precursor synthesis via the 
methylerythritol phosphate (MEP) pathway [3–5]. Because humans synthesize isoprenoids via an 
enzymatically distinct metabolic route (mevalonate pathway), FSM is a highly specific inhibitor 
of malaria parasite growth [3,5] and is well-tolerated in humans [6,7].  
 
FSM was originally developed as an antibacterial [8] and is currently under evaluation as a 
partner agent for combination therapy against uncomplicated P. falciparum malaria 
(clinicaltrials.gov identifier NCT02198807). Several studies have paired FSM with the antibiotic 
clindamycin (CLN), a protein translation inhibitor (clinical trials NCT02198807, NCT01361269, 
NCT01002183, NCT00214643, and NCT00217451) [6,9,10]. One such Phase II clinical trial, 
performed in Mozambique in 2010, evaluated the efficacy of a FSM-CLN combination on 
uncomplicated malaria in children aged 6-35 months, the youngest cohort tested to date [11,12]. 
A high parasite cure rate was observed at day 7 post-treatment with FSM-CLN (94.6%). 
Unfortunately, the cure was not durable, and the post-treatment PCR-corrected day 28 cure rate 
was 45.9% (17/39), due to recrudescent infections. Parasite recrudescence is common in clinical 
studies of FSM efficacy, with an overall day 28 cure rate of ~70% in adults [12].  
 
The safety and specificity of MEP pathway-targeting therapeutics, such as FSM, are highly 
desirable. However, the failure of FSM treatment to result in lasting cure has led to concern 
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regarding the clinical utility of FSM or related antimalarials. We recently found that FSM 
resistance is readily achieved in culture due to mutations in the metabolic regulator PfHAD1 
(PlasmoDB ID PF3D7_1033400) [13]. Additionally, CLN resistance has been reported in 
clinical isolates of P. falciparum, attributed to mutation in the apicoplast 23S rRNA [14].  
 
In this study, we address whether observed recrudescence is produced by selection for mutations 
in previously identified candidate genes or novel resistance loci. Using selective whole genome 
amplification (SWGA) and sequencing, we characterize P. falciparum field isolates from blood 
spot samples to evaluate the genetic landscape of drug resistance before and after FSM-CLN 
treatment. Specifically, we evaluate for enrichment in genetic changes associated with decreased 
susceptibility to either FSM or CLN.  
 
3.3 METHODS 
 
3.3.1 Study information 
The study criteria have been previously described [11]. The study evaluated 37 children ages 6-
35 months with uncomplicated malaria. Inclusion and exclusion criteria are outlined in the 
original study [11]. Patients were administered a three-day, twice-daily course of oral FSM-
CLN. Blood spots were collected at days 0, 7, 14, and 28, and if applicable, upon recrudescence. 
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3.3.2 Clinical trial information 
The original trial in Mozambique, sponsored by Jomaa Pharma, was conducted in 2010 
according to the ICH Good Clinical Practice guidelines. The protocol was approved by the 
National Mozambican Ethics Review Committee and the Hospital Clinic of Barcelona Ethics 
Review Committee. The clinicaltrials.gov identifier is NCT01464138. 
 
3.3.3 Selective whole genome amplification 
Blood spotting and DNA isolation has been previously described [11]. SWGA of P. falciparum 
genomes was performed as described previously [15], including primer sets (Supplementary 
Table 2) and reaction conditions. Reactions contained 10 ng template and 3.5 µM primer set 6A. 
Reactions were cleaned using Ampure beads (Beckmann Coulter) at a 1:1 DNA:bead ratio. 
Samples underwent a second round of SWGA using primer set 8A and 15-30 ng DNA. 
 
3.3.4 PCR of SWGA products 
Selective amplification of P. falciparum genomes was verified by PCR using P. falciparum- or 
human-specific primers (Supplementary Table 1). Human DNA and human-specific primers 
were kindly provided by Shiming Chen (Washington University). Reactions contained 2 µM 
each primer, 25-50 ng bead-cleaned SWGA product, and BIO-X-ACT Short PCR Mix (Bioline). 
Vendor-recommended cycling conditions were used, with modifications: (55 °C and 60 °C 
annealing for P. falciparum- and human-specific primers, respectively; 68 °C extension). 
Amplicons were visualized by agarose gel electrophoresis. 
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3.3.5 Whole genome sequencing 
Library preparation, Illumina sequencing, read alignments, and variant calling were performed 
by the Washington University Genome Technology Access Center (GTAC).  Bead-cleaned 
SWGA product DNA (0.5-1.2 µg) was sheared, end-repaired, and adapter-ligated. PCR-based 
libraries were sequenced on an Illumina HiSeq 2500 to generate 101 bp paired end reads. Reads 
were aligned to the 3D7 reference (PlasmoDB v24) using Novoalign (V2.08.02) [16]. Duplicate 
reads were removed. SNPs were called using samtools (mpileup) [17], filtered (quality ≥20, read 
depth ≥5), and annotated using snpEff (3.3c, build 2013-06-28) [18]. 
 
P. falciparum reads are available through the NCBI BioProject database (PRJNA315887) and 
Sequence Read Archive (SRP072442).  
 
For some analyses (comparison of SNPs in resistance genes, GO analysis), only sample pairs 
with both exomes showing sufficient coverage (≥60% covered at ≥5X, indicated in 
Supplementary Table 3) were used. Given a per-base error rate of 0.1-0.5% for Illumina 
sequencing [19,20], 5X coverage equates to >99.9% accuracy. Studies have indicated reasonable 
sensitivity and accuracy for our variant caller at this cutoff [21]. 
 
3.3.6 SNPhylo plot generation 
Multi-sample VCFs were converted to hapmap format. SNPhylo [22] was run with the default 
settings, with an LD cutoff of 0.8. 
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3.3.7 Multiplicity of infection (MOI) determination 
MOI was determined using the WHO-recommended PCR-based genotyping procedures at the 
MSP1 (PF3D7_0930300), MSP2 (PF3D7_0206800), and GLURP (PF3D7_1035300) loci [23]. 
 
3.3.8 Sequencing of the apicoplast 23S rRNA locus 
The apicoplast 23S rRNA (PlasmoDB ID PCF10_API0010:rRNA) locus was amplified by PCR. 
Reactions contained 2 µM of each primer 23S_1 and 23S_6 (Supplementary Table 1), 4-5 µL of 
blood spot DNA, and CloneAmp HiFi PCR Premix (Clontech). Vendor-recommended cycling 
conditions were used (55 °C primer annealing). Amplicons were Sanger sequenced using primers 
23S_1 – 23S_6 (Supplementary Table 1). 
 
3.3.9 GO analysis 
GO term enrichment of genes containing SNPs unique to post-treatment samples was determined 
using the PlasmoDB Gene Ontology Enrichment tool [24] (Bonferroni-corrected P-value <0.01). 
 
3.4 RESULTS 
 
3.4.10 Selective whole genome amplification of blood spot DNA generates 
parasite templates for whole genome sequencing 
We evaluated blood spot DNA (mixed human and P. falciparum) from 12 patient samples with 
microscopic recrudescent infection (12 pre- and post-treatment pairs, 24 samples total). Pilot 
unmodified, low-input library preparation methods resulted in <5% reads mapping to the P. 
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falciparum genome. For this reason, we used SWGA to amplify P. falciparum DNA. This 
method uses the processive Φ29 DNA polymerase and genome-specific primers to selectively 
amplify a target genome from a mixed sample [25–27] and has been recently used to characterize 
chimpanzee Plasmodium genomes [15]. 
 
Enrichment of the P. falciparum genome was verified by PCR (Figure 1). We amplified P. 
falciparum genomes from a broad range of parasite densities (18-315,064 parasites/µL whole 
blood). Amplified samples were used to prepare libraries for Illumina sequencing. 
 
The samples displayed varying degrees of sequencing success (Supplementary Table 3). An 
average (± S.E.M.) of 55.1% ± 2.9% of reads mapped to the P. falciparum genome, resulting in 
48.1% ± 3.5% of the genome covered at ≥5X. This is comparable to previous studies using 
SWGA to sequence microbial genomes [27,28]. The genome coverage we obtain is consistent 
with very low proportions (<0.01%) of parasite DNA in the blood spot samples [15]. While more 
reads will increase genome coverage, including typically low-coverage intragenic regions, 
coverage is likely to be limited by incomplete genome representation in the sample, as very low 
proportions of parasite DNA are likely to result in incomplete or inefficient SWGA of some 
genome regions. Given the low coverage of AT-rich intragenic regions, our analyses focused on 
protein-coding regions of the P. falciparum genome. We observe an average of 69.0% ± 4.4% of 
the exome covered ≥5X, with as much as 90% of the exome covered ≥5X (Supplementary Table 
3).  
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We observe an average of 35,451 ± 1,220 total genome SNPs in our sequenced samples, 
consistent with recent studies of African field isolates [29,30]. Of these, 15,862 ± 534 are exome 
SNPs. We find an average of 10,755 ± 349 non-synonymous SNPs in our samples with sufficient 
exome coverage (≥60% covered at ≥5X). 
 
3.4.11 SNP profiling confirms recrudescent infections 
Maximum-likelihood phylogenetic tree construction from our exome SNP profiles from the 12 
pre- and post-treatment sample pairs demonstrates clustering by patient-of-origin (Figure 2). 
These data support the conclusion that all infections analyzed indeed reflect failure to completely 
clear the original infection (recrudescence), as opposed to novel, independent infections. Pre-
treatment and post-treatment samples share a majority (66.0 ± 3.4%) of non-synonymous SNPs, 
while independent (between-patient) pre-treatment infections are less related and share only 24.6 
± 0.4% of non-synonymous SNPs (strains with ≥60% of the exome at ≥5X, N=8). These data 
confirm the genotyping reported in the original study [11], which established recrudescence 
through WHO-recommended PCR-based genotyping at three P. falciparum loci: MSP1, MSP2, 
and GLURP [23].  
 
3.4.12 Multiplicity-of-infection (MOI) pre- and post-treatment 
In high transmission areas, patients may be simultaneously infected with multiple parasite 
strains. This genetic variation provides a potential reservoir for the development of resistance to 
antimalarials, both within a given patient and in the larger P. falciparum population. 
Multiplicity-of-infection (MOI) has been shown to decrease after recrudescence following 
chloroquine treatment [31], and, unsurprisingly, increased MOI is correlated with treatment 
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failure [32]. However, during any individual infection, selective pressures during infection (such 
as immune evasion) and drug treatment are expected to decrease genetic diversity. We therefore 
assessed MOI before and after recrudescence. 
 
All infections were polyclonal, with a mean pre-treatment MOI of 3.9 ± 0.3. This is slightly 
higher than MOIs reported in other pediatric studies in Mozambique [33,34]. MOI decreased 
modestly in two-thirds of the samples after treatment and recrudescence, with a mean post-
treatment MOI of 3.2 ± 0.2 (p=0.0065, paired t-test). This reduction was not a result of lower 
parasitemias in recrudescent infections, as average post-treatment parasite density was 
approximately equal to average pre-treatment parasite density (76,225 ± 33,944 vs. 70,977± 
20,498 parasites/µL). Additionally, MOI and parasite density were not correlated (Pearson r = -
0.041, p = 0.849). 
 
Of note, loss-of-function mutations in the FSM-resistance gene PfHAD1 have been infrequently 
reported in the genomes of field P. falciparum isolates (PlasmoDB, accessed April 2016), 
suggesting that such alleles are rare [24]. Therefore, if resistance emerges during the course of 
infection in a given patient, recrudescence due to outgrowth of a rare resistant clone should result 
in a dramatic decrease in MOI. This was not observed in our population, suggesting that FSM 
resistance alone is unlikely to account for recrudescence of patients treated with FSM-CLN.  
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3.4.13 Genotyping of known resistance loci does not reveal a change in the 
resistance landscape between pre- and post-treatment samples 
To evaluate whether FSM-CLN recrudescent parasites have genetic changes associated with 
drug resistance, we investigated the genomes of paired pre- and post-treatment parasites for 
genetic markers of antimalarial resistance. We evaluated loci previously implicated in resistance 
to FSM or CLN, as well as loci documented to contribute to resistance to other clinically 
available antimalarials. 
 
FSM targets the isoprenoid synthesis enzyme 1-deoxy-D-xylulose 5-phosphate reductoisomerase 
(PfDXR, PF3D7_1467300). Following FSM-CLN treatment, recrudescent samples are not 
enriched in alternative PfDXR alleles (Figure 3, Supplementary Table 4). One sample (114) 
possesses the Q361R PfDXR allele, previously reported in African isolates [24]. The homologous 
residue (R276) in FSM-sensitive Escherichia coli DXR (NCBI reference NP_414715.1) is 
identical to the mutated residue (361R). Therefore, the DXR Q361R variant is unlikely to confer 
FSM resistance. 
 
We have recently identified a metabolic regulator, PfHAD1, whose loss results in FSM 
resistance in cultured P. falciparum [13]. No PfHAD1 loss-of-function alleles were identified in 
our samples (Figure 3, Supplementary Table 4), consistent with a known lack of variation in this 
gene in field samples [24]. The N70S allele seen in a number of strains has been previously 
reported as a common wild-type variant [24], which does not confer FSM resistance [13]. Two 
pre-treatment samples (103 and 118) possessed additional polymorphisms in PfHAD1, S265L 
and E150K, respectively (Figure 3, Supplementary Table 4). These alleles are not predicted to 
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affect PfHAD1 function [Polyphen-2 scores < 0.005 (benign)] [35] and are not enriched in the 
recrudescent samples. Altogether, our data indicate that known markers of FSM resistance in 
PfDXR and PfHAD1 do not emerge during the course of FSM treatment. Thus, known 
mechanisms of FSM resistance observed in the laboratory are unlikely to represent the 
underlying mechanism behind FSM-CLN failure. Since recrudescent parasites were not culture-
adapted, we cannot distinguish whether these parasites were resistant or just failed to be cleared. 
Therefore, it is possible that resistance-causing mutations in PfDXR, PfHAD1, or other loci might 
occur if parasites were subjected to longer drug exposures.  
 
Resistance to the FSM partner agent, CLN, has also been reported in P. falciparum [14]. In this 
previous study, mutation (A1875C) in the 23S rRNA locus (PFC10_API0010) is associated with 
an approximately 100-fold increase in clindamycin IC50 for clinical isolates [14]. Insufficient 
coverage of the plastid genome was obtained from whole genome sequencing; we therefore used 
targeted gene amplification and sequencing to interrogate for polymorphisms in 
PFC10_API10010. No samples possessed the A1875C variant. All sequenced samples matched 
the FSM- and CLN-sensitive 3D7 control strain (Supplementary Data 1, available online [36]). 
Notably, from our sequencing of laboratory 3D7 and HB3 strains, we identify variations not 
reported in the genome reference (T451A, A454T, and 401insG) (Supplementary Data 1, 
available online [36]) [24]. These changes may have emerged over time during culturing of 
laboratory isolates. 
 
Finally, we interrogated the prevalence of other drug resistance markers before and after FSM-
CLN treatment (Figure 3, Supplementary Table 4). Specifically, we evaluated variation in the 
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locus encoding the multi-drug transporter PfMDR1 (PF3D7_0523000), which modulates parasite 
sensitivity to hydrophobic antimalarials, such as mefloquine and halofantrine [37]. Strains 
possessing PfMDR1 mutations are sensitive to FSM and PfMDR1 mutations are not predicted to 
impact FSM effectiveness [3,9]. Three PfMDR1 variants (wild-type, Y184F, and N86Y) were 
identified in our analyzed strains, but PfMDR1 haplotype frequencies were not significantly 
different in pre- and post-treatment populations (p>0.5).  
 
ACTs, introduced in Mozambique in 2004 [38], may have selected for parasites able to withstand 
drug treatment such as FSM-CLN. Alleles of PfK13 (Kelch13, PF3D7_1343700) have been 
implicated in artemisinin resistance. We identify two PfK13 variants in our population (K189T 
and A578S), neither of which has been implicated in laboratory artemisinin resistance. The 
K189T variant is common in African isolates [39,40] and is not believed to cause increased 
clearance times following ACT. While the A578S variant has been associated with increased 
clearance times [41], this mutation was only observed in a small fraction of our strains. 
Additionally, strains possessing known resistance mutations in PfK13 are FSM sensitive 
(Edwards RL et al., submitted) suggesting that selection for artemisinin resistance does not result 
in FSM resistance. 
 
In our small study population, selection with FSM-CLN did not appear to alter frequency of 
PfMDR1 alleles or alleles of additional known genetic loci associated with antimalarial 
resistance, including PfCRT (chloroquine), PfATP4 (multiple drug classes), PfDHFR 
(antifolates), and PfDHPS (antifolates) (Figure 3, Supplementary Table 4) [42–46].  
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Our approach permitted an unbiased search for any novel non-synonymous SNPs that are 
associated with recrudescence following FSM-CLN treatment. To better understand SNPs that 
were unique to or enriched in recrudescent samples, we also subtracted pre-treatment non-
synonymous SNPs from post-treatment non-synonymous SNPs. The eight recrudescent strains 
analyzed had an average of 3,448 ± 604 unique non-synonymous SNPs (approximately 33% of 
their total non-synonymous SNPs).  
 
Sixty-eight SNPs were shared in ≥50% of the samples (Supplementary Table 5). However, no 
non-synonymous SNPs were shared between all 8 recrudescent samples, demonstrating that, in 
this small population, a genetic marker of recrudescence was not present. 
 
Selective pressures in vivo are likely to be distinct from those described in vitro. We 
hypothesized that certain biological processes may be enriched for genetic variation in our post-
treatment samples. We therefore performed gene ontology (GO) analysis on the genes with SNPs 
shared in ≥50% of recrudescent samples (Supplementary Table 5) to understand the functions of 
genes containing SNPs enriched upon recrudescence. Our analysis reveals enrichment for 
immune evasion and parasitism-related functions (Table 1). This result has been observed in 
other studies of variation in P. falciparum populations [14,30]. Because these genes are among 
the most variable in a population, they are likely to display changes in allele frequency following 
a population bottleneck, such as recrudescence. Notably, GO analysis did not reveal enrichment 
in pathways associated with drug resistance or with the mechanism of action of FSM (isoprenoid 
synthesis) or CLN (protein translation). While a novel genetic route to FSM or CLN resistance is 
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possible, we see no evidence for enrichment of new SNPs or pathways in our unbiased genome 
analysis. 
 
3.5 DISCUSSION 
 
 
Fosmidomycin (FSM) is an antimalarial with a novel, parasite-specific mechanism-of-action, a 
well-characterized target, and exceptional clinical safety. Despite this promise, FSM 
combination treatment of uncomplicated P. falciparum infection in children was unsuccessful 
due to unacceptably high rates of parasite recrudescence [11]. Parasite FSM resistance arises 
readily in culture and has been attributed to loss-of-function mutations in PfHAD1 [13]. These in 
vitro studies suggested that selection for FSM resistance alleles during clinical infection and/or 
FSM treatment may represent a mechanism to explain clinical failures following FSM treatment.  
 
To address this concern, we have surveyed the genetic diversity in Mozambican pediatric P. 
falciparum malaria infections before and after treatment failure with FSM-CLN. Overall, our 
data indicate that drug resistance does not account for treatment failures following FSM-CLN 
therapy. Our results confirm that treatment and recrudescence represent a population bottleneck, 
as MOI is decreased in recrudescent samples. Since resistance alleles are thought to represent 
only a miniscule proportion of the pre-treatment population, the modest decrease in MOI that we 
observe is inconsistent with the selection of resistant strains from the population.  
 
Importantly, we do not find evidence of SNPs enriched in parasites following FSM-CLN 
treatment. Specifically, we do not identify enrichment for alleles already experimentally 
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implicated in FSM or CLN resistance. Our use of whole genome sequencing permits an unbiased 
screen for additional SNPs that may contribute to resistance, regardless of whether these alleles 
are directly responsible or otherwise associated with a recrudescent phenotype. While we are 
limited by the retrospective nature of our study and our inability to phenotype culture-adapted 
recrudescent parasites, both FSM and CLN have single, well-characterized targets and known 
SNPs underlying resistance [13,14]. We therefore conclude that neither FSM nor CLN resistance 
is responsible for clinical failure of FSM-CLN.  
 
Our study was designed to evaluate the hypothesis that a simple coding mutation may underlie 
recrudescence in FSM-CLN-treated parasites. The results of our study cannot exclude other 
potential routes to resistance, such as non-coding mutations resulting in regulatory variation or 
non-genetic changes in gene expression or homeostatic responses. Further studies may address if 
and how these mechanisms contribute to resistance to FSM, CLN, and other antimalarials. 
 
Our study highlights an important caution in applying the results of forward genetic screening in 
cultured parasites to clinical populations. As resistance alleles are identified in vitro, it is 
important to recognize that selective pressures during natural human infection (immune pressure, 
metabolic requirements) are likely to be distinct. Our data indicate that mutation in PfHAD1 is 
not readily achieved in clinical populations. Perhaps mutation of PfHAD1 comes at a fitness cost 
in P. falciparum, similar to what has been found for other resistance loci, such as PfCRT and 
PfATP4 [47,48]. However, PfHAD1 mutation appears to reduce fitness during human infection 
and not during culture, as loss of PfHAD1 is easily achieved in laboratory selections. 
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Finally, our study illustrates the utility of SWGA for the analysis of P. falciparum genomes from 
blood spot samples. This method has applications for future field studies, as blood spots are 
easier to acquire than whole blood. Further optimization will facilitate the extraction of more 
data from these types of samples. Furthermore, our data provide additional validation of PCR-
based strategies to determine MOI and recrudescence. We find that the high rate of 
recrudescence following FSM-CLN treatment in children was not overestimated due to use of 
the standard 3-locus PCR genotyping protocol [11]. Eventual use of whole genome sequencing 
for genotyping field populations will provide more information regarding variation within a 
geographic region and within patients. 
 
This work supports the current hypothesis that the disappointing clinical efficacy of FSM 
combinations is likely due to challenges of partner drug selection and formulation [12]. The short 
serum half-life of both FSM and CLN (1-3 h) limits parasite exposure and presumably reduces 
the selective pressure for resistance [8,49]. However, this limited serum exposure almost 
certainly contributes to decreased clinical efficacy. Currently, FSM is being evaluated in 
combination with the bisquinolone piperaquine in a Phase II clinical trial in Gabon 
(NCT02198807). Piperaquine has a notably long half-life (>20 days) [50], which holds promise 
to limit recrudescence when paired with FSM. Our findings support the continued development 
of antimalarials targeting PfDXR and the MEP pathway, as well as the development of 
alternative FSM combinations. 
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3.6 FIGURES  
 
 
!
Figure 1. SWGA causes enrichment of P. falciparum DNA from mixed samples that can be 
detected by PCR.  
Shown is an agarose gel of SWGA amplicons obtained using P. falciparum-specific (top) and 
human-specific (bottom) primers. Markers indicate DNA size in base pairs.  
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Figure 2. Samples cluster by patient, indicating recrudescent infections.  
SNPhylo [22] was used to construct a maximum likelihood phylogenetic tree of SNP profiles 
from initial (pre-treatment) and recrudescent (post-treatment) infections. Bootstrap values were 
100 for all pre- and post-treatment branch points. Samples are numbered by infection. Scale bar 
represents units of substitution. 
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Figure 3. Resistance landscape before and after recrudescence.  
Only infection pairs with sufficient exome coverage were analyzed (≥60% at ≥5X, N=8). Shown 
are the percentages of pre- and post-treatment samples with indicated non-reference (3D7) alleles 
at resistance loci. Any codons not shown match the 3D7 reference in all samples. 
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3.7 TABLES  
 
Table 1. Gene ontology (GO) analysis of genes containing SNPs unique to recrudescent 
samples.  
GO term ID Description P-value 
GO:0051704 multi-organism process 1.5 x 10-4 
GO:0044403 
symbiosis, encompassing mutualism through 
parasitism 
1 x 10-3 
GO:0044419 interspecies interaction between organisms 1 x 10-3 
GO:0016337 cell-cell adhesion 3.6 x 10-3 
GO:0009405 pathogenesis 4.6 x 10-3 !! !
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Supplementary Table 1. PCR primers used in this study.  
Primer name Primer sequence (5’ -> 3’) Use 
23S_1 GATGTCTATAATTTTTATTAAATAAGAAAGACG 
Apicoplast 23S rRNA amplification, 
Sanger sequencing 
23S_2 AGGTTAAATATATTTAAATAATGAAGCCA 
Apicoplast 23S rRNA Sanger 
sequencing 
23S_3 AGAGTGCGTAAAAGCTCATTAATTTAATAA 
Apicoplast 23S rRNA Sagner 
sequencing 
23S_4 GCGACTGTTTAACAAAAACACAAATC 
Apicoplast 23S rRNA Sanger 
sequencing 
23S_5 CGGAGGAGTACAATGTTATATTTATT 
Apicoplast 23S rRNA Sanger 
sequencing 
23S_6 ATTCAACTTATTAGGAATTATACACTAAATA 
Apicoplast 23S rRNA amplification, 
Sanger sequencing 
Pfal_F GGTTTCAGAACAGAATTTGGAGAGT 
P. falciparum-specific amplification of 
SWGA products 
Pfal_R TCCTATCTATCACCCTTGAACCTTT 
P. falciparum-specific amplification of 
SWGA products 
Human_F CTCCTGTAGTCCCAGCTACTTG 
Human-specific amplifiication of 
SWGA products 
Human_R AATTCTGGAACAACTCCCCTCT 
Human-specific amplification of 
SWGA products 
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Supplementary Table 2. Primer sets used for SWGA reactions.  
Asterisks (*) indicate phosphorothioate bonds. Primers have been previously described [15]. 
Primer set 6A Primer set 8A 
Primer name Primer sequence Primer name Primer sequence 
SASPfSWGA6.1 TAAATAAAAA*A*A SASPfSWGA8.1 TTTTTTTATT*T*A 
SASPfSWGA6.2 CATAAAAAA*A*A SASPfSWGA8.2 TATTATTATT*T*A 
SASPfSWGA6.3 TAAATAATAA*T*A SASPfSWGA8.3 TTTTTTTAT*G*T 
SASPfSWGA6.4 ATCATAATA*A*T SASPfSWGA8.4 ATTATTATG*A*T 
SASPfSWGA6.5 TAACAAAAAA*A*A SASPfSWGA8.5 TTTTTTTTGT*T*A 
SASPfSWGA6.6 TAATAAATAA*A*A SASPfSWGA8.6 TATTTATTAT*T*A 
SASPfSWGA6.7 TAACATAGG*T*C SASPfSWGA8.7 GACCTATGT*T*A 
SASPfSWGA6.8 TAGTAGTAG*T*A SASPfSWGA8.8 TACTACTAC*T*A 
SASPfSWGA6.9 ATAATAAATA*A*T SASPfSWGA8.9 TATTATTTAT*T*A 
SASPfSWGA6.10 CATAATAATA*A*T SASPfSWGA8.10 TATTATTATT*G*T 
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Supplementary Table 3. Whole genome sequencing statistics for samples sequenced in this 
study. Sample pairs with sufficient exome coverage (>60% at ≥5X) for further analysis are 
indicated in bold.  
Patient 
Sample (pre- or 
post-treatment)  
Parasite 
density 
(parasites/µL) 
Total reads 
% Reads mapped 
to P. falciparum 
genome 
% Genome 
>5X 
% Exome 
>5X 
103 pre 3,605 126,792,578 46.67% 38.44% 60.46% 
103 post 286,447 85,566,496 64.80% 47.85% 71.69% 
105 pre 5,589 69,281,634 51.83% 22.29% 34.93% 
105 post 38 89,675,366 90.43% 65.62% 88.48% 
108 pre 77,220 92,607,064 56.89% 33.43% 51.91% 
108 post 121,685 130,536,610 61.64% 49.01% 73.77% 
113 pre 54,080 57,901,552 44.56% 33.59% 53.57% 
113 post 18 115,118,156 32.06% 17.86% 25.97% 
114 pre 39,520 142,997,152 52.06% 47.60% 73.39% 
114 post 1,323 94,691,726 47.34% 40.73% 62.10% 
118 pre 164,320 95,589,360 50.31% 45.07% 69.97% 
118 post 315,064 176,525,898 68.09% 72.27% 92.42% 
119 pre 199,680 137,251,874 68.77% 70.77% 92.03% 
119 post 22,537 82,233,988 59.91% 54.58% 81.23% 
121 pre 29,120 108,754,820 68.12% 66.78% 89.60% 
121 post 39 158,120,464 44.13% 47.07% 69.18% 
127 pre 44,720 122,622,608 61.89% 60.71% 86.20% 
127 post 158,515 137,474,360 64.48% 65.01% 88.93% 
128 pre 185,120 135,016,170 51.51% 46.59% 70.95% 
128 post 6,818 151,147,456 60.57% 62.37% 87.13% 
130 pre 13,312 63,915,724 49.03% 26.14% 41.67% 
130 post 25 64,516,982 16.11% 14.30% 20.29% 
132 pre 35,443 106,972,976 63.63% 72.02% 91.57% 
132 post 2,187 117,596,246 47.00% 53.88% 78.52% 
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Supplementary Table 4. SNPs identified in known resistance loci. 
Sample 
PfCRT 
(PF3D7_070
9000) 
PfMDR1 
(PF3D7_0
523000) 
PfDHFR 
(PF3D7_041
7200) 
PfDHPS 
(PF3D7_0
810800) 
PfK13 
(PF3D7_1
343700) 
PfATP4 
(PF3D7_121
1900) 
PfDXR 
(PF3D7_14
67300) 
PfHAD1 
(PF3D7_1
033400) 
103-pre WT Y184F 
N51I, C59R, 
S108N K540E A578S WT WT S265L 
103-post WT N86Y 
N51I, C59R, 
S108N K540E A578S 
G1128R, 
Q1081K WT WT 
114-pre 
M74I, 
N75E, K76T Y184F 
N51I, C59R, 
S108N K540E WT 
G1128R, 
Q1081K, 
D1079G, 
G776V, 
G223S Q361R WT 
114-post WT Y184F 
N51I, C59R, 
S108N WT WT G223S Q361R WT 
118-pre WT N86Y 
N51I, C59R, 
S108N K540E WT WT WT E150K 
118-post WT N86Y 
N51I, C59R, 
S108N K540E WT 
G1128R, 
Q1081K WT N70S 
119-pre 
D24Y, 
M74I, 
N75E,  
K76T, 
Q271E, 
R371I N86Y 
N51I, C59R, 
S108N K540E WT G1128R WT N70S 
119-post 
D24Y, 
M74I, 
N75E, 
K76T, 
Q271E N86Y 
N51I, C59R, 
S108N K540E WT G1128R WT N70S 
121-pre WT Y184F 
N51I, C59R, 
S108N K540E WT T558A WT N70S 
121-post WT Y184F 
N51I, C59R, 
S108N K540E K189T N1045K WT WT 
127-pre WT WT 
N51I, C59R, 
S108N G437A WT 
Q1081K, 
E30D WT N70S 
127-post WT WT 
N51I, C59R, 
S108N G437A WT 
G1128R, 
Q1115K, 
Q1081K, 
E30D WT N70S 
128-pre 
M74I, 
N75E, K76T WT 
N51I, C59R, 
S108N K540E K189T Q1081K WT WT 
128-post 
M74I, 
N75E, 
K76T, 
Q271E, 
R371I WT 
N51I, C59R, 
S108N K540E K189T 
G1128R, 
Q1081K WT WT 
132-pre 
D24Y, 
M74I, 
N75E, K76T N86Y 
N51I, C59R, 
S108N K540E WT WT WT WT 
132- 
post 
M74I, 
N75E, K76T 
N86Y, 
Y184F 
N51I, C59R, 
S108N K540E WT WT WT WT 
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Supplementary Table 5. Unique, non-synonymous SNPs shared in ≥50% of recrudescent 
(post-treatment) samples.!
# 
strain
s Chrom Position Locus Product Description Ref SNP 
Old 
AA/ 
New 
AA 
1
0
3 
1
1
4 
1
1
8 
1
1
9 
1
2
1 
1
2
7 
1
2
8 
1
3
2 
4 1 158547 
PF3D7_
0103500 
conserved Plasmodium 
protein, unknown 
function A T K/N 
 
X 
 
X X 
  
X 
4 2 145125 
PF3D7_
0203000 
repetitive organellar 
protein, putative (ROPE) C G E/Q 
  
X 
  
X X X 
4 2 203816 
PF3D7_
0204600 
conserved Plasmodium 
protein, unknown 
function C T G/D X X X X 
    
4 2 667545 
PF3D7_
0216100 
conserved Plasmodium 
protein, unknown 
function C T E/K 
 
X 
 
X X 
 
X 
 
4 2 900068 
PF3D7_
0222800 stevor T G C/G X 
 
X X 
   
X 
4 3 43675 
PF3D7_
0300100 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR) T G N/K X X 
  
X 
 
X 
 
4 3 550797 
PF3D7_
0313500 
GTP-binding protein 
EngA, putative C A R/S X 
 
X 
  
X X 
 
4 3 622763 
PF3D7_
0315200 
circumsporozoite- and 
TRAP-related protein 
(CTRP) G C E/Q X 
 
X 
 
X 
 
X 
 
4 3 851156 
PF3D7_
0320400 
oocyst capsule protein 
(Cap380) C T A/T X X X 
   
X 
 
4 3 853052 
PF3D7_
0320400 
oocyst capsule protein 
(Cap380) T C M/V X 
 
X 
  
X X 
 
4 3 909278 
PF3D7_
0321700 
microtubule and actin 
binding protein, putative C T E/K 
 
X 
  
X 
 
X X 
4 4 73407 
PF3D7_
0401000 rifin (RIF) C A C/F X X 
 
X 
   
X 
4 4 73479 
PF3D7_
0401000 rifin (RIF) C G G/A X X X X 
    
4 4 251022 
PF3D7_
0404600 
conserved Plasmodium 
membrane protein, 
unknown function T G F/V X 
 
X 
  
X X 
 
4 4 262055 
PF3D7_
0404700 
dipeptidyl 
aminopeptidase 3 
(DPAP3) C T D/N 
 
X X X X 
   
4 4 472117 
PF3D7_
0410300 
protein phosphatase 
PPM1, putative (PPM1) T G N/H X 
 
X X 
   
X 
4 4 520965 
PF3D7_
0411800 
conserved Plasmodium 
protein, unknown 
function T C K/E X 
 
X 
 
X 
 
X 
 
4 4 520967 
PF3D7_
0411800 
conserved Plasmodium 
protein, unknown 
function A T V/E X 
 
X 
 
X 
 
X 
 
4 4 1102488 
PF3D7_
0424400 
surface-associated 
interspersed protein 4.2 
(SURFIN 4.2) 
(SURF4.2) G A M/I X 
 
X 
  
X X 
 
4 4 1137176 
PF3D7_
0425200 
Plasmodium exported 
protein (hyp15), 
unknown function G C D/H 
 
X 
 
X X 
  
X 
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6 4 1167005 
PF3D7_
0425800 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR) G T Q/H 
 
X X X X X 
 
X 
4 5 633280 
PF3D7_
0515300 
phosphatidylinositol 3-
kinase (PI3K) A G I/V X 
   
X X 
 
X 
4 5 1004577 
PF3D7_
0524100 
conserved Plasmodium 
protein, unknown 
function G A R/K 
  
X X X X 
  
4 6 524370 
PF3D7_
0612600 
PP-loop family protein, 
putative T A N/Y X X X 
   
X 
 
4 6 665740 
PF3D7_
0615900 
conserved Plasmodium 
protein, unknown 
function C T D/N X X X 
   
X 
 
4 6 1368413 
PF3D7_
0632600 rifin, pseudogene (RIF) G T R/M X 
   
X X X 
 
4 7 350194 
PF3D7_
0707500 
conserved Plasmodium 
protein, unknown 
function A G S/G 
 
X 
  
X 
 
X X 
4 7 470161 
PF3D7_
0710200 
conserved Plasmodium 
protein, unknown 
function C A L/I X 
 
X 
   
X X 
4 7 634749 
PF3D7_
0713900 
conserved Plasmodium 
protein, unknown 
function C T D/N 
 
X X 
   
X X 
4 7 911077 
PF3D7_
0721000 
conserved Plasmodium 
membrane protein, 
unknown function G C M/I 
 
X 
 
X X 
  
X 
4 7 911078 
PF3D7_
0721000 
conserved Plasmodium 
membrane protein, 
unknown function C G R/G 
 
X 
 
X X 
  
X 
4 7 1100677 
PF3D7_
0726200 
serine/threonine protein 
kinase, FIKK family 
(FIKK7.1) G A E/K X 
 
X 
  
X X 
 
4 7 1358889 
PF3D7_
0731500 
erythrocyte binding 
antigen-175 (EBA175) A G K/E X X X 
   
X 
 
4 8 50206 
PF3D7_
0800300 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR) G C S/T 
 
X 
 
X 
 
X 
 
X 
4 8 135161 
PF3D7_
0801900 
conserved Plasmodium 
protein, unknown 
function A C N/H X X 
 
X X 
   
5 8 135171 
PF3D7_
0801900 
conserved Plasmodium 
protein, unknown 
function A G H/R X X 
 
X X 
 
X 
 
4 8 1325994 
PF3D7_
0831100 
surface-associated 
interspersed protein 8.1 
(SURFIN 8.1) 
(SURF8.1) A C H/P X 
 
X 
  
X X 
 
4 8 1400201 
PF3D7_
0832400 stevor G T Q/K 
 
X X X 
  
X 
 
4 9 27785 
PF3D7_
0900100 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR) C G T/S X X 
  
X 
  
X 
4 9 453285 
PF3D7_
0910000 
SET domain protein, 
putative (SET4) A G V/A 
 
X X 
  
X X 
 
4 9 1492960 
PF3D7_
0937700 rifin (RIF) G A S/N X 
 
X X 
   
X 
4 10 68850 
PF3D7_
1001100.
1 
acyl-CoA binding 
protein, isoform 1, 
ACBP1 (ACBP1) A T L/I 
 
X 
 
X X 
  
X 
4 10 721205 PF3D7_ conserved Plasmodium A G M/V X 
 
X 
 
X 
 
X 
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1018100 protein, unknown 
function 
4 10 758639 
PF3D7_
1019000 
eukaryotic translation 
initiation factor subunit 
eIF2A, putative G A G/E 
  
X 
  
X X X 
4 10 758644 
PF3D7_
1019000 
eukaryotic translation 
initiation factor subunit 
eIF2A, putative A T N/Y 
  
X 
  
X X X 
4 10 1399387 
PF3D7_
1035300 
glutamate-rich protein 
(GLURP) A C K/Q X 
 
X 
  
X X 
 
4 11 410321 
PF3D7_
1110300 
conserved Plasmodium 
protein, unknown 
function G T Q/K X X X 
 
X 
   
4 11 627737 
PF3D7_
1116600 
dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit STT3, putative 
(STT3) C T D/N 
  
X X X 
  
X 
4 11 658260 
PF3D7_
1117200 
conserved Plasmodium 
protein, unknown 
function T A N/K X 
   
X 
 
X X 
4 12 51465 
PF3D7_
1200600 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR2CSA) G C Q/E X X 
   
X X 
 
4 12 77787 
PF3D7_
1201000 
Plasmodium exported 
protein (PHISTb), 
unknown function C T E/K X 
 
X 
 
X 
 
X 
 
4 12 77847 
PF3D7_
1201000 
Plasmodium exported 
protein (PHISTb), 
unknown function C T E/K X 
    
X X X 
4 12 529418 
PF3D7_
1211900 
non-SERCA-type Ca2+ -
transporting P-ATPase 
(ATP4) C T G/R X 
 
X 
  
X X 
 
4 12 642447 
PF3D7_
1215900 
serpentine receptor, 
putative (SR10) A G N/S X X X 
   
X 
 
4 12 1390639 
PF3D7_
1233600 
asparagine and aspartate 
rich protein 1 (AARP1) A G N/D X 
  
X X 
  
X 
4 12 1543212 
PF3D7_
1237100 
conserved Plasmodium 
protein, unknown 
function G A A/V 
 
X X X 
  
X 
 
4 12 1721650 
PF3D7_
1240600 
erythrocyte membrane 
protein 1, PfEMP1 
(VAR) G A G/S 
 
X 
 
X X 
  
X 
4 12 1749231 
PF3D7_
1241200 
conserved Plasmodium 
protein, unknown 
function C G S/T 
   
X X X 
 
X 
4 13 54740 
PF3D7_
1300600 rifin (RIF) C T R/K 
  
X X X X 
  
4 13 2103626 
PF3D7_
1352700 
P-loop containing 
nucleoside triphosphate 
hydrolase, putative A G I/M 
 
X X 
  
X X 
 
4 14 8038 
PF3D7_
1400200 rifin (RIF) C T D/N X 
 
X X 
   
X 
4 14 17604 
PF3D7_
1400500 rifin (RIF) G C H/Q X 
 
X 
  
X X 
 
4 14 1496415 
PF3D7_
1436700 
conserved Plasmodium 
protein, unknown 
function G C P/A 
 
X X 
  
X X 
 
4 14 2035328 
PF3D7_
1449600 
conserved Plasmodium 
protein, unknown G T Q/K X 
 
X 
  
X X 
 
 131 
function 
5 14 2764134 
PF3D7_
1467600 
conserved Plasmodium 
protein, unknown 
function T C Y/C X X X 
 
X 
 
X 
 
4 14 2821537 
PF3D7_
1468600 
aminophospholipid 
transporter, putative T G L/V X X X 
    
X 
4 14 3235381 
PF3D7_
1478600 
EMP1-trafficking protein 
(PTP3) C A H/N 
 
X X 
 
X 
 
X 
 
4 14 3235382 
PF3D7_
1478600 
EMP1-trafficking protein 
(PTP3) A T H/L 
 
X X 
 
X 
 
X 
 !
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4.1 ABSTRACT 
 
In the malaria parasite Plasmodium falciparum, the synthesis of isoprenoids from glycolytic 
intermediates is essential for parasite survival. The antibiotic fosmidomycin (FSM) is a well-
validated inhibitor of isoprenoid synthesis and an effective antimalarial. In FSM-resistant P. 
falciparum, we identify a loss-of-function mutation in HAD2 (PF3D7_1226300) as causative for 
resistance. Enzymatic characterization shows that HAD2, a member of the haloacid 
dehalogenase-like hydrolase (HAD) superfamily, functions as a purine phosphatase. Harnessing 
a growth defect in HAD2-mutant parasites, we select for suppression of HAD2-mediated FSM 
resistance and uncover hypomorphic suppressor mutations in the locus encoding the glycolytic 
enzyme PFK9 (PF3D7_0915400). Metabolic profiling demonstrates that FSM resistance is 
achieved via increased steady-state levels of MEP pathway and glycolytic intermediates and 
confirms reduced PFK9 function in the suppressed strains. Together, these data point to HAD2 
as a novel and essential regulator of parasite metabolism and drug sensitivity and expand our 
understanding of this large and important family of regulators.  
 
4.2 INTRODUCTION 
 
Malaria remains a persistent global health burden, causing hundreds of millions of infections and 
nearly a half million deaths per year [1]. The most severe malaria cases are caused by the 
apicomplexan parasite Plasmodium falciparum. One of the greatest challenges in malaria 
eradication is the continued development of resistance to antimalarial drugs. Delayed parasite 
clearance times have been observed after use of artemisinin combination therapies (ACTs), the 
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current frontline treatment for malaria in endemic areas [1,2]. New antimalarials are urgently 
needed. As an obligate intracellular parasite of human erythrocytes, the parasite has a defined 
and unique metabolism that may be exploited for the discovery of new drug targets and the 
development of new therapies. 
 
In the red blood cell niche, Plasmodium parasites are highly dependent on glucose metabolism. 
Infection with Plasmodium spp. results in nearly 100-fold increase in glucose import in red blood 
cells [3–5]. Despite these energy requirements, the parasite demonstrates little aerobic respiration 
via the TCA cycle and instead relies on anaerobic glycolysis to produce ATP [6–9]. This is 
evidenced by studies showing that most parasite glucose is excreted as lactate [10,11]. 
 
Besides ATP production, glucose also has a number of anabolic fates in P. falciparum. One such 
fate is the synthesis of isoprenoids. Isoprenoids are a large class of hydrocarbons with extensive 
structural and functional diversity [12]. They are present and essential in all organisms, including 
P. falciparum [13,14] and a number of related microbes [15,16]. In the malaria parasite, 
isoprenoids perform a number of essential functions, such as protein prenylation and 
dolichylation and synthesis of GPI anchors [17–23]. In other organisms, isoprenoids also 
function in essential cellular processes such as cell wall synthesis, aerobic respiration, and 
photosynthesis [12]. 
 
Despite their diversity, all isoprenoids are synthesized from the five-carbon building block, 
isopentyl pyrophosphate (IPP). Evolution has produced two distinct pathways for IPP synthesis: 
the mevalonate pathway, which is found in archaea, fungi, animals, and the cytoplasm of plants; 
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and the methylerythritol phosphate (MEP) pathway, which is found in most bacteria, plant 
chloroplasts, and apicomplexan parasites such as P. falciparum [24]. Because of its absence in 
the human host and its essential role in the parasite, the MEP pathway is an excellent target for 
antimalarial development. The antibiotic and antimalarial fosmidomycin (FSM) is a competitive 
inhibitor of the first committed enzymatic step of the MEP pathway, catalyzed by 1-deoxy-D-
xylulose-5-phosphate reductoisomerase (DXR, E.C. 1.1.1.267) [25–27]. FSM has been validated 
as a specific inhibitor of the MEP pathway in P. falciparum [14, 28–31] and is an excellent 
chemical tool to study MEP pathway biology. 
 
The utilization of glucose by the parasite for the production of energy and secondary metabolites 
such as isoprenoids is likely subject to regulation. We previously used a screen for FSM 
resistance to identify HAD1, a negative metabolic regulator whose loss results in increased levels 
of MEP pathway intermediates and resistance to MEP pathway inhibition. HAD1 is a 
cytoplasmic sugar phosphatase that may hydrolyze glycolytic intermediates upstream of the 
MEP pathway [32]. HAD1 belongs to the haloacid dehalogenase-like hydrolase (HAD) enzyme 
superfamily (Interpro families IPR023214 and IPR000150) [33]. While HADs are found in all 
kingdoms of life, HAD1 is most related to bacterial members of this superfamily [32,34], which 
have been implicated in metabolic regulation, stress response, and phosphate homeostasis [35–
39]. However, many members of this superfamily remain uncharacterized. The study of HAD 
proteins in evolutionarily and metabolically distinct organisms such as P. falciparum will greatly 
facilitate our understanding of this large and important class of enzymes. 
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In many systems, metabolic regulation of a pathway is often centered on the first committed 
enzymatic step [40]. In glycolysis, this step is catalyzed by phosphofructokinase (PFK, E.C. 
2.7.1.11) [41]. PFKs in other organisms have been found to be subject to allosteric regulation, 
including inhibition by ATP and citrate and activation by AMP, ADP, and fructose 2,6-
bisphosphate [42,43]. PFKs of some apicomplexans have been studied and are found to be most 
related to pyrophosphate (PPi)-utilizing PFKs from plants [44–47]. A previous study described 
P. falciparum PFK9, one of two PFKs encoded in the P. falciparum genome [44]. The second 
PFK (PFK11) is expressed mainly in the gametocyte stages of the parasite lifecycle and is not 
believed to be catalytically active. Mony et al. [44] describe PFK9 as a single polypeptide 
encoding two subunits (α and β). While full-length recombinant enzyme could not be purified, 
PFK from cell lysate and the recombinant β subunit were found to be active with ATP as the 
phosphoryl donor. In these assays, PFK9 was found to be insensitive to most tested allosteric 
regulators [44]. Further studies are required to understand how the parasite utilizes this 
canonically important step of glycolysis for metabolic regulation. 
 
In this study, we describe the role of HAD2, another HAD family member in P. falciparum. We 
find that HAD2 functions as a negative metabolic regulator whose loss results in increased MEP 
pathway and glycolytic metabolites and resistance to FSM. In vitro, HAD2 dephosphorylates 
purine monophosphates, such as AMP and GMP. Selection for suppression of FSM resistance 
identifies mutations in PFK9. Through our forward genetics approach, we further define the role 
of the HAD protein family and uncover novel mechanisms of regulation of essential parasite 
metabolism and drug sensitivity.  
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4.3 METHODS 
 
4.3.1 Reagents 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. 
 
4.3.2 Parasite culture maintenance 
All strains are derived from the genome reference strain 3D7 [48] (MRA-102, MR4, ATCC, 
Manassas, VA). Unless otherwise indicated, parasites were maintained in a 2% suspension of 
human erythrocytes in RPMI medium (Sigma Aldrich, SKU R4130) modified with 2.25 g/L 
NaHCO3, 2 g/L glucose, 1.19 g/L HEPES, 2.5 mg/L thymidine, 0.22 g/L sodium pyruvate, 50 
mg/L hypoxanthine, 10 µg/mL gentamycin, and 5 g/L Albumax (Life Technologies, Carlsbad, 
CA). Parasites were maintained at 37 °C in 5% O2/5% CO2/90% N2. 
 
4.3.3 Generation of FSMR strain E2 and E2 clones 
FSMR strain E2 was generated as previously described [32]. Briefly, a clone of genome reference 
strain 3D7 (MRA-102, MR4, ATCC, Manassas, VA) was used as a parent strain. Culture was at 
4% parasitemia at the start of selection with 0.5 µM FSM. Selection was scaled to 3 µM FSM in 
0.5-1 uM increments. Clones of strain E2 were isolated by limiting dilution. 
 
4.3.4 Quantification of FSM resistance 
Asynchronous parasite cultures were diluted to 0.5-1.0% parasitemia. Assays were performed in 
opaque 96-well plates in 100 µL volumes with FSM concentrations ranging from 0.63 nM to 1 
mM. After 3 days, media was removed and parasitemia was measured by DNA content using 
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Picogreen fluorescence (Life Technologies, Carlsbad, CA) as previously described [49]. Half 
maximal inhibitory concentration (IC50) values were calculated by nonlinear regression analysis 
using Graphpad Prism software. 
 
4.3.5 Generation of recombinant HAD2 
The predicted coding sequence of HAD2 (PlasmoDB ID PF3D7_1226300) was amplified from 
P. falciparum genomic DNA by PCR using the following primers: 5’-
CTCACCACCACCACCACCATATGGCTTCTAGTAACGATGTACA-3’ and 5’-
ATCCTATCTTACTCACTTATTTTTTTTTCAAGTCAAATACTTTTTTTAA-3’. Ligation-
independent cloning was used to clone the PCR product into vector BG1861 [50], which 
introduces an N-terminal 6xHis fusion to the expressed protein. Sanger sequencing was used to 
verify the cloned construct. BG1861:6xHis-HAD2 construct was transformed into One Shot 
BL21(DE3)pLysS Escherichia coli cells (Life Technologies, Carlsbad, CA) according to 
supplier instructions. Protein expression was induced with isopropyl-β-D-thiogalactoside at mid-
log growth (OD600 0.4 – 0.5). After 3 hours, cells were collected by centrifugation and stored at -
20°C.  
 
Induced cell pellets were resuspended in lysis buffer containing 1 mg/mL lysozyme, 20 mM 
imidazole, 1 mM dithiothreitol, 10 mM Tris HCl (pH 7.5), 30 U benzonase (EMD Millipore, 
Darmstadt, Germany), and Complete Mini EDTA-free protease inhibitor tablets (Roche Applied 
Science, Penzberg, Germany). 6xHis-HAD2 was bound to nickel agarose beads (Gold 
Biotechnology, St. Louis, MO) and eluted in 300 mM imidazole, 20mM Tris HCl (pH 7.5), and 
150 mM NaCl. This eluate was further purified by size-exclusion gel chromatography using a 
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HiLoad 16/600 Superdex 200 pg column (GE Healthcare) equilibrated in 50 mM Tris HCl (pH 
7.5), 1 mM dithiothreitol, and 1 mM MgCl2. The elution fractions containing HAD2 were pooled 
into a centrifugal filter and concentrated to approximately 3 mg/ml. Glycerol was added to a final 
concentration of 10% (w/v), and the solution was immediately flash frozen in liquid nitrogen and 
stored at -80°C.  
 
The purification of recombinant HAD1 has been previously described [32]. 
 
4.3.6 Antisera generation 
Anti-HAD1 antisera has been previously described (MRA-1256, MR4, ATCC, Manassas, VA) 
[32]. Anti-HAD2 polyclonal antisera was raised against 6xHis-HAD2 in rabbits by Cocalico 
Biologicals (Reamston, PA) using their standard protocol. Titermax was used as an adjuvant. 
Antisera specificity was confirmed by immunoblot of purified recombinant 6xHis-HAD2 and 
6xHis-HAD1 (Supplemental Figure 10) as well as for P. falciparum lysate lacking HAD2 
(Supplemental Figure 9B, strain S1). Anti-HAD2 and anti-HAD1 antisera were found to be 
specific for their respective antigens. 
 
4.3.7 Immunoblotting 
Lysates from saponin-lysed parasites were separated on a polyacrylamide gel and transferred to a 
polyvinylidene difluoride membrane. Membranes were blocked in 5% non-fat dry milk in PBS, 
0.1% Tween-20. HAD2 was detected in using a 1:2,000-5,000 dilution (against P. falciparum 
lysates) or 1:15,000 (against recombinant protein) of anti-HAD2 rabbit polyclonal antisera 
(Cocalico Biologicals, Reamstown, PA). Anti-HAD1 antisera was used at a 1:20,000 dilution 
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[32]. Rabbit polyclonal anti-heat shock protein 70 (Hsp70) was detected using a 1:5,000 dilution 
(AS08 371, Agrisera Antibodies, Vännäs, Sweden). All blots used an HRP-conjugated goat anti-
rabbit IgG secondary antibody at 1:20,000 (ThermoFisher Scientific 65-6120). When necessary, 
blots were stripped by washing with 200 mM glycine, 0.1% SDS, 1% Tween-20, pH 2.2 before 
re-probing. 
 
4.3.8 Quantitative PCR of DXS and DXR 
Parasite pellets from saponin-lysed infected erythrocytes were stored at -80 °C. Total RNA was 
extracted using the Ambion Purelink RNA Mini kit (Life Technologies, Carlsbad, CA) according 
to kit instructions. After the first wash step, an on-column DNase (Qiagen, Venlo, Netherlands) 
treatment was performed. RNA was stored at -80 °C in RNase-free water until use. To synthesize 
cDNA, one µg of total RNA was used in reverse transcriptase reactions using the Quantitect 
Reverse Transcription kit (Qiagen, Venlo, Netherlands).  
 
Thirty ng of cDNA was used as a template in quantitative PCR reactions containing Fast SYBR 
Green PCR Master Mix (Applied Biosystems, Waltham, MA) and 300 nM each primer. Primers 
used were as follows: 
DXS (Pf3D7_1337200): 5’- AACGTGGATAAAGTACACATTGC-3’ and 5’- 
TGATATACTTACGGCATTTGTTGG-3’ 
DXR (PF3D7_1467300): 5’- ACATGGCCTGATAGAATAAAAACA-3’ and 5’- 
TTCATTTGACGCATTTAGTACAGTT-3’ 
 
Beta tubulin and 18S rRNA were used as control genes: 
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Beta tubulin (PF3D7_1008700): 5’- ATCCCATTCCCACGTTTACATT-3’ and 5’- 
TCCTTTGTGGACATTCTTCCTC-3’ 
18s rRNA (PF3D7_0112300): 5’- GAACGAGGAATGCCTAGTAAGCA-3’ and 5’- 
TTCATCATATCTTTCAATCGGTAGGA-3’. 
 
Thermocycling was performed using an Applied Biosystems 7500 Fast RT PCR System with the 
following parameters: 95 °C for 30 seconds and 40 cycles of 95 °C for 3 seconds, 60 °C for 30 
seconds. Controls lacking reverse transcriptase and template both produced no significant signal. 
Melt curve analysis was used to verify that all primer sets produce single products.  
 
Ct values were calculated using Applied Biosystems 7500 Fast System software. Relative 
expression levels of DXS and DXR were calculated using the ΔΔCt method. ΔCt represents the Ct 
value of the reference gene (beta tubulin and 18s rRNA combined) subtracted from the target. 
ΔΔCt represents the ΔCt value of the parental sample subtracted from the sample of interest. Fold 
changes are calculated as 2-ΔΔCt. 
 
4.3.9 Whole genome sequencing and SNP analysis 
Parasite genomic DNA was prepared for sequencing as previously described [32]. One 
microgram of genomic DNA was sheared, end repaired, and adapter ligated. Libraries were 
sequenced on an Illumina HiSeq 2500 in Rapid Run mode to generate 101 bp paired end reads. 
Reads were aligned to the P. falciparum 3D7 reference genome (PlasmoDB v7.2) using 
Novoalign (V2.08.02). Duplicate reads were removed. SNPs were called using samtools, using a 
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quality score cutoff of 20 and a read depth cutoff of 5. SNPs were annotated using snpEff. 
Parental SNPs were removed by comparing to previous sequenced parental genomes [32]. 
 
Greater than 75% of the exome was covered >5X for all samples. Whole genome sequencing 
data from this study is available through the NCBI BioProject database (PRJNA222697) and 
Sequence Read Archive (SRP038937). Library preparation, Illumina sequencing, read alignment, 
and variant analysis were performed by the Genome Technology Access Center (GTAC) at 
Washington University. 
 
4.3.10 Sanger sequencing 
The E2 A469T (R157X) HAD2 SNP was verified by amplifying P. falciparum genomic DNA 
using the following gene-specific primers: 5’-GGATATACTTTATTAGATGAGAC-3’ and 5’-
ATTATATGTTGTAAATATGGTCAATT-3’. The PFK9 locus was amplified using the 
following primers, which also include sites for ligation-independent cloning: 5’-
CTCACCACCACCACCACCATATGGATACCAAGAGTGGAGATAAAA-3’ and 5’- 
ATCCTATCTTACTCACTTAGTTCATTCTTTTTCTCTGGTTTTC-3’. Amplicons were 
sequenced using the following primers: 5’-CACAGGTAATGAATTCCCAGC-3’, 5’-
ATCATCGGCATTCTGACATAAC-3’, 5’-GATCTATGCGTTTTGAACAATTAG-3’, 5’-
CCTGTTAAGCCACTTTCAATAAC-3’, 5’-CCCAGTTGATTCTCTATCCATTAA-3’, 5’-
GGTCCATTTGATGCTTCGAAAC-3’, 5’-CGTTGTTATACTGTAAAGACTCCA-3’, and 5’-
CTAGTCCCATTTCTTTTGAAATAAGAA-3’. Amplicons sequenced by the Washington 
University Protein and Nucleic Acid Laboratory using BigDye Terminator v3.1 Cycle 
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Sequencing Reagents (Life Technologies, Carlsbad, CA). Chromatogram files were viewed 
using DNAStar SeqMan software.  
 
4.3.11 HAD2 activity assays 
Assay reactions were performed at 37°C in clear 96-well half-area plates and measured using a 
FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). Assay data was 
analyzed and reaction rates determined using GraphPad Prism software.  
 
Phosphatase activity of recombinant enzyme was initially evaluated against the substrate pNPP 
(New England Biolabs, Ipswich, MA). Reactions contained 10 mM pNPP, 50 mM Tris HCl (pH 
7.5), 5 mM MgCl2, 0.5 mM MnCl2, and 0.25-4 µg purified recombinant enzyme. Para-
nitrophenyl production was quantified by absorbance at 405 nm.  
 
Specific enzyme activity against phosphorylated sugar substrates was measured using the 
EnzChek Phosphate Assay Kit (Life Technologies, Carlsbad, CA) according to supplier 
instructions. Substrates were purchased from Sigma-Aldrich (St. Louis, MO), except for DOXP 
and MEP (Echelon Biosciences, Salt Lake City, UT) and fructose 1-phosphate (Santa Cruz 
Biotechnology, Dallas, TX). Reactions were performed in 50 µL volumes containing 1 mM 
substrate and 150–750 ng recombinant purified enzyme.  
 
Kinetic parameters were measured using 150 ng recombinant purified HAD2 enzyme, with 
continuous measurement of product formation in response to 0.06 – 10 mM substrate. 
Michaelis–Menten parameters Km and Vmax were determined by non-linear regression (GraphPad 
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Prism). The reaction rate (kcat) and catalytic efficiency (kcat/Km) were also determined from these 
parameters. 
 
4.3.12 Measurement of AMP levels 
Trophozoite pellets were prepared as described above. Briefly, synchronized early trophozoites 
were lysed with saponin, washed with cold 2 g/L glucose in PBS, and frozen at -80 °C. Samples 
were extracted and prepared for ultra-high performance liquid chromatography tandem mass 
spectrometry (IP-RP–UPLC–MS/MS) as previously described [51].  
 
4.3.13 P. falciparum growth assays 
Asynchronous parasite cultures were seeded at ~1% parasitemia. Samples were taken every 1-2 
days for 12 days and fixed in 4% paraformaldehyde, 0.05% glutaraldehyde in PBS. Media was 
exchanged daily. Parasites were subcultured 1:2 or 1:4 throughout the assay to avoid growth rate 
perturbations due to high parasite density. Fixed samples were washed with PBS and stained 
with 0.01 mg/ml acridine orange (Invitrogen) in PBS. Parasitemia was determined by measuring 
fluorescence on a BD Biosciences LSRII flow cytometer. Parasitemias were corrected for 
subculturing and data was plotted as % growth from day 0. 
 
4.3.14 Preparation of soluble P. falciparum whole-cell lysate 
Cultures were synchronized with 5% sorbitol. Synchronized trophozites were isolated 32 hours 
post-invasion by treatment of infected erythrocytes with 0.1% saponin. Isolated trophozites were 
washed three times in 100 µL buffer containing 100 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM 
DTT, 10% glycerol (w:w), and supplemented according to manufacturer instructions with 
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Complete Mini EDTA-free protease inhibitor tablets (Roche). Lysates were prepared by three 
sonication steps at 4°C (Fischer Scientific Model 550 Sonic Dismembrator at an amplitude 
setting of 3.5), followed by centrifugation at 4°C (10,000 xg, 10 min). Supernatant was isolated 
and total protein concentration of lysate was determined using a bicinchoninic acid (BCA)-linked 
assay kit and performed according to manufacturer’s instruction (Thermo Scientific Pierce). 
Lysates were prepared fresh and kept on ice for all assays. 
 
4.3.15 Assay of PFK9 activity from lysate 
The activity of PFK9 in lysate was monitored by linking it to the oxidation of NADH via linking 
enzymes, as adapted from Mony et al [44] and as originally described by Beutler [52]. Reactions 
were performed in 150 µL volumes with assay buffer containing 100 mM Tris-HCl (pH 7.5), 1 
mM MgCl2, 1 mM DTT, 0.25 mM NADH, 1 mM ATP, 3 mM fructose 6-phosphate, as well as 
excess of linking enzymes aldolase (7.5 U), triose-phosphate isomerase (3.8 U), and glycerol 3-
phosphate dehydrogenase (3.8 U). After adding fresh cell lysate (15 µg total protein content), the 
absorbance at 340 nm was measured at 37°C for 40 min. Activity (µmol/min/mg total protein) 
was determined from a linear regression taken between 25 min and 35 min of the absorbance 
curve. For some experiments, a range of substrate (ATP or fructose 6-phosphate) or lysate 
concentations were used as indicated. In some cases, Bacillus stearothermophilus PFK (BsPFK) 
was used as a positive control.  
 
4.3.16 LC-MS/MS sample preparation 
All cultures were grown to >5% parasitemia at 4% hematocrit in 25 mL volumes. Cultures were 
synchronized with 5% sorbitol to obtain ring-stage parasites. At approximately 20 hours post-
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invasion (early trophozoites), parasites were isolated by saponin lysis, washed with cold 2 g/L 
glucose in PBS, and frozen at -80 °C until extraction. Samples were extracted in 600 µL of ice-
cold extraction solvent [chloroform, methanol, and acetonitrile (2:1:1, v/v/v)] using two liquid-
nitrogen cooled 3.2 mm stainless steel beads and homogenization in Tissue-Lyser II instrument 
(Qiagen, Venlo, Netherlands) at 20 Hz for 5 minutes in a cold sample rack. Ice-cold water was 
added and samples were homogenized for 5 more minutes at 20 Hz. Samples were centrifuged at 
14,000 rcf at 4°C for 5 min. The polar phase was lyophilized and re-dissolved in 100 µL water 
and analyzed by LC-MS/MS. 
 
4.3.17 LC-MS/MS analysis of MEP pathway and glycolytic intermediates 
LC-MS/MS was performed on a 4000QTRAP system (AB Sciex, Framingham, MA) in multiple-
reaction monitoring mode (MRM) using negative ioniziation. The specific parameters used for 
analysis of MEP pathway metabolites have been previously described [28]. Liquid 
chromatography separation was done using ion pair reverse-phase chromatography [53]. The ion 
pair reagent used was 10 mM tributylammonium acetate (pH 5.1-5.5). The referenced method 
[53] was modified: (1) RP-hydro 100 mm × 2.0 mm, 2.5 µm high performance liquid 
chromatography column (Phenomenex, Torrance, CA), (2) flow rate of 0.14 mL/min, (3) solvent 
A of 10 mM tributylammonium acetate in 5% methanol, (4) binary LC gradient (20% solvent B 
(100% methanol) from 0 to 2.5 min, 30% B for 12.5 min, 80% B for 5 min, and column 
equilibration at for 5 minutes), and (5) 20 µL autosampler injection volume. 
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4.3.18 pTEOE110:HAD2 plasmid construction 
The pTEOE110:HAD2-GFP construct contains the heat shock protein 110 (PF3D7_0708800) 5’ 
UTR and a C-terminal GFP tag. Human dihydrofolate reductase (hDHFR) is present as a 
selectable marker. Inverted terminal repeats are included for integration into the genome by a co-
transfected piggyBac transposase (pHTH, MRA912, MR4, ATCC, Manassas, VA).  
 
HAD2 was amplified with the following primers: 5’-
GATCCTCGAGATGGCTTCTAGTAACGATGTACATT-3’ and 5’-
GATCCCTAGGTTTTTTTTTCAAGTCAAATACTTTTTTTAATAAG-3’ and cloned into 
AvrII and XhoI sites in the pTEOE110 plasmid. Insertion and sequence was verified by colony 
PCR and Sanger sequencing. 
 
4.3.19 Parasite transfections 
Transfections were performed as previously described [32]. Briefly, 50-100 µg of plasmid DNA 
was precipitated and resuspended in Cytomix solution (25 mM HEPES pH 7.6, 120 mM KCl, 
0.15 mM CaCl2, 2mM EGTA, 5 mM MgCl2, 10 mM K2HPO4).  
 
A 4 mL, 2% hematocrit, 5% ring-stage P. falciparum culture was washed with Cytomix and 
resuspended in the DNA/Cytomix solution. The culture was electroporated at 950 µF and 0.31 
kV, washed with media, and returned to normal culture conditions. Parasites expressing the 
construct were selected by continuous treatment with 5 nM WR92210 (Jacobus Pharmaceuticals, 
Princeton, NJ). Transfectants were cloned by limiting dilution and presence of the HAD2-GFP 
construct was verified by PCR using gene-specific and GFP-specific primers (5’-
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AGGATATACTTTATTAGATGAGAC-3’ and 5’-CCGTATGTTGCATCACCTTC-3’). The 
presence of the endogenous HAD2 and PFK9 mutations were verified by Sanger sequencing. 
 
4.3.20 Live fluorescent microscopy 
Erythrocytes infected with E2 Hsp110:HAD2-GFP parasites were stained with 10 ng/µL Hoescht 
33258 (Life Techologies, Carlsbad, CA) and mounted under coverslips on polysine adhesion 
slides. Cells were viewed on an Olympus BH8 microscope (Tokyo, Japan). Minimal adjustments 
to contrast and brightness were applied equally to all microscopy images using GIMP software.  
 
4.3.21 Electron microscopy 
P. falciparum-infected erythrocytes were fixed in 4% paraformaldehyde/0.05% glutaraldehyde 
(Polysciences Inc., Warrington, PA) in 100 mM PIPES/0.5 mM MgCl2, pH 7.2 for 1 hour at 4°C. 
Samples were then embedded in 10% gelatin and infiltrated overnight with 2.3 M sucrose/20% 
polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C. Samples were trimmed, frozen in liquid nitrogen, 
and sectioned with a Leica Ultracut UCT cryo-ultramicrotome (Leica Microsystems Inc., 
Bannockburn, IL). Fifty nm sections were blocked with 5% fetal bovine serum/5% normal goat 
serum for 30 minutes and subsequently incubated with rabbit anti-GFP (ab6556) (Abcam, 
Cambridge, MA), goat anti-rabbit IgG (H+L) conjugated to 18 nm colloidal gold (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA). Sections were washed in PIPES buffer 
followed by a water rinse, and stained with 0.3% uranyl acetate/2% methylcellulose. Samples 
were viewed with a JEOL 1200EX transmission electron microscope (JEOL USA Inc., Peabody, 
MA) equipped with an AMT 8 megapixel digital camera (Advanced Microscopy Techniques, 
Woburn, MA). All labeling experiments were conducted in parallel with controls omitting the 
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primary antibody. These controls were consistently negative at the concentration of colloidal 
gold-conjugated secondary antibodies used in these studies. 
 
4.4 RESULTS 
 
4.4.1 FSMR strain E2 possesses a nonsense allele of HAD2, a homolog of the 
MEP pathway regulator HAD1 
The MEP pathway is responsible for the synthesis of the essential isoprenoid precursors IPP and 
DMAPP. This pathway is specifically inhibited by the antibiotic fosmidomycin (FSM) 
[14,28,54]. We previously generated 20 P. falciparum strains resistant to FSM [32]. While loss 
of a negative regulator, HAD1, is responsible for the resistance phenotype in 17 of these strains, 
3 strains remain uncharacterized, including strain E2. We report a FSM IC50 for strain E2 of 4.8 
± 1.2 µM (parental IC50 ~1 µM), similar to our previously reported value for this strain [32]. This 
resistance phenotype is not due to changes in the HAD1 locus or changes in DXS, DXR, or HAD1 
expression (Supplementary Figure 1, Supplementary Figure 2). We performed whole genome 
sequencing on this strain to identify genetic changes that may result in FSM resistance. The 
sequences of previously described parental and control strains [32] were used to filter SNPs also 
found in these strains. SNPs found in stain E2 are listed in Supplementary Data 1. We prioritized 
changes found in coding regions and eliminated changes found in highly variable loci such as 
rifins and var genes [55,56]. Among the changes identified in E2 is an A469T mutation in 
PF3D7_1226300 (PlasmoDB[57] ID), hereafter referred to as HAD2. Sanger sequencing of the 
HAD2 locus in strain E2 confirms the presence of the A469T allele. This allele encodes a 
truncated R157X variant and therefore we expect HAD2 function is lost in strain E2.  
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Interestingly, HAD2 is a close homolog of the known MEP pathway regulator and sugar 
phosphatase HAD1 [32]. Sequence homology places both proteins in the haloacid dehalogenase-
like hydrolase (HAD) superfamily and within this family, the Cof-like hydrolase subfamily 
(Interpro IPR000150) [33]. HAD2 and HAD1 protein sequences share ~29% sequence identity 
and ~53% sequence similarity (Supplementary Figure 3). HAD2 possesses the four conserved 
sequence motifs found in HAD proteins (Supplementary Figure 3).  
 
While no structural information exists for HAD2, the structure of the Plasmodium vivax HAD2 
(PVX_123945, PvHAD2) has been solved (PDB ID 2B30). This protein shares 93% sequence 
identity and 98% sequence similarity to with HAD2. PvHAD2 shows strong structural similarity 
to HAD1 and other HADs, with a core and cap domain structure (Supplementary Figure 4). We 
hypothesized that HAD2, like HAD1, regulates metabolism in P. falciparum malaria parasites. 
 
4.4.2 HAD2 is a purine monophosphatase 
Based on sequence homology to HAD1 and other HAD proteins, we predicted that HAD2 would 
function enzymatically as a phosphatase. The in vitro phosphatase activity of HAD2 was 
confirmed by reacting purified recombinant enzyme against para-nitrophenyl phosphate (pNPP), 
a promiscuous chromogenic phosphorylated substrate [32,34,58]. HAD2 was found to yield 
colored p-nitrophenyl product at 1.05 ± 0.22 µmol/min/mg enzyme. 
 
Recent work on the HAD2 homolog from P. vivax (PvHAD2) has demonstrated a varied 
substrate profile for this enzyme that includes sugar phosphates and nucleotide phosphates [59]. 
 156 
We tested HAD2 against a wide range of phosphorylated substrates. Surprisingly, we find that 
HAD2 shows markedly lower activity against sugar phosphate substrates than HAD1 and its 
PvHAD2 homolog (Figure 1) [59]. In contrast, we find that HAD2 is active against a number of 
phosphorylated nucleotide substrates (Figure 1). In particular, HAD2 appears to prefer the purine 
monophosphates adenosine 5’-monophosphate (AMP) and guanosine 5’-monophosphate (GMP), 
while HAD1 is minimally active against nucleotides (Figure 1). Kinetic parameters for HAD2 
against its top 5 substrates can be found in Supplementary Table 1. 
 
We hypothesized that loss of HAD2-mediated purine nucleotidase function in FSMR strain E2 
may result in changes in cellular AMP levels. We evaluated AMP levels using a recently 
described liquid chromatography- mass spectrometry (LC-MS) method [51]. We do not find that 
AMP levels are increased in strains lacking functional HAD2 (Supplementary Figure 5). 
 
4.4.3 HAD2 is expressed throughout the parasite intraerythrocytic lifecycle 
To determine if HAD2 was functional during a specific stage of the parasite lifecycle, we 
evaluated HAD2 expression throughout intraerythrocytic development. We also compared the 
expression profile of HAD2 to HAD1. Polyclonal anti-HAD2 antisera was generated in rabbits 
against recombinant HAD2. The specificities of anti-HAD1 and anti-HAD2 antisera for their 
respective HAD proteins were verified (see Methods). 
 
Sorbitol-synchronized parasites were sampled at various timepoints and parasite lysates were 
probed by immunoblot with anti-HAD1 and anti-HAD2 antisera (Figure 2). Samples were also 
evaluated by microscopy to verify the developmental stage (Figure 2A). HAD1 and HAD2 are 
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both expressed throughout the asexual cycle, and protein expression appears to peak during the 
trophozoite and schizont stages (Figure 2B), consistent with RNA expression profiling of these 
genes [60,61]. 
 
4.4.4 FSMR had2R157X parasites have a growth defect that drives loss of FSM 
resistance 
FSMR had2R157X parasites have impaired growth compared to the parental strain (Figure 3, purple 
vs. black lines). Upon long term in vitro culture (>1 month) in the absence of FSM, we observe 
that the FSMR had2R157X strain increases in growth rate. Importantly, we find that improved 
growth corresponds with loss of FSM resistance. We hypothesize that in FSMR had2R157X 
parasites, FSM resistance via loss of HAD2 results in a fitness cost. Strain E2 may represent a 
mixed population containing slow growing, FSMR parasites and fast growing, FSM-sensitive 
(FSMS) parasites. Over time, the FSMS population thus predominates. To test this hypothesis, we 
cloned the E2 strain via limiting dilution and randomly selected five clones. Consistent with the 
presence of a mixed parasite population, three of the six clones are FSMR (designated clones R1, 
R2, and R3), and two are FSMS (designated S1 and S2) (Figure 4, Figure 5A). Additionally, the 
FSMS clones grow noticeably faster than the FSMR clones (Figure 3, teal vs. purple line). To test 
whether the FSMS strains had lost FSM resistance by reverting their had2R157X mutation, we 
genotyped all E2 clones at the HAD2 locus. All five E2 clones maintained loss of HAD2 via the 
had2R157X truncation mutation.  
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4.4.5 Long-term culture selects for suppressor mutations in PFK9 
We predicted that the FSMS E2 clones, driven by a fitness advantage, had acquired suppressor 
mutation(s) at an additional locus, resulting in loss of FSM resistance and an increase in growth 
rate. We performed whole genome sequencing on the five E2 clones to identify any genetic 
changes that segregated with the FSMR and FSMS (suppressed) phenotypes. Indeed, we find that 
a mutation of the locus encoding phosphofructokinase-9 (PFK9, PF3D7_0915400) is present in 
all the suppressed (FSMS) E2 clones and none of the FSMR E2 clones (Figure 4, Supplementary 
Figure 6, Supplementary Table 2). PFK9 is the only mutated locus that segregates with the 
change in FSM tolerance. 
 
Of note, the R157X mutation in HAD2 was one of only two SNPs common to the FSMR clones, 
increasing our confidence that had2R157X is the causative change driving FSM resistance in these 
strains. A second common SNP was found in PF3D7_0107600, which encodes a putative protein 
kinase whose P. berghei homolog has been implicated in control of latency of sporozoites [62] 
and is not expressed in asexual stage parasites [57]. 
 
Phosphofructokinase (PFK) catalyzes the first committed and canonically rate-limiting step of 
glycolysis, the conversion of fructose 6-phosphate to fructose 1,6-bisphosphate. PFK9 is a single 
polypeptide expressed in asexual stage parasites and is comprised of two domains, designated 
alpha and beta [44]. In other systems (plants, yeast, humans) the alpha domain is typically 
regulatory, and the beta domain is catalytic [63–66]. Although we and others have been 
unsuccessful in purifying full-length recombinant PFK9, previous work suggests that the N-
terminal beta domain has more independent catalytic activity than the C-terminal alpha domain 
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[44]. The previous study describes PFK9 as being similar to PPi-utilizing PFKs from plants, 
although it was demonstrated to have weak ATP-utilizing activity [44]. The T1206I variant 
found in our E2 clones maps to the alpha domain (Supplementary Figure 6, Supplementary Table 
2).  
 
4.4.6 Suppressor alleles encode hypomorphic variants of PFK9 
In silico analysis of the pfk9T1206I suppressor allele using Polyphen-2 suggests that it negatively 
impacts PFK9 function (Table 1) [67]. As we were unable to obtain full-length recombinant 
protein, we tested the effects of the suppressor mutation on PFK activity in P. falciparum lysate. 
A linked enzyme assay to measure PFK activity was implemented as previously described 
[44,52]. The assay is linear with respect to total protein content and is specific for parasite PFK 
activity (Supplementary Figure 7).  
 
We find that strains possessing the pfk9T1206I mutation have significantly reduced PFK activity 
when compared to both the parental strain and the E2-RX clones (PFK9WT) (Figure 5B). 
Interestingly, the FSMR E2 clones also show reduced PFK activity despite possessing a wild-type 
PFK allele. This may be explained by changes in PFK9 expression in FSMR clones. 
 
4.4.7 HAD2 regulates glycolysis at PFK9 
We identify hypomorphic variants in the glycolytic enzyme PFK9 that suppress FSM resistance 
in strains lacking HAD2.  Thus, we hypothesized that HAD2 acts as a negative glycolytic 
regulator, possibly at the step catalyzed by PFK9. Loss of HAD2 would result in increased levels 
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of glycolytic and MEP pathway metabolites and FSM resistance. Reduced activity of PFK9 
would negate this increase, restoring normal metabolite levels and FSM tolerance.  
 
To test this model, we performed metabolic profiling on the parental parasite strain as well as E2 
clones R1-R3 and S1-S2 (Figure 5C). Levels of the MEP pathway intermediate DOXP are 
significantly increased in FSMR strains lacking HAD2 (Figure 5C, p < 0.05, one-way analysis of 
variance (ANOVA)). While not statistically significant for all strains, we also observe increases 
in steady-state MEcPP levels in our FSMR strains. As DOXP is the substrate for the FSM target 
enzyme DXR, our data are consistent with FSMR strain E2 achieving FSM resistance via 
increased levels of DOXP counteracting competitive inhibition of DXR by FSM, similar to the 
mechanism previously proposed for HAD1 [32]. 
 
In order to better understand the role of PFK9 in suppressing FSM resistance in strains lacking 
functional HAD2, we measured the steady-state levels of a number of glycolytic intermediates, 
including fru6P and FBP, the substrate and product of PFK9 (Figure 5C). We observe that FSMR 
resistant E2 clones possessing the had2R157X allele have increased levels of FBP. This is 
consistent with HAD2-mediated negative regulation acting at the PFK step.  
 
Furthermore, strains possessing the pfk9T1206I suppressor allele display nearly parental levels of 
glycolytic and MEP pathway intermediates (Figure 5C). This is consistent with the hypothesis 
that hypomorphic alleles of PFK9 are able to suppress increased metabolite levels caused by loss 
of HAD2.  
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Additionally, FBP levels are highly correlated with the levels of MEP pathway intermediates 
DOXP and MEcPP (Pearson r = 0.93 and 0.99, respectively; p < 0.001). This is not the case for 
the upstream metabolites glu6/fru6P, which shows little correlation with DOXP or MEcPP 
(Pearson r < 0.7, p > 0.05). DOXP, MEP, and FBP levels are all significantly correlated with 
FSM IC50 (Pearson r > 0.8, p < 0.02).  
 
4.4.8 Suppression and complementation support model of HAD2- and PFK9-
mediated metabolic regulation 
Our model of PFK9-mediated suppression of FSM resistance in strains with the had2R157X allele 
predicts that a fitness defect selects for acquisition of suppressor mutations in PFK9. To further 
test this hypothesis, we grew the three FSMR E2 clones (had2R157X, PFK9WT) without FSM for >1 
month (Figure 4). 
 
As previously observed, these strains also lost their FSM resistance phenotype (Supplementary 
Table 2) and exhibited increased growth rates (Figure 3). We sequenced HAD2 and PFK9 in 
these three suppressed strains. Indeed, all maintained the had2R157X mutation and had acquired 
new, independent PFK9 mutations (Figure 4, Supplementary Figure 5, Supplementary Table 2), 
which correlated with increased growth rate and FSM sensitivity (Supplementary Table 2). As 
predicted, these strains also demonstrate reduced PFK activity in our lysate assay 
(Supplementary Figure 8). 
 
Our model also predicts that restoration of functional HAD2 in FSMR strain E2 will restore FSM 
sensitivity. To test this hypothesis, we used the piggyBac transposon system to express GFP-
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tagged HAD2, driven by the heat shock protein 110 (Hsp110) promoter in strains with the 
had2R157X allele [32,68,69]. 
 
We were unable to obtain successful transfectants from the FSMR clones (had2R157X, PFK9), 
perhaps because of these strains possess decreased overall fitness. However, we were able to 
rescue loss of HAD2 in a suppressed FSMS E2 clone (had2R157X, pfk9T1206I) (Supplementary 
Figure 9A). The transformed strain was confirmed to maintain its endogenous HAD2 and PFK9 
mutations, as well as successful expression of exogenous HAD2-GFP (Figure 3, Supplementary 
Figure 9B). Consistent with our model of HAD2 as a negative regulator of glycolysis and the 
MEP pathway, expression of HAD2-GFP in had2R157X, pfk9T1206I parasites results in increased 
sensitivity to FSM compared to both the suppressed and parental parasite strains (Figure 5D, 
Supplementary Figure 9C).  
 
The creation of HAD2-GFP parasites allowed us to assess the in vivo substrates available to 
HAD2 via live fluorescence microscopy. We observe that HAD2-GFP is localized throughout 
the cytoplasm in asexual P. falciparum trophozoites and schizonts (Figure 6). HAD2 appears to 
be excluded from the food vacuole. This is consistent with the lack of a predicted signal 
sequence for HAD2 using SignalP, PlasmoAP, and PlasMit algorithms [70–72]. Like HAD1 
[32], HAD2 does not appear to primarily concentrate in the apicoplast, the site of isoprenoid 
synthesis by the MEP pathway. 
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4.5 DISCUSSION 
 
Using resistance to the inhibitor FSM, we identify the purine phosphatase HAD2 as a novel 
regulator of parasite metabolism. Parasites lacking HAD2 exhibit increased steady-state levels of 
glycolytic and MEP pathway intermediates that allow them to overcome FSM inhibition. HAD2 
appears to be necessary for parasite fitness, and we select for mutations that suppress the HAD2-
mediated FSM resistance and growth defect. We find that mutations in phosphofructokinase 
(PFK9) restore wild-type growth rates and FSM sensitivity, connecting HAD protein function to 
regulation of essential central carbon metabolism in the parasite.  
 
We observe strong correlation between levels of MEP pathway metabolites DOXP and MEcPP 
and FBP, the product of PFK9 (Pearson r > 0.9, p < 0.001). This is consistent with the lack of a 
rate-limiting enzymatic step between PFK and the MEP pathway enzyme DXR. Similar to what 
has been described in E. coli [73], FBP appears to be able to function as an indicator of 
metabolic flux, which is subject to perturbations from drug treatment or genetic mutation. A 
recent study described FBP-centered metabolic regulation in the related apicomplexan 
Toxoplasma gondii, which constitutively expresses and regulates the gluconeogenic enzyme 
fructose 1,6-bisphosphatase (FBPase) to fine-tune its glucose metabolism [74]. While P. 
falciparum does not appear to possess an FBPase necessary for gluconeogenesis, it is possible 
that the parasite possesses FBP-sensing mechanisms for tuning its metabolism, perhaps via 
regulators such as HAD1 and HAD2.  
 
HAD2 is a member of the HAD superfamily and a homolog of the previously described 
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metabolic regulator HAD1 [32]. Both enzymes belong to the Cof-like hydrolase subfamily 
(IPR000150) [33], which mainly comprises proteins from bacteria and plastid-containing 
organisms (plants and apicomplexans). These enzymes display wide and varied substrate 
preference [34,37,75–79], although the function of most members remains unknown. Along with 
our previous studies on HAD1 [32,80], we define the role of these proteins in P. falciparum and 
contribute to the greater understanding of this evolutionarily conserved and important protein 
family. 
 
Our approach demonstrates the power of a forward genetics approach to uncover novel biology 
in a clinically relevant, non-model organism. We employ a previously described screen for FSM 
resistance [32] to uncover a novel resistance mutation and employ a second selection for parasite 
fitness to identify changes that suppress our resistance phenotype. While fitness costs associated 
with antimalarial resistance mutations have long been observed (summarized in [81,82]), our 
study represents, to our knowledge, the first to utilize this fitness defect to identify suppressor 
mutations in a non-target locus. Fitness assessment of resistance mutations may allow for 
suppressor screening for other antimalarials and other target pathways.   
 
Resistance screens in malaria are often used for inhibitor target identification [83–88]. However, 
we utilize relatively low drug selection concentrations (≤10X IC50) and a high sample number to 
uncover mutations in non-target loci that regulate essential biochemical pathways in the parasite. 
Indeed, our screen did not uncover any genetic changes in the FSM target, DXR. This 
underscores the importance of interpreting the results of a resistance selection with caution and 
the necessity of genetically validating resistance mutations.  
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The novel points of metabolic regulation we uncover in this study may serve as targets for future 
antimalarial development. We describe a novel resistance mutation in HAD2 that results in a 
significant decrease in parasite fitness. This is consistent with the recent observation that loss of 
the HAD2 homolog in Plasmodium berghei results in a significant growth defect during 
infection [89]. Thus, HAD2 mutations are unlikely to be biomarkers of clinical FSM resistance. 
However, HAD2 is an excellent target for development of future antimalarials. HAD2 lacks 
close homologs in mammals. Recombinant HAD2 is easily expressed and assayed and its use of 
common cellular metabolites (purines) lends itself to informed inhibitor screening and 
optimization. 
 
In addition to HAD2, our work highlights the glycolytic enzyme PFK9 as an important point of 
regulation in essential parasite glucose metabolism. While the parasite is able to tolerate 
mutation to the PFK9 locus in a had2R157X background, these mutations likely come with a 
fitness defect in wild-type parasites. A kinetic model of parasite glycolysis shows that PFK has a 
high flux control coefficient, is sensitive to competitive inhibition, and is effective at reducing 
flux through glycolysis [90,91], making it a leading candidate for targeting essential glucose 
metabolism in the parasite. Like HAD2, PFK9 is plant-like and divergent from its mammalian 
homologs [44]. These differences may be exploited for PFK inhibitor design.  
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4.6 FIGURES  
 
Figure 1. HAD2 is a purine monophosphatase with a unique substrate specificity profile. 
Displayed are the means +/- standard error of the mean (S.E.M.) of the specific enzyme activity 
for HAD1 (A) and HAD2 (B) from at least three independent experiments. HAD1 activity 
against sugar phosphates was previously described [32]. Sugar phosphates (white bars) are 
ordered from left to right by increasing number of carbon atoms (3 – 15). Nucleotides (black 
bars) are ordered from left to right by increasing degree of phosphorylation. Abbreviations: 
Glc2P, glycerol 2-phosphate; Glc1P, glycerol 1-phosphate; Gly3P, glyceraldehyde 3-phosphate; 
DHAP, dihydroxyacetone phosphate; Glu1P, glucose 1-phosphate; PEP, phosphoenolpyruvate; 
2-PGA, 2-phosphoglyceric acid; Ery4P, erythrose 4-phosphate; Ribu5P, ribulose 5-phosphate; 
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DOXP, deoxyxylulose 5-phosphate; Rib5P, ribose 5-phosphate; 2drib5P, 2-deoxyribose 5-
phosphate; MEP, methylerythritol phosphate; Fru1P, fructose 1-phosphate; Man6P, mannose 6-
phosphate; Glu6P, glucose 6-phoshpate; Fru6P, fructose 6-phosphate; Fru1,6bisP, fructose 1,6-
bisphosphate; Gal1P, galactose 1-phosphate; Sorb6P, sorbitol 6-phosphate; Man1P, mannose 1-
phosphate; Sedo7P, sedoheptulose 7-phosphate; Tre6P, trehalose 6-phosphate; Pyr5P, pyridoxal 
5’-monophosphate; GMP, guanosine 5’-monophosphate; AMP, adenosine 5’-monophosphate; 
XMP, xanthosine 5’-monophosphate; IMP, inosine 5’-monophosphate; CMP, cytidine 5’-
monophosphate; dCMP, 2’-deoxycytidine 5’-monophosphate; dGMP, 2’-deoxyguanosine 5’-
monophosphate; TMP, thymidine 5’-monophosphate; UMP, uridine 5’-monophosphate; dUMP 
2’-deoxyuridine 5’-monophosphate;  ADP, adenosine 5’-diphosphate; TDP, thymidine 5’-
diphosphate; UDP, uridine 5’-diphosphate; CDP, cytidine 5’-diphosphate; GDP, guanosine 5’-
diphosphate; CTP, cytidine 5’-triphosphate; ATP, adenosine 5’-triphosphate. 
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Figure 2. HAD2 and HAD1 are expressed throughout the intraerythrocytic parasite 
lifecycle. 
(A) Synchronized 3D7 parental parasites were sampled at various timepoints (0-48 hours) 
throughout a single asexual lifecycle. (B) Samples were probed for HAD1 and HAD2 expression 
using polyclonal antisera. Expression peaks during the trophozoite and schizont stages. Data are 
representative of at least three independent experiments. 
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Figure 3. FSM resistance results in a fitness cost. 
A representative FSMR clone with the had2R157X allele (R1, purple line) has a reduced growth 
rate compared to the wild-type parental strain (black). The growth defect is rescued in two 
representative clones with mutations in PFK9 (S1 and S3, teal lines). Error bars represent S.E.M. 
from at least three independent experiments.  
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Figure 4. Model of parasite populations and genetic changes that modulate FSM sensitivity. 
Parasites are colored by their FSM tolerance phenotype (teal for FSMS, purple for FSMR). 
Cloned strains are named by FSM tolerance phenotype (E2-SX, sensitive; E2-RX, resistant). A 
FSMS parental strain was selected under FSM pressure to enrich for FSMR strain E2 (had2R157X). 
After relief of FSM pressure, a fitness advantage selects for suppressor mutations in PFK9 
(pfk9mut, yellow star) that result in FSM sensitivity. Upon cloning, FSMR clones are grown 
without FSM pressure. As before, fitness advantage selects for suppressor mutations in PFK9 
that result in increased growth rate and loss of FSM resistance. 
 
 171 
 
 
Figure 5. HAD2 and PFK9 alleles alter FSM resistance, PFK activity, and metabolite levels 
in P. falciparum. 
(A) FSM IC50s for parental (par) strain and E2 clones. Colors represent the log2 of the fold 
change (FC) over the parental strain, as indicated in the legend. Cloned strains are named by 
FSM tolerance phenotype (SX, sensitive; RX, resistant). Data are representative of at least three 
independent experiments. (B) Measurement of PFK activity of P. falciparum lysate indicates that 
E2-SX clones with PFK9 suppressor mutations have reduced PFK activity. Error bars represent 
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S.E.M. from at least three independent experiments. P-values were determined using a one-way 
analysis of variance (ANOVA; Tukey’s post-test). * = P < 0.05, *** = P < 0.001, **** = P < 
0.0001. (C) LC-MS/MS metabolic profiling of glycolytic and MEP pathway intermediates of 
parental and E2 clone strains confirms decreased PFK activity (FBP levels) in E2-SX strains 
with PFK9 suppressor mutations. FSMR strains achieve resistance via increased levels of MEP 
pathway intermediates, which correlate with FBP. Colors represent the log2 of the fold change 
(FC) over the parental strain, as indicated in the legend. Data are representative of at least two 
independent biological replicates each composed of at least two technical replicates. Isomer pairs 
that cannot be confidently distinguished are indicated (glu6P/fru6P and DHAP/gly3P). (D) When 
loss of HAD2 is rescued in had2R157X, pfk9T1206I parasites, the resulting strain is over-sensitive to 
FSM, due to having functional HAD2 and a hypomorphic PFK9 allele.  
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Figure 6. HAD2 is localized to the cytoplasm. 
Shown is live microscopy of E2 HAD2-GFP parasites, stained with Hoescht 33258 nuclear stain. 
Scale bars, 2 µm. 
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Supplementary Figure 1. FSMR strain E2 does not have increased levels of DXS or DXR 
transcripts. 
Shown are relative expression levels calculated from duplicate independent experiments 
comprised of three technical replicates. Error bars represent S.E.M. N.s. = not significant, P > 
0.05, by an unpaired Student’s t-test. 
  
 175 
 
Supplementary Figure 2. HAD1 expression is unchanged in FSMR strain E2.  
Shown are immunoblots of the parent strain and FSMR strain E2. Marker units are kilodaltons 
(kDa). Top panel was probed with anti-HAD1 antisera. Bottom panel was probed with anti-heat 
shock protein 70 antisera as a loading control. Expected protein masses: HAD1, 33 kDa; Hsp70, 
74 kDa. Blot is representative of at least three independent experiments. 
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Supplementary Figure 3. HAD2 is a homolog of the MEP pathway regulator HAD1. 
Alignment was produced using Clustal Omega [92] and BoxShade. Residues highlighted in 
black are identical. Residues highlighted in grey are similar. HAD1 and HAD2 share ~29% 
sequence identity and ~53% sequence similarity. Like HAD1, HAD2 possesses the four 
sequence motifs found in HAD proteins (blue boxes).  
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Supplementary Figure 4. P. vivax HAD2 is structurally similar to P. falciparum HAD1. 
PDB structures were compared using rigid-body alignment (TM-align) in Lasergene Protean 3D 
software. P. vivax HAD2 (PDB ID 2B30) is shown in ochre and P. falciparum HAD1 (4QJB) is 
shown in blue. Ions (Mg2+, Ca2+, Cl-) are shown in green. Cap domains are indicated by lighter 
coloring.  
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Supplementary Figure 5. AMP levels are unchanged in E2 FSMR parasites. 
Data shown are the result of three independent experiments. Error bars represent S.E.M. N.s. = 
not significant (p=0.95, unpaired Student’s t-test). Y-axis units are arbitrary, computed from the 
area under the mass spectrometer signal and normalized to an internal standard and cell number.  
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Supplementary Figure 6. Map of suppressor mutations in PFK9.  
Mutations are designated by black lines and labeled with the resulting amino acid change. The 
1418 amino acid protein is composed of two domains, designated beta and alpha, which are 
connected by a short linker. 
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Supplementary Figure 7. Assay of PFK activity from P. falciparum lysate is linear and 
specific.  
(A) Schematic of linked enzyme assay of PFK activity. PFK catalyzes the phosphorylation of 
fructose 6-phosphate (fru6P) to fructose 1,6-bisphosphate (FBP). Excess linking enzymes 
aldolase (ALD), triose-phosphate isomerase (TPI), and glycerol 3-phosphate dehydrogenase 
(GDH) produce glycerol 3-phosphate. NADH utilization is monitored spectrophotometrically at 
340 nm. (B) The assay is linear with respect to total lysate protein content. Error bars represent 
S.E.M. of two technical replicates. (C) The assay is specific for P. falciparum lysate-dependent 
PFK activity. Error bars represent S.E.M. of three independent experiments.  
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Supplementary Figure 8. Suppressor mutations in PFK9 result in reduced activity. 
Measurement of PFK activity of P. falciparum lysate indicates that the second set of E2-SX 
clones with PFK9 suppressor mutations have reduced PFK activity, compared to parental (par) 
and FSMR strains (RX, as shown in Figure 4B). Error bars represent S.E.M. from at least two 
independent experiments. P-values were determined using a one-way analysis of variance 
(ANOVA; Tukey’s post-test). * = P < 0.05, ** = P < 0.01, **** = P < 0.0001. 
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Supplementary Figure 9. Rescue of HAD2 confirms role as a negative regulator.  
(A) Successful transfection of pTEOE110:HAD2-GFP in strain S1 (had2R157X, pfk9T1206I) was 
confirmed by PCR using construct-specific primers. Marker units are in base pairs (bp). 
Expected size of amplicon is 738 bp. (B) Immunoblot confirming successful expression of 
HAD2-GFP in strain S1. Marker units are kilodaltons (kDa). The top blot was probed with anti-
HAD2 antisera. The bottom blot was probed with anti-heat shock protein 70 antisera as a loading 
control. (C) Representative IC50 graph showing expression of HAD2-GFP in strain S1 
(had2R157X, pfk9T1206I) results in oversensitivity to FSM. The parental strain has a FSM IC50 of 0.8 
± 0.1 µM, and S1 has an IC50 of 0.5 ± 0.08 µM. When loss of HAD2 is rescued in strain S1, the 
resulting strain has an IC50 of 0.3 ± 0.1 µM. Data are means and S.E.M.s of at least three 
independent experiments. 
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Supplementary Figure 10. Anti-HAD1 and anti-HAD2 polyclonal antisera are specific for 
their target HAD antigens.  
Recombinant 6xHis-HAD1 and 6xHis-HAD2 probed with (A) rabbit anti-HAD1 polyclonal 
antisera [32] and (B) rabbit anti-HAD2 polyclonal antisera.  
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4.7 TABLES 
 
Supplementary Table 1. Kinetic parameters for HAD2. 
Shown are the means ± standard error of the mean (S.E.M.) of at least three independent 
experiments. Abbreviations used: AMP, adenosine 5’-monophosphate; GMP, guanosine 5’-
monophosphate; 2dGMP, 2’-deoxyguanosine 5’-monophosphate; XMP, xanthosine 5’-
monophosphate; IMP, inosine 5’-monophosphate. 
Substrate Km (mM) Kcat (sec-1) kcat//Km (M-1 sec-1) 
AMP 1.0   ± 0.2 1.7 ± 0.3 1.7   x 103 
GMP 0.30 ± 0.07 2.0 ± 0.1 6.9   x 103 
2dGMP 0.30 ± 0.01 3.2 ± 0.5 11.0   x 103 
XMP 0.73 ± 0.09 3.6 ± 0.1 5.0   x 103 
IMP 8.4 ± 0.6 2.5 ± 0.1 0.30 x 103 
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Supplementary Table 2. Genotypes of strains used to identify HAD2 and PFK9 mutations 
influencing FSM sensitivity. 
E2 represents the uncloned strain that resulted from FSM selection. E2 clones are indicated by 
the E2-XX format, with resistant strains designated E2-RX and sensitive strains designated as 
E2-SX. Genotypes are indicated by their resulting amino acid change. Predicted effect of amino 
acid changes were determined using Polyhen-2 [67]. 
Strain HAD2 variant PFK9 variant 
PFK9 mutation 
Polyphen-2 score FSM IC50 (µM) 
parent WT WT NA 0.8 ± 0.1 
E2 R157X WT NA 2.2 ± 0.4 
E2-R1 R157X WT NA 4.3 ± 1.2 
E2-R2 R157X WT NA 4.0 ± 0.2 
E2-R3 R157X WT NA 5.5 ± 0.7 
E2-S1 R157X T1206I 0.915  (possibly damaging) 0.5 ± 0.08 
E2-S2 R157X T1206I 0.915  (possibly damaging) 0.6 ± 0.08 
E2-S3 R157X S335L 0.998  (probably damaging) 0.7 ± 0.4 
E2-S4 R157X N1359Y 0.974  (probably damaging) 0.2 ± 0.06 
E2-S5 R157X S1267L 0.663  (possibly damaging) 0.2 ± 0.05 
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Conclusion and future directions 
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5.1 SUMMARY 
 
The human malaria parasite, Plasmodium falciparum, requires a constant supply of glucose for 
synthesis of ATP and essential secondary metabolites, including isoprenoids. We utilized 
resistance to the isoprenoid synthesis inhibitor fosmidomycin (FSM) to uncover novel 
mechanisms of drug resistance and metabolic regulation in the parasite. In this work, we present 
the discovery and characterization of PfHADs as a novel class of parasite metabolic regulators. 
The PfHADs are members of the haloacid dehalogenase-like hydrolase (HAD) superfamily, a 
large and diverse protein class found in all kingdoms of life. In P. falciparum, PfHADs function 
as negative regulators, whose loss results in upregulation of essential metabolism and increased 
drug tolerance. We find that PfHADs are phosphatases that hydrolyze intracellular 
phosphometabolites, including sugar phosphates and nucleotides, and define the genetic, 
enzymatic, structural, and metabolic basis for resistance and regulation by these proteins. 
Additionally, we evaluate the genetic changes following FSM treatment failure (recrudescence) 
in human patients and find that PfHADs are not biomarkers of recrudescence.  
 
5.2 SUBSTRATE SPECIFICITY OF THE HAD SUPERFAMILY 
 
We define the function of two HAD family members in the malaria parasite, P. falciparum. Both 
HAD1 and HAD2 belong to the Cof-like hydrolase subfamily (Interpro IPR000150) [1], 
composed mostly of bacterial proteins. While the cellular function of most members remains 
unknown, several bacterial HADs have been implicated in metabolic regulation [2–6]. 
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Enzymatic and structural studies of HADs have found them to have wide and varied substrate 
profiles [7–9], leading to the hypothesis that HADs are platforms for enzyme evolution [10,11]. 
This flexibility in substrate specificity may be harnessed to modify or create enzymes to produce 
desirable metabolites. Bacterial homologs of PfHADs have been found to increase production of 
metabolites such as lycopene, ribose, and amino acids [2–4]. However, few efforts have been 
made to alter the substrate specificities of these enzymes to further increase their utility.  
 
Our findings support the notion that, even outside of bacteria, Cof-like HAD family members 
have wide and varied substrate profiles. Thus, given the structural and functional information 
generated from our studies and others [12–14], Plasmodium HADs are an effective platform to 
study determinants of substrate specificity in this enzyme family. Findings may be applied to 
homologous proteins in biological systems applicable to bioengineering, such as bacteria or 
algae. 
 
HAD1 and HAD2 share ~29% sequence identity and ~53% sequence similarity (Chapter 4, 
Supplementary Figure 3). Interestingly, the P. falciparum genome also encodes a third Cof-like 
HAD protein, designated as HAD3 (PlasmoDB ID PF3D7_1226100) [15]. HAD3 shares >20% 
identity and >40% similarity with both HAD1 and HAD2. HAD3 is primarily expressed in the 
gametocyte (sexual) stages of the parasite lifecycle and the in vivo function has not yet been 
investigated for this protein [15,16]. However, studies from our laboratory find that recombinant 
HAD3 is a phosphatase capable of utilizing both sugar phosphates and nucleotides as substrates 
(data not shown). The overlapping substrate profiles of HAD1, HAD2, and HAD3 and their 
close sequence similarity are ideal for a comparative approach to enzyme engineering. This 
! 197 
approach would be aided by the previous structural characterization of HAD1, including the 
description of several substrate-bound structures (Appendix A) [12,13], as well as Plasmodium 
vivax HAD2 [14]. 
 
5.3 THE CELLULAR FUNCTION OF HAD1 
 
We find that HAD1 functions as a sugar phosphatase (Chapter 2, Figure 6) with access to 
substrates upstream of the MEP pathway. Electron microscopy confirms the primarily cytosolic 
localization of HAD1 observed by fluorescent microscopy of live and immunostained parasites 
(Chapter 2, Figure 7 and Supplementary Figure 4). However, we also observe a small fraction of 
HAD1 in the lumen and membrane of the apicoplast, the site of isoprenoid synthesis via the 
MEP pathway (Appendix B, Figure B2). Membrane-associated HAD1 is not detectable via 
cellular fractionation (Appendix B, Figure B3).  
 
Given the possible membrane localization of HAD1, we tested the ability of the recombinant 
protein to bind membrane lipids. In a lipid-binding assay, HAD1 does not appear capable of 
binding the major lipid species of the apicoplast membrane [17], including phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI). However, we find that 
HAD1 is capable of binding phosphatidylinositol phosphates (PIPs) (Appendix B, Figure B4). 
Interestingly, HAD1 does not appear to utilize PIPs or their cognate inositol phosphates as 
substrates in vitro (Appendix B, Figure B5). Profiling of PIPs from parental and FSMR strains 
will illuminate whether HAD1 has any effect on PIP levels in vivo. PIPs are well-established 
second messengers in other systems [18], and in P. falciparum, PIP-binding proteins have been 
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implicated in parasite development, drug resistance, and trafficking of hemoglobin to the food 
vacuole [19–22]. Further experiments are required to determine if the small fraction of 
apicoplast-localized HAD1 performs a meaningful biological function and if and how this 
function may be related to regulation of the MEP pathway or central carbon metabolism. It may 
be possible to create HAD1 mutants that are incapable of binding PIPs but maintain sugar 
phosphatase activity. These HAD1 mutants could be assayed for their ability to restore FSM 
sensitivity and metabolite levels in FSMR strains lacking HAD1. 
 
Given HAD1’s broad substrate specificity and primarily cytosolic localization, specific function 
or in vivo substrate specificity of HAD1 may be conferred by its interaction with other proteins. 
Immunoprecipitation of HAD1 may identify interactors that point to regulation of a specific 
pathway or metabolite by HAD1. Genetic manipulation of these interactors may reveal HAD1-
related phenotypes, such as increased metabolite levels and FSM resistance.  
 
Our model predicts that HAD1 dephosphorylates intermediates of glycolysis, upstream of the 
MEP pathway (Chapter 2, Figure 9). A number of metabolic profiling approaches can be used to 
further test this model. LC-MS/MS measurement of glycolytic intermediates in FSMR parasite 
strains with loss of HAD1 function and FSMR strains rescued with Hsp110:HAD1-GFP may 
identify changes in glycolytic intermediates attributable to loss of HAD1. However, this 
approach is limited to the measurement of steady-state levels of a focused set of metabolites. 
Unbiased profiling of a broader class of phosphorylated metabolites may identify other 
unexpected changes due to loss of HAD1 and HAD2. Additionally, metabolic flux analysis using 
isotope-labeled sugars may provide insight on reaction rates affected by HAD1 or HAD2. 
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5.4 HAD2 FUNCTION AND METABOLIC REGULATION IN P. 
FALCIPARUM 
 
While we define HAD1 and HAD2 as metabolic regulators, there is still much to learn regarding 
the mechanism of this regulation in the parasite. In particular, it is not yet clear how HAD2 is 
able to influence levels of glycolytic intermediates, namely the PFK9 product fructose 1,6-
bisphosphate (FBP). As a purine phosphatase, HAD2 may modulate levels of canonical PFK 
regulators, such as AMP. In a previous study using recombinant PFK9 beta domain, AMP was 
found to have a modest, albeit variable, activating effect on catalytic activity [23]. Further 
experiments will be required to understand if AMP exerts this effect on full-length enzyme, 
which would include the potentially regulatory alpha domain. Additionally, it would be 
informative to test PFK9 activity in the presence of other HAD2 substrates, such as GMP, XMP, 
IMP, and dGMP (Chapter 4, Figure 1), as these compounds may function as non-canonical 
allosteric regulators whose levels are modulated by HAD2. These efforts are currently limited by 
our inability to successfully express and purify full-length recombinant PFK9. 
 
We find that mutations in PFK9 are able to suppress FSMR resistance and metabolite changes 
caused by loss of HAD2. We find that these PFK9 variants have reduced catalytic activity in 
assays using P. falciparum lysate and result in reduced levels of the PFK product, FBP (Chapter 
4, Figure 5). The exact mechanism of this suppression is unknown, but may be informative to 
HAD2 function. While PFK9 mutants may be achieving suppression via gross reduction in PFK 
activity, it is also possible that these mutations affect a specific function of PFK, such as 
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activation or binding by an allosteric regulator. This model predicts that mutations that 
successfully suppress the FSMR phenotype will be clustered, perhaps near an allosteric binding 
site. Generation of additional PFK9 suppressor mutations and structural studies of these 
mutations can be used to test this hypothesis. 
 
Our work identifies the PFK9 product, FBP, as highly correlated with MEP pathway metabolites 
(Chapter 4, Figure 5). This finding is consistent with a recent study identifying PFK9 as having a 
high glycolytic flux control coefficient, meaning that perturbations to this enzymatic step have 
the greatest impact on pathway flux [24,25]. As FBP appears to be an indicator of parasite 
glycolytic and MEP pathway metabolite levels, it is possible that the parasite is utilizing this 
indicator to monitor and respond to changes in its metabolism. FBP-sensing mechanisms have 
been described in E. coli [26], which possesses an FBP-responsive transcription factor, Cra 
(FruR), that drives expression of a number of genes related to central carbon metabolism [26–
28]. The Apicomplexan Toxoplasma gondii modulates expression of a fructose 1,6-
bisphosphatase (FBPase) for regulation of its glucose metabolism [29].  
 
Further experiments are required to understand the existence and role FBP-responsive factors in 
P. falciparum. Transcriptional profiling of HAD1 and HAD2 mutant parasites may reveal genes 
that are differentially expressed upon relief of negative glycolytic regulation by HADs. However, 
P. falciparum transcriptional control has been shown to be driven by a limited suite of 
transcription factors in a robotic fashion correlating with protein function during development. It 
has been hypothesized that post-transcriptional regulation may instead play a more dominant role 
in controlling parasite gene expression [30–32]. 
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Perhaps more likely is the possibility that FBP may function in enzymatic regulation. FBP is 
known to activate the downstream glycolytic enzyme pyruvate kinase in other systems [33]. 
However, P. falciparum pyruvate kinase was found to be insensitive to activation by FBP [34]. 
Further studies are required to understand if FBP regulates other glycolytic enzymes. Instead, 
HAD1 or HAD2 may be sensitive to regulation by FBP, which may be easily tested using in 
vitro enzyme assays. Immunoprecipitation of protein interactors HAD2 and PFK9 may reveal 
enzymes or pathways subject to regulation by FBP. 
 
5.5 TARGETING HAD1, HAD2, AND PFK9 
 
The screen for FSM resistance yielded 17 parasite strains possessing 13 deleterious HAD1 alleles 
that result in loss of protein function. We hypothesized that loss of HAD1 has a negligible effect 
on parasite fitness in culture and that HAD1 mutations are thus easy to acquire. Indeed, we find 
that loss of HAD1 does not result in a significant growth defect compared to the parental strain 
(Appendix B, Figure B1). This observation is consistent with in vivo growth assays of genetic 
mutants in Plasmodium berghei infections [35]. Thus, it appears that HAD1 is dispensable for 
asexual stage growth. However, little variation is seen in this gene in clinical isolates, even after 
FSM treatment [15, 23] (Chapter 3, Figure 3). It is possible that loss of HAD1 has deleterious 
effects on parasite fitness during human or insect infection. 
 
In contrast, our screen produced only one strain with a deleterious mutation in HAD2. HAD2 
mutants appear to have an appreciable fitness defect, as HAD2 mutants grow considerably 
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slower than the parental strain (Chapter 4, Figure 3). This growth defect has also been observed 
for HAD2 mutants in P. berghei infections [35]. Further and more detailed profiling of the 
lifecycle of HAD2 mutants is necessary to illuminate stage-specific growth effects of HAD2 
loss.  
 
Given its necessity for parasite fitness in asexual stage growth, HAD2 is a candidate target for 
antimalarial development. Like the MEP pathway enzymes, HAD2 does not have a close 
homolog in humans, reducing concerns regarding the host toxicity of HAD2 inhibitors. 
Screening efforts would be greatly aided by the ease with which recombinant HAD2 is expressed 
and assayed. Presumably, parasites may acquire resistance to HAD2 inhibition via mutation of 
PFK9. In vivo fitness assessments of had2 pfk9 parasites are necessary to determine if this is 
likely to occur during infection. 
 
PFK9 is also an attractive target for antimalarial development. Given the necessity of glycolysis 
in the parasite, PFK9 is likely essential. Using kinetic models, PFK9 has been identified as an 
effective step to reduce glycolytic flux [24,25]. PFK9 possesses low sequence similarity to the 
human enzyme [23]. Due to its similarity to plant PPi-PFKs and the parasite’s unique 
metabolism, PFK9 may also be subject to regulatory mechanisms distinct from the host enzyme 
which may be exploited for inhibition. Further work is required to develop an assay of PFK9 that 
is efficient for inhibitor screening, as recombinant PFK9 has not been successfully purified [23]. 
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5.6 FOSMIDOMYCIN AS AN ANTIMALARIAL 
 
Fosmidomycin’s (FSM) promise as an antimalarial has been dampened by high rates of 
recrudescence [37,38]. However, FSM possesses a number of valuable characteristics as an 
antimalarial: it is well-validated, highly specific [39,40], and non-toxic in humans [41,42]. 
Previous clinical trials (clinicaltrials.gov identifiers NCT02198807, NCT01361269, 
NCT01002183, NCT00214643, and NCT00217451) used the antibiotic clindamycin (CLN) as a 
partner agent for FSM, due to early findings of synergy between the two drugs [41,43,44]. Both 
FSM and CLN exhibit short serum half-lives (1-3 hours) [45,46]. The short exposure time to 
effective levels of both drugs likely contributes to the reduced treatment efficacy observed in 
these trials. We do not find a genetic signature of recrudescence following FSM treatment failure 
(Chapter 3). This finding supports the hypothesis that FSM treatment failure is not due to 
resistance-causing mutations and instead is primarily due to partner drug selection.  
 
FSM is currently being tested in a clinical trial (NCT02198807), where it is partnered with 
piperaquine, a bisquinolone with a long serum half-life (>20 days) [47] that is also being 
evaluated as part of an artemisinin combination therapy (ACT) [48]. Results of this trial will 
show whether FSM treatment is more effective when partnered with a drug with a long half-life. 
Additionally, a number of groups are pursuing chemical modification of FSM to improves its 
potency and half-life [49–51]. We encourage further studies on the efficacy of FSM and the 
development of other MEP pathway inhibitors. 
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5.7 FINAL THOUGHTS 
 
The causative agent of human malaria, P. falciparum, remains a threat to global health. 
Developing resistance to current therapies remains an ever-present challenge to malaria 
eradication. An understanding of drug resistance mechanisms as well as novel target pathways is 
necessary for the development of future antimalarials. In this work, we have described the 
mechanism of resistance to fosmidomycin, an inhibitor of essential isoprenoid synthesis in the 
parasite. We uncovered the PfHADs, a novel class of parasite metabolic regulators. Additional 
studies will continue to define the role of these proteins in parasite biology.  
 
 
!
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A.1 ABSTRACT 
 
Haloacid dehalogenases (HADs) are a large enzyme superfamily of more than 500,000 members 
with roles in numerous metabolic pathways. Plasmodium falciparum HAD1 (PfHAD1) is a sugar 
phosphatase that regulates the methylerythritol phosphate (MEP) pathway for isoprenoid 
synthesis in malaria parasites. However, the structural determinants for diverse substrate 
recognition by HADs are unknown. Here, crystal structures were determined of PfHAD1 in 
complex with three sugar phosphates selected from a panel of diverse substrates that it utilizes. 
Cap-open and cap-closed conformations are observed, with cap closure facilitating substrate 
binding and ordering. These structural changes define the role of cap movement within the major 
subcategory of C2 HAD enzymes. The structures of an HAD bound to multiple substrates 
identifies binding and specificity-determining residues that define the structural basis for 
substrate recognition and catalysis within the HAD superfamily. While the substrate-binding 
region of the cap domain is flexible in the open conformations, this region becomes ordered and 
makes direct interactions with the substrate in the closed conformations. These studies further 
inform the structural and biochemical basis for catalysis within a large superfamily of HAD 
enzymes with diverse functions. 
 
A.2 INTRODUCTION 
 
The HAD superfamily, the name of which derives from bacterial haloacid dehalogenases, is one 
of the largest classes of enzymes and is represented throughout all kingdoms of life [1]. This 
superfamily is comprised of more than 500,000 members (InterPro IPR023214) that have 
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evolved to serve diverse biological functions [2]. HADs have been shown to play roles in 
primary [3,4] and secondary metabolism [5–8], regulation of metabolic pools [9], cell 
housekeeping [10–13], and nutrient uptake [14]. HADs are promiscuous enzymes, displaying 
catalytic activity towards a broad range of substrates [15]. The majority of HADs are involved in 
variations of phosphoryl-transfer reactions [16] and include phosphoesterases, ATPases, 
phosphonatases and sugar phosphomutases [17,18]. HADs contain four highly conserved 
sequence motifs, which coordinate a magnesium ion and bind the phosphoryl group of substrate 
compounds. Together, these HAD-motif residues comprise a self-contained scaffold for catalysis 
through a phosphoaspartyl intermediate [17,19,20]. Further biochemical and structural studies, 
combined with biological function studies, are needed to understand how substrate recognition 
and catalysis are achieved by these promiscuous enzymes in order to carry out their diverse 
metabolic regulatory functions. 
 
We recently identified and reported the crystal structure of the first HAD protein from 
Plasmodium falciparum, which we called PfHAD1 [21]. PfHAD1 is a sugar phosphatase that 
regulates substrate availability to the methylerythritol phosphate (MEP) pathway for isoprenoid 
precursor biosynthesis (Figure A1). Understanding the regulation of the MEP pathway is 
important, as the pathway is an attractive target for drug development. While isoprenoids are 
essential for all organisms, humans employ a completely different isoprenoid-biosynthesis 
pathway: the mevalonate pathway. The MEP pathway has been chemically and genetically 
validated to be essential in a number of important pathogens, including P. falciparum [22–24], 
Toxoplasma gondii [25], Mycobacterium tuberculosis [26], and Escherichia coli [27]. 
Furthermore, isoprenoid production is of interest for a wide range of commercially important 
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natural products such as pharmaceuticals and microbial biofuels. Thus, structural insight into the 
regulation of the MEP pathway is important for its implications in drug development and for 
metabolic engineering to enhance isoprenoid production for commercial interests. 
 
PfHAD1 serves as an excellent candidate for structural studies of substrate binding and catalysis 
within the HAD superfamily because its cellular function has been defined. We found that 
changes in PfHAD1 confer malaria-parasite resistance to the antimalarial fosmidomycin by 
sequencing P. falciparum parasites lines that are fosmidomycin-resistant [21]. Fosmidomycin is 
a small-molecule inhibitor of the MEP pathway. Fosmidomycin-resistant parasite strains are 
highly enriched in genetic changes in the PfHAD1 locus that result in loss of PfHAD1 activity. 
These genetic changes correlate with a metabolic effect of increased cellular levels of MEP 
pathway intermediates. Complementation of a deleterious PfHAD1 allele restores sensitivity to 
fosmidomycin. While the metabolic effects and a biological phenotype of PfHAD1 have been 
described, the substrate specificity and mechanism of catalysis for PfHAD1, or HADs generally, 
have not been well defined. 
 
The essential structural element of HADs is a Rossmannoid fold characterized by a three-layered 
α/β sandwich comprised of repeating β–α units [16,19]. The HAD Rossmannoid fold is 
distinguished from other Rossmann folds by two motifs called the ‘squiggle' and ‘flap' elements 
[16,17]. The squiggle element occurs immediately following the first β-strand of the 
Rossmannoid fold and assumes a nearly complete single-helical turn. The flap element is a β-
hairpin downstream of the squiggle. While the core Rossmannoid folds of HAD enzymes have 
undergone minimal modifications, the introduction of a cap-insertion module has added a 
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sophisticated means of substrate recognition and diversification of enzyme function by 
presenting new surfaces for interaction with substrates [15]. HAD proteins can be classified into 
three general categories based on the topology and location of their cap insertions: C0, C1 or C2. 
The C0 element consists of short loops or β-strands that do not fold into its own structural unit, 
whereas the C1 element folds into an independently folded cap domain that is distinct from the 
catalytic core domain. The insertion in C0 and C1 HADs occurs in the middle of the β-hairpin of 
the flap motif. The C2 element also folds into its own distinct domain, but the cap insertion 
occurs in the linker following the third β-strand of the Rossmannoid fold. 
 
In addition to providing substrate-specificity determinants, the cap module plays a role in solvent 
access and exclusion from the active site, which is a necessary aspect of catalysis via the two-
step phosphoaspartyl-transferase mechanism [19,28]. The C0 HADs, which lack a cap domain, 
primarily use large macromolecule substrates [28,29] or oligomerization [6,8,30] as a means of 
substrate binding and solvent exclusion from the catalytic site. The C1 HADs employ extensive 
movement of the cap domain, which is dependent on winding and unwinding of the squiggle 
element, to form open and closed conformations [17,31,32]. The role of cap movement in C2 
HADs, such as PfHAD1, has not been extensively explored. It has been postulated that the 
squiggle–flap elements in C2 HADs also exhibit drastic movements to exclude solvent from the 
substrate-binding site [16,19]. However, to our knowledge evidence for this movement in C2 
HADs has not been established. 
 
Detailed structural analysis of the determinants for substrate ambiguity and specificity in HAD 
enzymes has not been investigated. To investigate the structural basis for substrate recognition 
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and catalysis in P. falciparum PfHAD1, we constructed, purified and characterized a 
catalytically inactive PfHAD1-D27A mutant. We determined three substrate-bound crystal 
structures: those of PfHAD1-D27A complexed with mannose 6-phosphate (Man6P), glucose 6-
phosphate (Glu6P) or glyceraldehyde 3-phosphate (Gly3P). Our crystallographic and enzymatic 
activity data provide insights into the structural determinants for substrate recognition and the 
role of C2 cap-domain movement in substrate binding, ordering and catalysis. We find that a 
large cap-domain movement results in sealing of the substrate-binding cavity. This movement is 
important for the enzymatic mechanism, as it positions cap residues in the correct orientation to 
bind and order substrates prior to catalysis. These results alter the paradigm that substrate 
specificity is imparted by the squiggle–flap motifs and is instead driven by cap closure. The 
structures of multiple substrate-bound complexes identified key specificity-determining residues 
within the cap. These specificity-determining residues are conserved in unique patterns within 
the HAD superfamily that aid in functional characterization. Understanding the PfHAD1 
mechanism informs catalysis of the entire HAD superfamily, which regulates important 
metabolic pathways. 
 
A.3 METHODS 
 
A.3.1 Reagents 
All reagents were purchased from Sigma–Aldrich unless otherwise indicated. 
 
A.3.2 Site-directed mutagenesis for PfHAD1 mutants 
Wild-type PfHAD1 (WT-PfHAD1) was cloned as described previously [21]. Site-directed 
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mutagenesis to create the D27A allele was carried out using standard PCR-based techniques 
using the following primers: 5′-TGTTCCATC-TAAAGC-CGTAAAG-3′ and 5′-
CTTTAC-GGCTTTAG-ATGGAACA-3′. Sites for ligation-independent cloning were added 
using the following primers: 5′-
CTCACCACCACCACCACCATATGCACGAAATTGTA-GATAAGAA-3′ and 5′-
ATCCTATCTTACTCACTTATA-TGTCACAGAATGTCTTCA-3′. The resulting PCR product 
was inserted into the BG1861 expression vector [33] to produce 6×His-PfHAD1. The construct 
sequence was verified by Sanger sequencing. Site-directed mutagenesis was performed to 
generate the V151A, V151L, E152A, L173A, E205A and E205W mutants. 
 
A.3.3 Expression and purification 
E. coli BL21(DE3) pLysS competent cells (Life Technologies) harboring the WT-PfHAD1 or 
mutant expression plasmids were grown at 37°C in LB medium containing final concentrations 
of 0.1 mg ml−1 ampicillin and 0.3 mg/ml  chloramphenicol. Once the cells reached an OD600 of 
0.6, they were induced with 1 mM IPTG for 3–4 h. After this period, the cells were harvested by 
centrifugation at 4000 rpm for 10 min at 4°C. The cell pellets were suspended in 10 ml buffer A 
(50 mM Tris pH 8.0, 100 mM NaCl, 10 mM imidazole pH 8.0, 1 mM PMSF, 5 mM β-
mercaptoethanol) per liter of LB medium and were stored at −80°C. 
 
The cells were thawed in the presence of 0.25 mg ml−1 lysozyme and disrupted using sonication 
on ice for 60 s. The cell extract was obtained by centrifugation at 13,000 rpm for 30 min at 4°C 
and was applied onto Nickel Rapid Run agarose beads (Goldbio) equilibrated with buffer B (50 
mM Tris pH 8.0, 150 mM NaCl, 20 mM imidazole pH 8.0, 5 mM β-mercaptoethanol). Buffer B 
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was used to wash the nickel column three times with five column volumes. After washing, the 
protein was eluted with five column volumes of buffer C (buffer B with 300 mM imidazole). The 
PHAD1 was further purified by gel chromatography using a HiLoad 16/600 Superdex 200 pg 
column (GE Healthcare) equilibrated with buffer D [10 mM Tris pH 8.0, 150 mM NaCl, 5 mM 
dithiothreitol (DTT)]. The fractions containing PfHAD1 were pooled and concentrated using a 
10K molecular-weight cutoff Amicon centrifugal filter (Millipore). 
 
A.3.4 Enzyme assays 
Enzyme assays were performed as described previously [21]. Briefly, general phosphatase 
activity was measured by monitoring the hydrolysis of p-nitrophenylphosphate (pNPP) to p-
nitrophenyl. Reactions consisted of 10 mM pNPP (New England Biolabs), 50 mM Tris–HCl pH 
7.5, 5 mM MgCl2, 0.5 mM MnCl2 and 2 µg enzyme. Phosphate cleavage of phosphorylated 
sugar substrates was monitored using the EnzChek Phosphatase Assay Kit (Life Technologies). 
Reactions contained 1 mM substrate and 400 ng enzyme. All substrates were purchased from 
Sigma–Aldrich. For all assays, reaction rates were calculated using GraphPad Prism software. 
 
A.3.5 Crystallization 
For crystallization, PfHAD1-D27A was concentrated to 20 mg/ml and incubated for 30 min on 
ice with 5 mM substrate for co-crystallization studies. Crystals of apo PfHAD1-D27A or 
PfHAD1-D27A grown in 5 mM substrate were obtained by vapor diffusion using hanging drops 
equilibrated at 18°C against 500 µl of a reservoir consisting of 0.1 M HEPES pH 7.5, 20–25% 
PEG 8000. PfHAD1-D27A crystals were cryoprotected with 0.1 M HEPES pH 7.5, 30% PEG 
8000 and either no substrate for apo PfHAD1-D27A crystals or 5 mM substrate for co-crystals 
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before flash-cooling under liquid nitrogen. 
 
A.3.6 Data collection and processing 
X-ray data were collected from a single crystal using a wavelength of 1 Å on beamline 4.2.2 of 
the Advanced Light Source, Berkeley, California, USA. Data were collected with the CMOS 
detector and were processed with XDS [34]. All crystals had the same crystal packing and 
dimensions as the previously reported WT-PfHAD1 crystal [21]. R and Rfree flags were imported 
from the WT-PfHAD1 mtz file using UNIQUEIFY within the CCP4 package [35]. 
 
A.3.7 Structure determination and refinement 
Structure solution was performed within PHENIX [36] by refinement with the previously solved 
WT-PfHAD1 crystal structure (PDB entry 4qjb). Subsequent iterated manual building/rebuilding 
and refinement of models were performed using Coot [37] and PHENIX [36], respectively. The 
MolProbity structure-validation server [38] was used to monitor the refinement of the models. 
All final refined models have favorable crystallographic refinement statistics, as provided in 
Table A1. A stereo image of a representative region of the electron-density map is shown for 
each structure in Supplementary Figure A1. Figures were generated and rendered in PyMOL 
(v.0.99rc6; Schrödinger). 
 
A.3.8 Accession codes for NCBI BLAST search 
The PfHAD1 protein sequence was used as the query sequence to search for all nonredundant 
protein sequences in the NCBI database using the BLASTP 2.2.31+ (protein–protein BLAST) 
algorithm. Plasmodium (Taxid 5820) was excluded from the search. Sequence similarity was 
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found to Clostridium botulinum WP_012342032, Sebaldella termitidis WP_012859625, 
Atopococcus tabaci WP_028273050, Ilyobacter polytropus WP_013387187, Synergistes 
synergistes sp. 3_1_syn1 WP_008709579, Eucalyptus grandis KCW79177, Genlisea aurea 
EPS68728, Hammondia hammondi XP_008889525, Neospora caninum Liverpool 
XP_003883270, T. gondii GT1 EPR64229, E. coli EOU46719, M. tuberculosis NP_218330, C. 
reinhardtii ADF43173 and Arabidopsis thaliana ABO38782. UniProt accession codes for E. coli 
HAD homologs are as follows: YbiV, P75792; YidA, P0A8Y5; YbhA, P21829; YbjI, P75809; 
YigL, P27848; OtsB, P31678; Cof, P46891. 
 
A.4 RESULTS 
 
A.4.1 Generation of inactive PfHAD1-D27A for substrate-binding studies 
Based on the sequence and structural analysis of WT-PfHAD1 [21], Asp27 was predicted to 
perform a nucleophilic attack on the phosphate group of PfHAD1 substrates. The PfHAD1-
D27A mutant protein was generated and tested for catalytic activity towards a non-specific 
phosphatase substrate, p-nitrophenylphosphate (pNPP), and a representative panel of sugar 
phosphates, Man6P, Glu6P and Gly3P. These sugar phosphates represent six-carbon (6C; Man6P 
and Glu6P) and three-carbon (3C; Gly3P) sugar phosphates with different stereochemical 
properties that have biological relevance. Gly3P is one of the starting substrates for the MEP 
pathway, and Glu6P and Man6P are upstream precursors of Gly3P (Figure A1). PfHAD1-D27A 
lacks phosphatase activity towards all compounds tested (Supplementary Figure A2) and was 
employed for co-crystallization studies to obtain substrate-bound structures. 
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A.4.2 Overall structures of PfHAD1-D27A bound to substrates 
Crystal structures of PfHAD1-D27A in complex with Man6P, Glu6P or Gly3P were determined. 
All structures are of high resolution (1.8–2.0 Å) sufficient to define small-molecule binding, and 
a complete summary of crystallographic refinement statistics is given in Table A1. The PfHAD1-
D27A mutant has the same overall structure as WT-PfHAD1 (Figure A2A), with the active site 
found at the interface between the core and cap domains. In each structure, two monomers were 
present in the asymmetric unit. Overlay of the two monomers by superposition of the core 
domains shows that PfHAD1 adopts a ‘closed' and an ‘open' conformation (Figure A2B). 
Domain-movement analysis using DynDom [39,40] reveals an 18° rotation between the two 
conformations about the two hinge loops (residues 104–105 and residues 210–214) connecting 
the core and cap domains. 
 
For each of the substrate-bound structures, clear electron density corresponding to the substrate 
could be observed in the substrate-binding site of the closed conformation. The validity of the 
models was confirmed by inspecting the Fo − Fc density prior to the addition of the substrate 
models (Figure A3A) and inspecting the 2Fo − Fc electron-density maps after refinement with 
the substrate (Figure A3B). In the open conformation, electron density corresponding to the 
phosphate group could be visualized, but the electron density for the orientation of the sugar 
moiety was unclear (Figure A3C). Attempts to model in the substrate molecule were 
unsuccessful. Therefore, only the phosphate group was modeled in the open conformation 
(Figure A3D). 
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A.4.3 PfHAD1 substrate-binding site 
The active-site interactions in the co-crystal structures were examined more closely in order to 
investigate the structural basis for substrate binding and catalysis. HADs contain four highly 
conserved sequence motifs. These residues in PfHAD1 are as follows: motif I (Asp27 and 
Asp29), motif II (Thr61), motif III (Lys215) and motif IV (Asp238 and Asp242) (Figure A4A 
and A4B). In the initial reaction, the Asp27 nucleophile (which is absent in our PfHAD1-D27A 
mutant) is positioned to attack the phosphoryl group (Figure A4A an A4B). Asp29, which is 
positioned two residues away from Asp27, serves as a general acid/base residue to protonate the 
leaving sugar group. In the second reaction, Asp29 deprotonates a water molecule so that it can 
perform nucleophilic attack on the phosphoaspartyl intermediate, thus releasing free phosphate 
and restoring the enzyme to its native state (Figure A1). 
 
In addition to the conserved molecular interactions between the catalytic residues of the core 
domain and the phosphoryl group, residues in the cap domain make molecular interactions with 
the sugar moiety of the substrates in the closed conformation (Figure 4C, 4D, 4E). In this 
conformation, the substrate-binding site is closed off and free exchange of water molecules with 
the bulk solvent is prevented, thus favoring the aspartate-based nucleophilic reaction. The open 
conformation, on the other hand, exposes the active site to bulk solvent, allowing substrate 
release. Owing to the shift of the cap domain away from the core domain in this open 
conformation, no molecular interactions are made between the sugar moiety of the substrates and 
the substrate-binding residues of the cap domain. 
 
A comparison of the substrate-binding site in each of the three crystal structures reveals that 
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Man6P, Glu6P and Gly3P all make contacts with cap residues Glu152, Thr201, Phe202 and 
Tyr205 (Figure A4C, A4D, A4E). In addition, the larger 6C sugar phosphates (Man6P and 
Glu6P) make further contacts with cap residues Val151, Leu173, Glu207 and Arg63 from the 
catalytic domain (Figure A4C, A4D, A4E). Owing to their different stereochemistry, slightly 
different interactions are made by Man6P and Glu6P. These contacts are consistent with the 
increased enzyme activities observed toward Man6P and Glu6P over Gly3P (Supplementary 
Figure A2). Thus, distinct interactions for 6C and 3C sugar phosphates form the basis for 
substrate binding and specificity. 
 
A.4.4 The cap domain contains a key substrate-recognition element 
Although movement in the squiggle and flap elements has previously been postulated to be 
important for substrate binding and solvent exclusion in C2 HADs [16], no movement in these 
elements was observed between the open and closed conformations of PfHAD1. In our 
structures, the flap element does not form a complete β-hairpin, but rather a simple β-turn. The 
B-factor values for the two monomers were examined in order to identify whether these regions 
demonstrated high flexibility and disorder in our structures. We observed average B-factor 
values for the squiggle and flap elements in all three structures, indicating that these elements are 
ordered in our structures (Figure A5A and Supplementary Figure A3). However, we observed 
abnormally high B-factor values in an α-helical region of the cap domain that is important for 
substrate binding. Glu152 of this region has the highest B-factor value of ∼110 Å (Figure A4A 
and Supplementary Figure A3A). In contrast, this region becomes ordered in the closed 
conformation, where the cap residues make direct interactions with the sugar moieties (Figure 
A5B and Supplementary Figure A3B). Glu152 makes a conserved hydrogen-bond interaction 
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with an active-site water molecule in all of the substrate-bound structures (Figure A4C, A4D, 
and A4E). This water molecule hydrogen-bonds to sugar moieties of the substrates and helps to 
orient them in the active site. To test the relevance of Glu152 in catalysis, we generated a 
PfHAD1-E152A variant protein. Loss of Glu152 significantly lowers the enzyme activities 
equally for all substrates (Figure A5C), demonstrating its important role in substrate recognition. 
 
A.4.5 Substrate specificity informs the HAD superfamily 
Val151, Glu152, Leu173, Thr201, Phe202, Tyr205 and Glu207 are cap-domain residues that 
bind substrates and enable specificity for PfHAD1. Having identified the structural determinants 
for substrate binding and specificity, we asked whether these determinants define the large 
superfamily of HAD enzymes. We examined the conservation of these substrate-binding residues 
in an unbiased sampling of the ten closest PfHAD1 homologs identified solely by sequence 
similarity. 
 
Sequence alignment of these PfHAD1 homologs demonstrates that they are highly conserved in 
their catalytic core domains, but that their sequences diverge in their cap domains (Figure A6A 
and Supplementary Figure A4A). This is expected as our structural analysis indicates that the cap 
domains impart substrate specificity. Within these sequences, Glu207 is invariant and Leu173 is 
almost invariant, with substitutions to Met, Ile or Val in certain HADs (Figure A6B). These two 
residues therefore play a conserved role in substrate binding across HADs, but a minor role in 
specificity. Strikingly, analysis of the remaining residues suggests that HAD enzymes can be 
subdivided into two groups. In the first subdivision (Figure A6B, blue boxes) the hydroxyl group 
of Thr201 and the aromatic side chain of Tyr205 are well conserved, while Val151, Glu152 and 
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Phe202 are variable. The defining features of the second subdivision (Figure A6B, red boxes) 
include an invariant Tyr at residue 151, Ala/Pro at residue 201, Val/Ile at residue 202 and 
Met/Asn at residue 205. Therefore, while the overall sequence conservation in the cap domains is 
lower that the catalytic core domains, patterns of sequence conservation and divergence are 
observed in cap residues that are important for substrate recognition. These patterns are only 
evident through the structural definition of substrate recognition presented in this study. 
 
The analysis above used an unbiased sampling of proteins similar to PfHAD1. As PfHAD1 is a 
regulator of the MEP pathway in P. falciparum [21], we examined PfHAD1 homologs in other 
important pathogens and model organisms that also employ the MEP pathway: E. coli, M. 
tuberculosis, A. thaliana and C. reinhardtii (Supplementary Figure A4B). All of these species 
employ the MEP pathway, as determined by the presence of DXR, the first committed enzyme of 
the pathway. Again, similar patterns of conservation and variance emerge within these selected 
PfHAD1 homologs (Figure A6C). Val151 and Leu173 both provide hydrophobic contacts to the 
substrates and are important for sealing the substrate-binding cavity. However, Leu173 is 
strongly conserved while Val151 is variant (Figure A5B and A5C and above). We mutated each 
of these residues to alanine to compare the effects of nonconserved and conserved residues on 
catalysis (Figure A6D). Mutation of the conserved Leu173 resulted in an enzyme that was 
essentially inactive to all three substrates. In contrast, mutation of the nonconserved Val151 
retained ∼75% of the wild-type activity for all three substrates. These results are consistent with 
the plasticity at Val151 and other variant residues to allow altered substrate specificity of HAD 
proteins. 
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None of the homologs from the analyses above have known substrate preferences except for E. 
coli YidA. The patterns of conserved and substituted binding residues identified by this structural 
work provide a framework for the future determination of substrate preferences for related HAD 
enzymes. To evaluate the validity of this framework, we examined the C2-type E. coli HAD 
enzymes YbiV, YidA, YbhA, YbjI, YigL, OtsB, Cof and NagD, as the substrate preferences of 
each of these enzyme is well defined [12]; C0 and C1 HAD enzymes were omitted from this 
analysis as they have different domain architectures. YbiV and YidA both catalyze 
dephosphorylation of 3–6-carbon sugar phosphates similar to PfHAD1, with YbiV having 
greatest activity against fructose 1-phosphate and YidA preferring erythrose 4-phosphate. As 
predicted, we find that YbiV and YidA have similar patterns of conservation/divergence as 
PfHAD1: variable sequences at positions 151/152, Leu/Met at position 173, Tyr/Ser at position 
201, Tyr/Phe at position 205 and Asp/Glu at position 207 (Supplementary Figure A4C). In 
contrast, YbhA, YbjI, YigL, OtsB, Cof and NagD utilize structurally different phosphorylated 
metabolites. YbhA, YigL and Cof have greatest activity against pyridoxal 5-phosphate, YbjI is 
most active against flavin mononucleotides, OtsB has a preference for trehalose 6-phosphate and 
NagD is most active against adenosine triphosphate. These E. coli homologs diverge 
dramatically from PfHAD1 at the substrate-binding residues (Supplementary Figure A4C), 
further validating the correlation between structure and substrate preference. 
 
A.5 DISCUSSION 
 
In this study, we have solved co-crystal structures of the sugar phosphatase PfHAD1 bound to 
diverse sugar-phosphate substrates in order to investigate the structural determinants for 
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substrate recognition and specificity. By investigating molecular interactions within PfHAD1 
bound to multiple different substrates, our study is the first structural study to examine how the 
HAD enzyme family is able to remain promiscuous with substrate utilization: a common feature 
of the HAD superfamily members, which is otherwise unusual among enzymes that recognize 
metabolites. Our results demonstrate that PfHAD1 utilizes conserved residues in the catalytic 
domain to bind the phosphoryl group of sugar-phosphate substrates. Substrate specificity is 
determined by residues in the cap domain that make interactions with the sugar moiety, thereby 
defining which substrates PfHAD1 can utilize. 
 
Prior to this study, the role of cap movement in C2 HADs was unclear. It was speculated that C2 
HADs undergo structural changes in the squiggle and flap elements rather than the cap domain 
[16,17] to allow catalysis to occur. However, no direct biochemical or structural evidence for this 
squiggle–flap movement has been reported. The only other structural clue was reported for a 
cyanobacterial sucrose-phosphatase, for which an open and closed conformation of the cap 
domain in two different crystal forms was observed [41]. 
 
Here, we have observed open and closed conformations within the same crystal structures, and 
we find that these changes coordinate substrate binding and ordering. The open and closed 
conformations are likely to represent physiologically relevant states of PfHAD1 that are essential 
for substrate binding and catalysis (Figure A7). The open conformation of the enzyme allows a 
substrate molecule to bind the catalytic residues of the core domain with its phosphoryl group. In 
this open state, we see clear electron density for the phosphoryl group but not the sugar moiety 
that is facing bulk solvent. Upon inspection of the B-factor values in these structures, we observe 
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that a substrate-binding element in the cap domain is highly flexible and disordered. We have 
also captured the subsequent closed conformation of PfHAD1 in our structures. In this closed 
state, a substrate-binding cavity is formed at the interface between the core and cap domains that 
prevents the free exchange of water molecules with bulk solvent. The cap domain orders the 
substrate through polar and nonpolar interactions with the sugar moiety of the substrate, and low 
B factors are observed for the entire protein. This closed state provides an environment that 
favors an aspartate-based nucleophilic attack to occur. Subsequent opening of the cap would 
facilitate product release and allow the enzyme to be restored to its native state. 
 
We identified distinct residues that mediate substrate binding and specificity for PfHAD1. 
Analysis of these residues in HAD homologs identified patterns of conservation and variance 
that subdivide the superfamily and may predict their substrate specificities. This analysis 
suggests that the sub-divisions of HAD homologs may represent similar substrate-utilization 
profiles and/or biological functions in vivo. While mutation of the conserved cap residues are 
detrimental to enzyme function in these HADs, the variable cap residues are more suitable for 
changes to alter substrate specificity or for metabolic engineering. Understanding which residues 
to manipulate enables rational protein-engineering approaches to alter the substrate-utilization 
profiles of these enzymes. Future biochemical and structural studies of these PfHAD1 homologs 
will further our understanding of the substrate specificity and biological functions of these 
additional HAD enzymes. 
 
HAD superfamily members are widespread in biology, but few subfamilies have experimentally 
defined biological roles. We previously found that PfHAD1 regulates substrate availability to the 
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MEP pathway for isoprenoid precursor biosynthesis and that loss of PfHAD1 function has 
dramatic effects on the levels of MEP pathway intermediates [21]. PfHAD1 homologs in other 
organisms are restricted to phyla that also employ the MEP pathway, suggesting that PfHAD1-
like HADs are also regulators of the MEP pathway in these other organisms. Thus, our studies 
are an important first step in the development of chemical tools to disrupt or alter HAD enzyme 
functions. These tools will allow us to probe the biological and metabolic functions of HAD 
enzymes in living cells. As the MEP pathway is essential in parasites and pathogenic bacteria, 
defining the regulation of this pathway by HAD enzymes may lead to novel avenues for 
therapeutic intervention. 
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A.6 FIGURES  
 
Figure A1. Model of PfHAD1 regulation. 
PfHAD1 regulates substrate availability to the MEP pathway and is capable of catalyzing the 
phosphorolysis of small, 3–6-carbon sugar monophosphates upstream of the MEP pathway, 
including mannose 6-phosphate (Man6P), glucose 6-phosphate (Glu6P) and glyceraldehyde 3-
phosphate (Gly3P) [21].  
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Figure A2. PfHAD1 binds and orders substrates in a closed conformation. 
 (a) The overall PfHAD1-D27A + Man6P structure is shown here, with Man6P bound in the 
active site found at the interface between the core and cap domains. (b) Superimposition of the 
core domains of chain A and chain B reveals a shift in the cap domain relative to the core domain 
(gray), resulting in a closed (green) and an open (orange) conformation.  
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Figure A3. Substrates bind to the active site of PfHAD1-D27A. 
 (a) The Fo − Fc map (contoured at 2.5σ) of the substrate-binding site of the closed 
conformations prior to modeling of the substrate (from left to right: Man6P, Glu6P, Gly3P). 
Clear electron density can be observed for the entire substrate. (b) The 2Fo − Fc map (contoured 
at 1.0σ) of the closed substrate-binding site after refinement with the substrate model. (c) The Fo 
− Fc map (contoured at 2.5σ) of the open substrate-binding site prior to modeling of the 
substrate. Electron density for the entire substrate is ambiguous. (d) The 2Fo − Fc map 
(contoured at 1.0σ) of the open substrate-binding site after refinement with a phosphate-group 
model.  
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Figure A4. Distinct interactions for six-carbon and three-carbon sugar phosphates form the 
basis for substrate binding and specificity. 
 (a) The conserved HAD motifs I–IV make interactions with a magnesium ion, a conserved 
water molecule and the phosphoryl group. (b) An overlay of active-site residues from the WT-
PfHAD1 structure (colored light orange; PDB entry 4qjb) shows that the substrate-binding mode 
is conserved in the PfHAD1-D27A mutant. (c–e) Detailed van der Waals (colored green) and 
hydrogen-bond (dashed lines) interactions are shown between cap residues and the sugar moiety 
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of each substrate: (c) Man6P, (d) Glu6P, (e) Gly3P. For simplicity, hydrogen-bond interactions 
between the conserved HAD motifs I–IV and the substrate are not shown here.  
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Figure A5. The cap domain contains a flexible substrate-recognition element that is 
ordered upon substrate binding and cap closure. 
 (a) In the open conformation for Man6P, the region of the cap domain that is important for 
substrate recognition has high B-factor values, indicating disorder and flexibility in this region. 
(b) In the closed conformation for Man6P, this region becomes ordered, as reflected by the low 
B-factor values. (c) Enzyme activities for WT-PfHAD1 and PfHAD1-E152A are shown, 
normalized as a percentage of the WT-PfHAD1 activity for each substrate. Displayed are the 
means ± standard error of the mean of enzyme activity from at least three independent 
experiments.  
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Figure A6. Sequence alignment of substrate-binding cap-domain residues in PfHAD1 and 
PfHAD1 homologs from other organisms. 
 (a) PfHAD1 homologs in other organisms are highly conserved in their catalytic core domains 
(blue) but diverge in their cap-domain sequences (green). The black lines denote the five 
segments comprising the seven residues of the cap domain in PfHAD1 that are important for 
substrate binding. (b) The substrate-binding cap residues in the ten closest PfHAD1 homologs 
are shown. The blue and red boxes denote two subdivisions of PfHAD1 homologs. (c) The 
substrate-binding cap residues in PfHAD1 homologs from model organisms are shown. (d) 
Enzyme activities for WT-PfHAD1, PfHAD1-V151A and PfHAD1-L173A are shown, 
normalized as a percentage of the WT-PfHAD1 activity for each substrate. Displayed are the 
means ± standard error of the mean of enzyme activity from at least three independent 
experiments.  
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Figure A7. Model for catalysis in PfHAD1. 
The open conformation of PfHAD1 allows the substrate to access the active site and bind the 
conserved catalytic residues with the phosphoryl group. Subsequent cap closure prevents the free 
exchange of water molecules with bulk solvent and allows ordering of the substrate for catalysis. 
Opening of the cap allows solvent access to restore PfHAD1 to its native state. 
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Supplementary Figure A1. Stereo image of the electron density maps for representative 
regions of the substrate-bound PfHAD1-D27A structures.  
The 2fo-fc electron density map contoured at 1.0 σ is colored blue for (a) man6p, (b) glu6p, and 
(c) gly3p.  
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Supplementary Figure A2. PfHAD1-D27A is inactive.  
Mutation of the Asp-27 nucleophile to an alanine residue renders recombinant PfHAD1 enzyme 
inactive against all substrates tested: mannose-6-phosphate (man6P), glucose-6-phosphate 
(glu6P), glyceraldehyde 3-phosphate (gly3P), and para-nitrophenylphosphate (pNPP).  
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Supplementary Figure A3. The cap domain contains a flexible substrate recognition 
element that is ordered upon substrate binding and cap closure.  
(a) glu6p open conformation. (b) glu6p closed conformation. (c) gly3p open conformation. (d) 
gly3p closed conformation. In the open conformations (a,c), the region of the cap domain that is 
important for substrate recognition has high B-factor values, indicating disorder and flexibility in 
this region. In the closed conformations (b,d), this region becomes ordered, as reflected by the 
low B-factor values.  
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Supplementary Figure A4. Sequence alignment of PfHAD1 homologs from other 
organisms.  
Sequence alignments are shown for (a) an unbiased sampling of the ten closest PfHAD1 
homologs, (b) PfHAD1 homolog sequences from selected model organisms, (c) sequences of 
PfHAD1 homologs from E. coli with known substrate preferences. The cap domain is boxed in 
green, and substrate-binding core and cap residues in PfHAD1 are annotated with blue and green 
dots, respectively. The blue and red boxes denote two subdivisions of PfHAD1 homologs.  
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A.7 TABLES 
Table A1. Data collection and refinement statistics. 
    
 PfHAD1-D27A 
+ man6P 
PfHAD1-D27A 
+ glu6P 
PfHAD1-D27A 
+ gly3P 
Data collection    
   Space group P21 P21 P21 
   Cell dimensions    
      a, b, c, (Å) 77.60, 44.50, 84.50 77.70, 44.50, 84.80 77.60, 44.60, 84.10 
      α, β, γ (°) 90.00, 101.30, 90.00 90.00, 101.40, 90.00 90.00 101.30, 90.00 
   Resolution (Å)* 20-1.80 (1.90-1.80)* 20-1.90 (2.00-1.90)* 20-2.0 (2.10-2.00)* 
   Rmeas (%) 6.5% (65.2%) 8.4% (66.5%) 11.1% (74.0%) 
   I/σI 17.04 (2.45) 16.10 (2.42) 13.78 (2.20) 
   Completeness (%) 99.3% (99.6%) 98.9% (98.3%) 98.4% (97.7%) 
   Redundancy 3.68 (3.71) 3.77 (3.80) 3.79 (3.82) 
    
Refinement    
   Resolution (Å) 20-1.80 20-1.90 20-2.00 
   No. of reflections 52,536 44,805 38,024 
   Rwork/Rfree 18.83/21.91 17.89/21.95 17.32/22.10 
   No. of atoms    
      Protein 4,527 4,512 4,504 
      Mg 2 2 2 
      Ligand 21 21 15 
      Water 364 288 296 
   B-factors    
      Protein 29.90 29.80 34.30 
      Ligands 59.80 42.40 52.10 
      Water 30.20 28.80 32.50 
   Ramachandran    
      Favored (%) 97.72 97.70 97.16 
      Allowed (%) 2.28 2.30 2.84 
      Outliers (%) 0.00 0.00 0.00 
   R.m.s. deviations    
      Bond lengths (Å) 0.008 0.008 0.007 
      Bond angles (°) 1.198 1.187 0.969 
    PDB ID 4ZEV 4ZEW 4ZEX 
* Highest resolution shell is shown in parenthesis. 
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B.1 METHODS 
 
B.1.1 Growth assays 
Asynchronous parasites were cultured starting at 0.5-1% parasitemia. Samples were taken at day 
0 and every 2 days for 12 days. Samples were fixed (4% paraformaldehyde, 0.05% 
glutaraldehyde in PBS) and stored at 4 °C. Culture media was replaced daily and cultures were 
subcultured into fresh RBCs throughout the assay to ensure growth was not stunted due to high 
parasitemia. Fixed cells were washed with PBS, followed by staining with 0.01 mg/ml acridine 
orange (Invitrogen). Infected cells were counted using a BD LSRII flow cytometer. Data reflects 
corrections due to subculturing. 
 
B.1.2 PfHAD1 expression 
P. falciparum cultures (strain 3D7) were synchronized by treatment with 5% sorbitol. Parasites 
were allowed to complete one lifecycle (~48 hours) before beginning the experiment. Samples 
were taken at various timepoints for microscopy and immunoblot. Parasite morphology was 
evaluated using Giemsa-stained blood smears. PfHAD1 expression was evaluated by 
immunoblotting using anti-PfHAD1 antisera (1:20,000) [1].  
 
B.1.3 Electron microscopy 
P. falciparum-infected erythrocytes were fixed in 4% paraformaldehyde/0.05% glutaraldehyde 
(Polysciences Inc., Warrington, PA) in 100 mM PIPES/0.5 mM MgCl2, pH 7.2 for 1 hour at 4°C. 
Samples were then embedded in 10% gelatin and infiltrated overnight with 2.3 M sucrose/20% 
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polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C. Samples were trimmed, frozen in liquid nitrogen, 
and sectioned with a Leica Ultracut UCT cryo-ultramicrotome (Leica Microsystems Inc., 
Bannockburn, IL). Fifty nm sections were blocked with 5% fetal bovine serum/5% normal goat 
serum for 30 minutes and subsequently incubated with rabbit anti-PfHAD1 or rabbit anti-GFP 
(ab6556) (Abcam, Cambridge, MA), goat anti-rabbit IgG (H+L) conjugated to 12 or 18 nm 
colloidal gold (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Sections were 
washed in PIPES buffer followed by a water rinse, and stained with 0.3% uranyl acetate/2% 
methylcellulose. Samples were viewed with a JEOL 1200EX transmission electron microscope 
(JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera (Advanced 
Microscopy Techniques, Woburn, MA). All labeling experiments were conducted in parallel 
with controls omitting the primary antibody. These controls were consistently negative at the 
concentration of colloidal gold-conjugated secondary antibodies used in these studies. 
 
B.1.4 PIP-binding assays 
All steps were performed at room temperature. PIP strips from Echelon Biosciences (#P-6001) 
were blocked for 1 hr in blocking buffer (3% bovine serum albumin in PBS-T). Strips were 
incubated with 1-5 µg/mL recombinant 6xHis-PfHAD1 in blocking buffer for 1 hr. Strips were 
washed with PBS-T and incubated with 1:20,000 rabbit anti-PfHAD1 antisera in blocking buffer. 
Strips were washed and binding was detected using the colorimetric K-TMBP reagent (Echelon 
#K-TMBP). 
 
B.1.5 Enzyme assays 
PfHAD1 enzyme assays using inositol phosphates and phosphatidylinositols (diC8 lipids) were 
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performed as described for other PfHAD1 substrates [1] in Chapter 2, section 2.3.13, using 200 
ng recombinant enzyme and 1 mM substrate. PIPs and inositol phosphates were purchased from 
Echelon Biosciences and Sigma-Aldrich. 
 
B.1.6 Cellular fractionation  
Approximately 1 x 109 parasites were isolated by saponin lysis. Parasites were lysed by 
resuspension in hypotonic buffer (20 mM HEPES, 2 mM EGTA, Roche mini EDTA-free 
protease inhibitor tablets) and incubated on ice for 1-2 hours. All centrifugation steps were 
performed at 4 °C. Unlysed cells were removed by centrifugation at 5000 x g for 5 minutes. 
Lysate was ultracentrifuged at 100,000 x g for 1 hr to separate soluble and insoluble (membrane-
bound) fractions. Subsequent centrifugations were performed after washing and incubating with 
high salt (hypotonic buffer + 0.5 M sodium chloride) and carbonate (0.1 M sodium carbonate, 
pH 11) to release peripheral membrane proteins. Fractions were assayed by immunoblot using 
rabbit polyclonal anti-PfHAD1 antisera (1:20,000) [1], anti-aldolase (1:5,000, Abcam ab38905), 
and anti-PfERD2 (1:5,000, MRA-1 from MR4 repository) [2]. When necessary, HRP-conjugated 
goat anti-rabbit antibody was used as a secondary (1:20,000, ThermoFisher Scientific 65-6120). 
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B.2 PFHAD1 MUTANTS DO NOT HAVE A GROWTH DEFECT 
 
Figure B1. FSMR P. falciparum with PfHAD1 mutations do not have a growth defect.  
Shown is growth over time for the parental strain (black), two FSMR strains (AM1, deep red and 
D6, deep blue). FSMR strains rescued with functional PfHAD1 (Hsp110:PfHAD1-GFP) are 
shown in light red and blue. Strains D6, AM1, and AM1 Hsp110:PfHAD1-GFP are described in 
[1] and Chapter 2. Strain D6 Hsp110:PfHAD1-GFP was generated in the same way as AM1 
Hsp110:PfHAD1. Error bars represent S.E.M. from at least three independent experiments. 
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B.3 PFHAD1 LOCALIZATION VIA ELECTRON 
MICROSCOPY 
 
Figure B2. Localization of PfHAD1 by immunolabeling and electron microscopy.  
All images are of ACPL-GFP (apicoplast-localized GFP) parasites [3] stained with anti-PfHAD1 
polyclonal antisera and goat anti-rabbit conjugated with 18 nm collodial gold. Food vacuoles 
(FV) and red blood cell cytoplasm (RBC) are indicated. (A and B) PfHAD1 localization is 
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generally cytosolic, with some localization to membrane structures (endoplasmic reticulum) in 
the cytoplasm. (C) A small fraction of PfHAD1 localizes to apicoplast lumens or membranes. 
ACPL-GFP is stained with anti-GFP and goat anti-rabbit conjugated with 12 nm colloidal gold.  
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B.4 PFHAD1 DOES NOT BEHAVE LIKE A MEMBRANE 
PROTEIN  
 
Figure B3. PfHAD1 does not behave like a membrane-associated protein. 
Ultracentrifugation was used to fractionate P. falciparum cell lysate. Fractions were 
immunoblotted to probe for aldolase (PfALD), PfERD2, and PfHAD1. PfALD is a control for 
both cytoplasmic and peripheral membrane localization [5]. As expected, a fraction of PfALD is 
insoluble (membrane-localized), but this peripheral-membrane localization is sensitive to high 
salt concentrations. PfERD2 is an integral membrane protein in the endoplasmic reticulum [2]. 
PfERD2 is entirely insoluble and is resistant to both high salt and carbonate washes. PfHAD1 
behaves like a soluble protein (not membrane-localized).  
 
 
 
 
 
! 257 
B.5 PFHAD1 CAN BIND TO MEMBRANE LIPIDS 
 
 
Figure B4. PfHAD1 can bind membrane lipids.  
(A) Lipids spotted on phosphatidyl inositol phosphate (PIP) strip membrane. Abbreviations used: 
LPA, Lysophosphatidic acid; LC, Lysophosphocholine; PI, Phosphatidylinositol; PI(3)P, 
Phosphatidylinositol 3-phosphate; PI(4)P, Phosphatidylinositol 4-phosphate; PI(5)P, 
Phosphatidylinositol 5-phosphate; PE, Phosphatidylethanolamine; PC, Phosphatidylcholine; S1P, 
Sphingosine 1-phosphate; PI(3,4)P2, Phosphatidylinositol 3,4-bisphosphate; PI(3,5)P2, 
Phosphatidylinositol 3,5-bisphosphate; PI(4,5)P2, Phosphatidylinositol 4,5-bisphosphate; 
PI(3,4,5)P3, Phosphatidylinositol 3,4,5-trisphosphate; PA, Phosphatidic acid; PS, 
Phosphatidylserine. Membranes contain 100 pmol of lipid per spot. PIPs used are diC16 lipids. 
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(B-D). PfHAD1 is capable of binding a variety of PIPs. The G30E PfHAD1 variant found in 
FSMR strain D6 is also capable of binding PIPs, while the D27A catalytic mutant (described in 
[4] and Appendix A) is unable to bind. Data are representative of at least three independent 
experiments.  
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B.6 PFHAD1 IS UNABLE TO UTILIZE INOSITOL 
PHOSPHATES OR PIPS AS SUBSTRATES 
 
Figure B5. PfHAD1 activity against various phosphatidylinositols (diC8 lipids) and soluble 
inositol phosphates. 
Data shown are means and S.E.M.s of at least two independent experiments. Abbrevations used: 
glu6P, Glucose 6-phosphate; PI(3,5)P2, Phosphatidylinositol 3,5-bisphosphate; PI(3)P, 
Phosphatidylinositol 3-phosphate; PI(4)P, Phosphatidylinositol 4-phosphate; PI(5)P; I(1,4,5)P3, 
inositol (1,4,5)-triphosphate; myo-I1P, Myo-inositol 2-phosphate; I(3,5)P2, inositol (3,5)-
diphosphate, I(3)P, inositol 3-phosphate; I(4)P, inositol 4-phosphate; I(5)P, inositol 5-phosphate. 
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